Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
Novel aminopyrimidine derivatives modulate AhR activity, addressing the lack of effective treatments for diseases associated with aberrant AhR signaling by inhibiting tumor growth and regulating immune responses, offering therapeutic benefits for cancer and autoimmune disorders.
Patent Information
- Application Number
- CA3176957
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-27
- Filing Date
- 2021-03-29
- Publication Date
- 2026-11-03
- Estimated Expiration
- 2041-03-29
AI Technical Summary
Current treatments for diseases associated with aberrant aryl hydrocarbon receptor (AhR) signaling, such as cancer and autoimmune disorders, lack effective modulators to regulate AhR activity.
Development of novel aminopyrimidine derivatives represented by Formula (I) that act as modulators or antagonists of AhR, capable of inhibiting AhR activity and targeting conditions like cancer, fibrotic disorders, and dysregulated immune responses.
The aminopyrimidine derivatives effectively inhibit AhR activity, providing therapeutic benefits for conditions such as cancer, fibrotic disorders, and autoimmune diseases by inhibiting tumor growth, metastasis, and regulating immune responses.
Abstract
Description
DESCRIPTION [Invention Title] Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators Technical Field CROSS-REFERENCE TO RELATED APPLICATIONS The present application claims priority from U.S. Provisional Application No. 63 / 000,584, filed Mar. 27, 2020. The present invention relates to novel pyridopyrimidinone derivatives that can modulate the activities of aryl hydrocarbon receptor (AhR). The compounds of formula (I) of the present invention can also be used for inhibiting the growth of cancer cells, tumor cell metastasis and invasion and for the treatment of diseases related with dysregulated immune responses associated with AhR signaling (a sole agent or in combination with other active ingredients). [Background Art] Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and is well- known as an important intracellular chemosensor responsive to both natural and man-made environmental compounds. As is well known, the AhR is a member of the periodic circadian protein (PER) - AhR nuclear translocator (ARNT) - single-minded protein (SIM) superfamily of transcription factors in which the PER-ARNT-SIM(PAS) domain senses ligands. (Burbach et al, PNAS September 1, 1992 89 (17) 8185-8189) The AhR, activated by several binding ligands translocates to the nucleus and dimerizes with its partner protein, the ARNT. This heterodimeric complex interacts with the xenobiotic response elements (XREs) and it control the expression of AhR related genes directly or indirectly. One of the endogenous ligands to be well-characterized is kynurenine, generated by TDO (Opitz et al, Nature, 2011 Oct 5;478(7368):197-203) or IDO (Mezrich, J Immunol. 2010 Sep 15;185(6):3190-8.). Recent studies found that high concentrations of kynurenine in the plasma of diverse cancer patients and a high serum Kyn / Trp ratio correlates with poor prognosis after PD-1 blockade in several cancer types, including lung cancer, melanoma, and renal cell carcinomas. (Haoxin Li et al, Nat Commun. 2019 Sep 25;10(1):4346) It has been well-known lately that AhR regulates the functions of a plethora of cells of both the innate and adaptive immune system. Activated AhR attenuates the induction of cytokines that promote the polarization of pathogenic T cell subsets and reduces MHC class II expression. In addition, AhR activation by agonist or modulator, inhibits the differentiation of helper Th17 cell and stabilizes regulatory T cell. Invigorated AhR also induces the generation of its ligands via a positive feedforward loop involving indolamine 2,3-dioxygenase 1 (IDO1). (Nguyen et al., PNAS, 2010, 107(46):19961-19966, Mascanfroni, I. D. et al. Nat. Med., 2015, 21:638-646) As an immune escape mechanism, Tumor-repopulating cells (TRCs) drive PD-1 upregulation in CD8+ T cells through a Kyn-AhR pathway. (Yuying Liu et al, Cancer cell, 2018) Mar 12;33(3):480-494.e7.). Moreover, several studies have shown that AhR signaling plays important roles in diverse disease such as autoimmunity, infection, and cancer. AhR signaling may be related to autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS). (Xiao-Song Wang et al, Inflammopharmacology, 2020 Feb;28(1):63-81) Constitutive AhR activation reduces the type I IFN (IFN-I) antiviral response (Yamada et al, Nat immunol, 2016 Jun;17(6):687-94). The AhR activation is induced by multiple viruses to evade the host immune response, a strategy exploited in mouse models to limit the replication of Zika virus, SARS-COV-2 infection. (Federico Giovannoni et al, Cell Research, 2021 Dec., 31:1-2) The AhR may affect the proliferation, tissue invasion, metastasis, and angiogenesis of cancer cells (Jae Eun Cheong et al, Trends in Pharmacological Sciences, 2018 Mar;39(3):307-325). In addition, many cancer types can escape from immune recognition via an AhR pathway. Developing AhR-targeted therapeutics could be the potential opportunities to overcome immune related diseases. [Disclosure] [Technical Problem] Therefore, it is an object of the present invention to provide novel compounds, or an enantiomer, diastereomer, racemate, solvate, hydrate or pharmaceutically acceptable salt thereof as modulators of AhR. It is an object of the present invention to provide a pharmaceutical composition for the modulation of AhR activity, comprising the compounds as modulators of AhR. It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of disease, disorder, or condition associated with AhR activity such as a cancer or an autoimmune disease, comprising the compounds as modulators of AhR. It is an object of the present invention to provide a method for modulating AhR activity by administering the compounds as modulators of AhR. It is an object of the present invention to provide a method for preventing or treating prostaglandin related diseases by administering the compounds as modulators of AhR. It is an object of the present invention to provide a use of the prostaglandin anlalog for the modulation of AhR acitivity, or the prevention or treatment of disease, disorder, or condition associated with AhR. [Technical Solution] SUMMARY OF THE INVENTION The present invention provides novel compounds, or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof are effective as modulators or antagonists of AhR. The compounds are represented by formula (I) [Image disponible dans le document PDF, Image available in the PDF document] wherein: <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> are each independently <com:Math><semantics>CR2<annotation encoding="application / x-tex">CR^2< / annotation>< / semantics>< / com:Math>, N or <com:Math><semantics>NR3<annotation encoding="application / x-tex">NR^3< / annotation>< / semantics>< / com:Math>; Ar<com:Sup>1< / com:Sup> and Ar<com:Sup>2< / com:Sup> are each independently selected from substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl, substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl; D is H, halo, cyano, hydroxy, amino, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> -Song Wang et al, alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heteroaryl, E is absent(direct bond), amino, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heteroaryl, or D and E, together with the atoms to which they are attached, are combined to form substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring; G is absent(direct bond), H, halo, cyano, hydroxy, amino, nitro, ether(-O-), thioether(-S- ), sulfinyl(-SO-), sulfonyl(-SO<com:Sub>2< / com:Sub>-), sulfonylamido(-SO<com:Sub>2< / com:Sub>NR<com:Sup>4< / com:Sup>-), aminosulfonyl(-NR<com:Sup>4< / com:Sup>SO<com:Sub>2< / com:Sub>-), carbonyl(-(CO)-), amido(-(CO)NR<com:Sup>4< / com:Sup>-), reverse amido(-NR<com:Sup>4< / com:Sup>(CO)-), ester(-(CO)O-), substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> heterocycloalkyl, substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl; R<com:Sup>1< / com:Sup> is absent, H, halo, cyano, hydroxy, amino, N(R<com:Sup>5< / com:Sup>)2, OR<com:Sup>5< / com:Sup>, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl and substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl; <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is H, halo, cyano, hydroxy and <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>3< / com:Sup> is H, halo, cyano, hydroxyl and amino; and R<com:Sup>4< / com:Sup> is H, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkoxy and substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid; and R<com:Sup>5< / com:Sup> is H, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkoxy and substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid; In some embodiments of these aspects and all such aspects described herein, the AhR modulator of Formula (I) is an AhR modulator or AhR antagonist. In some aspects, described herein are methods of modulating AhR activity, more specifically constitutive AhR activity in a subject in need thereof. Such methods comprise administering to a subject having constitutive AhR activity a therapeutically effective amount of an AhR modulator, such as an AhR antagonist of Formula (I), described herein. In some embodiments of these aspects and all such aspects described herein, the methods further comprise the step of selecting the subject having constitutive AhR activity. Compounds of formula (I) of the present invention demonstrate a valuable pharmacological spectrum of action, which could not have been predicted. Compounds of the present invention have surprisingly been found to effectively inhibit AhR and it is possible therefore that said compounds be used for the treatment or prophylaxis of a disease or condition mediated by aryl hydrocarbon receptor (AhR), preferably cancer, cancerous consitions, tumor, fibrotic disorders, or conditions with dysregulated immune responses or other disorders associated with aberrant AhR signaling, in humans and animals. Examples of said diseases related with dysregulated immune response associated with AhR signaling are sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, inflammatory skin disorders and inflammatory eye disorders, autoimmune diseases, such as rheumatoid diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), etc. Examples of said fibrotic disorders are fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders. In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitroretinopathy and disorders of the connective tissue (for example sarcoidosis). In other aspects, described herein are methods of treating a cancer or a cancerous condition by modulating AhR activity. Such methods comprise administering to a subject having a cancer or cancerous condition a therapeutically effective amount of any of the pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), described herein. In some aspects, described herein are methods of inhibiting tumor cell invasiveness in a subject having a cancer, a cancerous condition, or a tumor. Such methods comprise administering to a subject having a cancer or a tumor a therapeutically effective amount of any of the pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), described herein. In some embodiments of these aspects and all such aspects described herein, the methods further comprise the step of selecting the subject having a cancer, a cancerous condition, or a tumor. Said cancer, cancerous condition, or tumor particularly suitable for treatment with an AHR inhibitor of the present invention are liquid and solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias. Examples of breast cancers include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma. Examples of brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour. Tumours of the male reproductive organs include, but are not limited to, prostate and testicular cancer. Tumours of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus. Examples of ovarian cancer include, but are not limited to serous tumour, endometrioid tumour, mucinous cystadenocarcinoma, granulosa cell tumour, Sertoli-Leydig cell tumour and arrhenoblastoma. Examples of cervical cancer include, but are not limited to squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumour, glassy cell carcinoma and villoglandular adenocarcinoma. Tumours of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers. Examples of esophageal cancer include, but are not limited to esophageal cell carcinomas and adenocarcinomas, as well as squamous cell carcinomas, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma and lymphoma. Examples of gastric cancer include, but are not limited to intestinal type and diffuse type gastric adenocarcinoma. Examples of pancreatic cancer include, but are not limited to ductal adenocarcinoma, adenosquamous carcinomas and pancreatic endocrine tumours. Tumours of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers. Examples of kidney cancer include, but are not limited to renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumour (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma and Wilms' tumour. Examples of bladder cancer include, but are not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma and small cell carcinoma. Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma. Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma. Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer. Head-and-neck cancers include, but are not limited to, squamous cell cancer of the head and neck, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell. Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system. Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma. Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. The term "treating" or "treatment" as stated throughout this document is used conventionally, for example the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as a carcinoma. The compounds or of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth the cancer is a breast cancer, squamous cell cancer, lung cancer, a cancer of the peritoneum, a hepatocellular cancer, a gastric cancer, a pancreatic cancer, a glioblastoma, a cervical cancer, an ovarian cancer, a liver cancer, a bladder cancer, a hepatoma, a colon cancer, a colorectal cancer, an endometrial or uterine carcinoma, a salivary gland carcinoma, a kidney or renal cancer, a prostate cancer, a vulval cancer, a thyroid cancer, a head and neck cancer, a B-cell lymphoma, a chronic lymphocytic leukemia (CLL); an acute lymphoblastic leukemia (ALL), a Hairy cell leukemia, or a chronic myeloblastic leukemia. In some such embodiments, the cancer is a hepatocellular cancer. Some embodiments of these methods can further comprise administration or treatment with one or more additional anti-cancer therapies. In some such embodiments, the additional anti-cancer therapy comprises surgery, radiation therapy, biotherapy, immunotherapy, chemotherapy, or any combination thereof. Some embodiments of these methods can further comprise administration or treatment with one or more anti-cancer therapeutic agents. In some such embodiments, the anti-cancer therapeutic agent is a chemotherapeutic agent, a growth inhibitor agent, an anti-angiogenesis agent, a cytotoxic agent, an anti-hormonal agent, a prodrug, or a cytokine. In a further embodiment of the present invention, the compounds of formula (I) of the present invention may be used to sensitize a cell to radiation, i.e. treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the present invention. In one aspect, the cell is treated with at least one compound of general formula (I) of the present invention. Thus, the present invention also provides a method of killing a cell, wherein a cell is administered one or more compounds of the present invention in combination with conventional radiation therapy. The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of formula (I) of the present invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of formula (I) of the present invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell. In other embodiments of the present invention, a cell is killed by treating the cell with at least one DNA damaging agent, i.e. after treating a cell with one or more compounds of formula (I) of the present invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g. cisplatin), ionizing radiation (X- rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents. In other embodiments, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non- limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell. In one aspect of the invention, a compound of formula (I) of the present invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of formula (I) of the present invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun. In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo. The compounds of the present invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutically active ingredients where the combination causes no unacceptable adverse effects. The present invention also covers such pharmaceutical combinations. For example, the compounds of the present invention can be combined with: 131 1-chTNT, abarelix, abiraterone, aclarubicin, adalimumab, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronic acid, alitretinoin, altretamine, amifostine, aminoglutethimide, hexyl aminolevulinate, amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, anetumab ravtansine, angiotensin II, antithrombin III, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, atezolizumab, axitinib, azacitidine, basiliximab, belotecan, bendamustine, besilesomab, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, blinatumomab, bortezomib, buserelin, bosutinib, brentuximab vedotin, busulfan, cabazitaxel, cabozantinib, calcitonine, calcium folinate, calcium levofolinate, capecitabine, capromab, carbamazepine carboplatin, carboquone, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, cobimetinib, copanlisib, crisantaspase, crizotinib, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daratumumab, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dianhydrogalactitol, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, dinutuximab, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin + estrone, dronabinol, eculizumab, edrecolomab, elliptinium acetate, elotuzumab, eltrombopag, endostatin, enocitabine, enzalutamide, epirubicin, epitiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, ethinylestradiol, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony stimulating factor, histamine dihydrochloride, histrelin, hydroxycarbamide, 1-125 seeds, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (1231), iomeprol, ipilimumab, irinotecan, Itraconazole, ixabepilone, ixazomib, lanreotide, lansoprazole, lapatinib, lasocholine, lenalidomide, lenvatinib, lenograstim, lentinan, letrozole, leuprorelin, levamisole, levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane, mercaptopurine, mesna, methadone, methotrexate, methoxsalen, methylaminolevulinate, methylprednisolone, methyltestosterone, metirosine, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, nabilone, nabiximols, nafarelin, naloxone + pentazocine, naltrexone, nartograstim, necitumumab, nedaplatin, nelarabine, neridronic acid, netupitant / palonosetron, nivolumab, pentetreotide, nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nintedanib, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, olaparib, olaratumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, osimertinib, oxaliplatin, oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palbociclib, palifermin, palladium-103 seed, palonosetron, pamidronic acid, panitumumab, panobinostat, pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, pegfilgrastim, peginterferon alfa-2b, pembrolizumab, pemetrexed, pentazocine, pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone + sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib, regorafenib, risedronic acid, rhenium-186 etidronate, rituximab, rolapitant, romidepsin, romiplostim, romurtide, roniciclib, samarium (153Sm) lexidronam, sargramostim, satumomab, secretin, siltuximab, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sonidegib, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, talimogene laherparepvec, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentan, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valatinib, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin. The compounds of the invention can further be combined with other reagents targeting the immune system, such as immune checkpoint inhibitors, e.g. aPD-1 / -L1 axis antagonists. PD-1, along with its ligands PD-L1 and PD-L2, function as negative regulators of T cell activation. AHR suppresses immune cell function while increasing cancer cell proliferation and motility. PD-L1 is overexpressed in many cancers and overexpression of PD-1 often occurs concomitantly in tumor infiltrating T cells. Thus results in attenuation of T cell activation and evasion of immune surveillance, which contributes to impaired antitumor immune responses. (Keir M E et al. (2008) Annu. Rev. Immunol. 26:677). Simultaneously targeting both the PD-1 / -L1 axis and AHR enhances antitumor immune responses more than in an additive manner, leading to a reduction of tumor growth that is unexpected. Thus, compositions comprising a PD-1 / -L1 axis antagonist and an AHR antagonist are surprisingly effective in enhancing an immune response and in the treatment of cancer. In addition, the inventive compounds can also be used as a therapeutic in a variety of other disorders wherein AHR is involved. Examples of other disorders associated with aberrant AhR signaling inflammation are vaccination for infection & cancer, viral infections, obesity and diet-induced obesity, adiposity, metabolic disorders, hepatic steatosis and uterine fibroids (uterine leiomyoma or uterine myoma) in women, chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropaties, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer, and Creutzfeld-Jakob. Also provided herein, in other aspects, are pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), and pharmaceutically acceptable excipients. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in for modulating constitutive AhR activity in a subject in need thereof. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in treating a cancer or a cancerous condition by modulating AhR activity. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in inhibiting proliferation, tissue invasion, metastasis and angiogenesis of cancer cells in a subject having a cancer, a cancerous condition, or a tumor. In some embodiments of these aspects and all such aspects described herein, the use further comprises the step of selecting the subject having a cancer, a cancerous condition, or a tumor. In some such embodiments, the cancer is a breast cancer, squamous cell cancer, lung cancer, a cancer of the peritoneum, a hepatocellular cancer, a gastric cancer, a pancreatic cancer, a glioblastoma, a cervical cancer, an ovarian cancer, a liver cancer, a bladder cancer, a hepatoma, a colon cancer, a colorectal cancer, an endometrial or uterine carcinoma, a salivary gland carcinoma, a kidney or renal cancer, a prostate cancer, a vulval cancer, a thyroid cancer, a head and neck cancer, a B-cell lymphoma, a chronic lymphocytic leukemia (CLL); an acute lymphoblastic leukemia (ALL), a Hairy cell leukemia, or a chronic myeloblastic leukemia. In some such embodiments, the cancer is a hepatocellular cancer. In some embodiments of these aspects and all such aspects described herein, the use further comprises one or more additional anti-cancer therapies. In some such embodiments, the additional anti-cancer therapy comprises surgery, radiation therapy, biotherapy, immunotherapy, or chemotherapy. In some embodiments of these aspects and all such aspects described herein, the use further comprises one or more anti-cancer therapeutic agents. In some such embodiments, the anti-cancer therapeutic agent is a chemotherapeutic agent, a growth inhibitor agent, an anti- angiogenesis agent, a cytotoxic agent, an anti-hormonal agent, a prodrug, or a cytokine. [Advantageous Effects] The novel compounds of Formula (I) according to the present invention effectively modulate AhR activity, and therefore they are useful as a therapeutic or prophylactic drug for various disease, disorder, or condition associated with AhR activity such as cancer, cancerous condition, tumor, fibrotic disease, conditions with dysregulated immune responses including autoimmune disease such as rheumatoid arthiritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), or other disorders associated with aberrant AhR signaling etc. [Best Mode] Hereinafter, the present invention will be described in more detail. Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, although the invention has been described in conjunction with specific methods and samples, their analogs or equivalents should be within the scope of the present invention. Furthermore, the numerical values set forth herein are considered to include the meaning of "about" unless explicitly stated. The definition of residues used herein is described in detail. Unless otherwise indicated, each residue has the following definition and is used in the sense as commonly understood by one of ordinary skill in the art. As used herein, the term "halo" "halogen", "halide (s)" includes fluoro, chloro, bromo and iodo. As used herein, the "alkyl" refers to an aliphatic hydrocarbon radical, and includes both linear and branched hydrocarbon radicals. For example, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl is an aliphatic hydrocarbon having 1 to 6 carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl. Unless otherwise defined, the alkyl refers to C<com:Sub>1-6< / com:Sub> alkyl, preferably C<com:Sub>1-4< / com:Sub> alkyl, more preferably C<com:Sub>1-3< / com:Sub> alkyl. As used herein, the "alkenyl" refers to an aliphatic hydrocarbon radical comprising at least one carbon-carbon double bond, and includes both linear and branched hydrocarbon radicals. The unlimited example of the "alkenyl" is vinyl, allyl, but-1-enyl or but-2-enyl. As used herein, the "alkynyl" refers to an aliphatic hydrocarbon radical comprising at least one carbon-carbon triple bond, and includes both linear and branched hydrocarbon radicals. The unlimited example of the "alkynyl" is ethynyl, propargyl, but-1-ynyl or but-2-ynyl. As used herein, the "haloalkyl" refers to an alkyl group substituted with one or more halogen atom, and the alkyl group is defined as above. The "halo" refers to F, Cl, Br, or I, and the term is compatibly used with the term "halogen". Unless otherwise defined, the haloalkyl refers tofluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl or 2,2,2-trifluoromethyl. As used herein, the term "alkoxy" refers to-O-alkyl or alkyl-O- group, and the alkyl group is defined as shown above. For example, it includes methoxy, ethoxy, n-propoxy, n- butoxy and t-butoxy. As used herein, the "alkoxyalkyl" refers to alkyl-O-alkyl group, and the alkyl group is defined as above. The unlimited example is methoxymethyl, ethoxymethyl, methoxyethyl or isopropoxymethyl. As used herein, the term "hydroxy" or "hydroxyl" alone or in combination with other terms means -OH. As used herein, "cyano" refers to —CN, "cyanoalkyl" refers to alkyl substituted with —CN, wherein the alkyl group is as defined above. As used herein, "amino" refers to —NH<com:Sub>2< / com:Sub>; and "nitro" refers to -NO<com:Sub>2< / com:Sub>. As used herein, "carboxy" refers to-C(O)-OH group. As used herein, "ester" refers to a group of <com:Math><semantics>−−C(O)<annotation encoding="application / x-tex">--C(O)< / annotation>< / semantics>< / com:Math>—OR, where R is alkyl may be <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math>, preferably C<com:Sub>1-8< / com:Sub>, C<com:Sub>1-6< / com:Sub> or C<com:Sub>1-4< / com:Sub> alkyl. Such ester groups may or may not be substituted with one or more suitable substituents. As used herein, the term "cycloalkyl" refers to a cyclic alkyl which may be substituted or unsubstituted, and for example, the C<com:Sub>3-20< / com:Sub> cycloalkyl represents a monovalent saturated hydrocarbon ring system having 3 to 20 carbon atoms. Examples of the cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl, cyclohexyl, cyclohexyl and the like. Preferably, unless otherwise defined, the cycloalkyl may be C<com:Sub>3-8< / com:Sub> cycloalkyl, or C<com:Sub>3-6< / com:Sub> cycloalkyl. As used herein, the term "aryl" refers to a monovalent aromatic hydrocarbon having, for example, 6 to 20 carbon atoms (<com:Math><semantics>C6−20<annotation encoding="application / x-tex">C_{6-20}< / annotation>< / semantics>< / com:Math>) that is derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. The aryl may include a bicyclic radical containing an aromatic ring fused to a saturated or partially unsaturated ring. Exemplary aryl groups may include radicals derived from benzene (phenyl), substituted phenyl, biphenyl, naphthyl, toluyl, naphthalenyl, anthracenyl, indenyl, indanyl, and the like. Unless otherwise defined, the aryl refers to <com:Math><semantics>C6−12<annotation encoding="application / x-tex">C_{6-12}< / annotation>< / semantics>< / com:Math> aryl, preferably <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl. As used herein, the "heteroaryl" refers to a monovalent or divalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon having 1 to 10 carbon ring members containing one or more, preferably one to three, heteroatoms selected among N, O, and S. Examples of the heteroaryl include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl, 1, 2, 4-thiadiazolyl, 1, 3, 4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, indolyl, and the like. Examples of the bicyclic heteroaryl include indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, quinolinyl, isoquinolinyl, furinyl, furopyridinyl, octahydropyranopyridine, benzodioxolyl and similar groups thereof, but are not limited thereto. Unless otherwise defined, the heteroaryl is <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> heteroaryl, preferably <com:Math><semantics>C3−7<annotation encoding="application / x-tex">C_{3-7}< / annotation>< / semantics>< / com:Math> heteroaryl, more preferably <com:Math><semantics>C3−5<annotation encoding="application / x-tex">C_{3-5}< / annotation>< / semantics>< / com:Math> heteroaryl. As used herein, the "heterocycloalkyl" refers to monocyclic, bicyclic, tricyclic or higher cyclic alkyl having 3 to 10 carbon ring members containing one or more, for example, one to four, heteroatoms selected among N, O, and S. In addition, the heterocycle according to the present invention may also be a fused or bridged heterocycloalkyl. Examples of non-aromatic rings include azetidinyl, oxetanyl, tetrahydrothienyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, oxapiperazinyl, oxapiperidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydroisothiazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridinyl, dihydropyridinyl, dihydrothiopyranyl, tetrahydropyrimidinyl, tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, indolinyl, indolinylmethyl, thiomorpholinyl, azepanyl, diazepanyl, N-oxide, azaadamantanyl, diazamantanyl, and the like, but are not limited thereto. Attachment of a heterocycloalkyl substituent can occur via a carbon atom or a heteroatom. A heterocycloalkyl group may be optionally substituted with one or more suitable groups via one or more aforementioned groups. Unless otherwise defined, heterocycloalkyl refers to heterocycloalkyl having 3 to 10 carbon ring members, preferably C<com:Sub>3-7< / com:Sub>heterocycloalkyl, more preferably heterocycloalkyl having 3 to 5 carbon ring atoms. Unless otherwise specified herein, the term "substituted" means that at least one hydrogen atom is substituted by one to three substituents selected from the group consisting of a halogen atom (e.g., F, Cl, Br, or I), a cyano group, a hydroxyl group, a thiol group, a nitro group, an amino group, an imino group, an azido group, an amidino group, a hydrazino group, a hydrazono group, an oxo group, a carbonyl group, a carbamyl group, an ester group, an ether group, a carboxyl group or a salt thereof, a sulfonic acid group or a salt thereof, phosphoric acid or a salt thereof, a C<com:Sub>1-6< / com:Sub> alkyl group, a halo C<com:Sub>1-6< / com:Sub> alkyl group, a hydroxy C<com:Sub>1-6< / com:Sub> alkyl group, a C<com:Sub>2-6< / com:Sub> alkenyl group, a halo C<com:Sub>2-6< / com:Sub> alkenyl group, a C<com:Sub>2-6< / com:Sub> alkynyl group, a halo C<com:Sub>2-6< / com:Sub> alkynyl group, a C<com:Sub>1-6< / com:Sub> alkoxy group, a halo C<com:Sub>1-6< / com:Sub> alkoxy group, a hydroxy C<com:Sub>1-6< / com:Sub> alkoxy group, a C<com:Sub>1-20< / com:Sub> alkylthio group, a C<com:Sub>1-6< / com:Sub> alkylsulfonyl group, a C<com:Sub>1-6< / com:Sub> alkylcarbonyl group, a C<com:Sub>1-6< / com:Sub> alkoxycarbonyl group, a C<com:Sub>3-20< / com:Sub> carbocyclic group (e.g., a C<com:Sub>3-9< / com:Sub> cycloalkyl group, a halo C<com:Sub>3-9< / com:Sub> cycloalkyl group, a C<com:Sub>3-9< / com:Sub> cycloalkenyl group, a halo C<com:Sub>3-9< / com:Sub> cycloalkenyl group, a C<com:Sub>1-9< / com:Sub> heterocycloalkyl group, a halo C<com:Sub>1-9< / com:Sub> heterocycloalkyl group, a C<com:Sub>2-9< / com:Sub> heterocycloalkenyl group, a halo C<com:Sub>2-9< / com:Sub> heterocycloalkenyl group) and a C<com:Sub>1-20< / com:Sub> heterocyclic group (e.g., a C<com:Sub>6-20< / com:Sub> aryl group, a C<com:Sub>6-20< / com:Sub> aryloxy group, a C<com:Sub>6-20< / com:Sub> arylthio group, a C<com:Sub>2-20< / com:Sub> heteroaryl group, a <com:Math><semantics>C2−20<annotation encoding="application / x-tex">C_{2-20}< / annotation>< / semantics>< / com:Math> heteroaryloxygroup, a <com:Math><semantics>C2−20<annotation encoding="application / x-tex">C_{2-20}< / annotation>< / semantics>< / com:Math> heteroarylthio group). Based on the studies conducted and the results obtained so far, it is believed that the following compounds of Formula (I), including isomers, mixtures of isomer as well as pharmaceutically acceptable salts and solvates thereof, are particularly interesting. Aryl Hydrocarbon Receptor The Aryl Hydrocarbon Receptor ("AhR") is a ligand-dependent member of the family of basic-helix-loop-helix transcription factors that has been found to be activated by numerous structurally diverse synthetic and naturally occurring compounds, such as polycyclic aromatic hydrocarbons, indoles, and flavonoids. In the absence of bound ligand, the AhR is present in a latent conformation in the cytoplasmic compartment of the cell associated with two molecules of the molecular chaperone heat shock protein 90 ("hsp90"), an immunophilin-like protein, XAP2, and the hsp90 interacting protein, p23. The term "aryl hydrocarbon receptor" or "AhR" as used herein refers to the 848 amino acid polypeptide, as described by, e.g., NP_001612, together with any naturally occurring allelic, splice variants, and processed forms thereof. Typically, AhR refers to human AhR. The term AhR is also used to refer to truncated forms or fragments of the AhR polypeptide, comprising, for example, specific AhR domains. Reference to any such forms of the AhR can be identified in the application, e.g., by "AhR (122-224)." AhR Modulators The inventors of the present invention have discovered that the novel AhR modulator compounds described herein, such as the small molecules of Formula (I), modulate constitutive AhR activity, by functioning as AhR antagonists. Further, they have discovered that such AhR modulator compounds can inhibit cancer cell growth, as well as tumor invasion, metastasis and angiogenesis. Accordingly, described herein are novel modulators of the AhR and constitutive AhR signaling for use in therapeutic compositions for, and methods of, treating and inhibiting cancer growth and tumor cell invasion, and immune related diseases such as autoimmune diseases. The AhR mediates a variety of functional responses, including, but not limited to de novo transcription of target genes or AhR battery genes having the DRE or XRE responsive element 5'-TNGCGTG-3'. Alternative pathways of AhR signaling have also been described, such as binding to retinoblastoma protein, estrogen receptor (ER), the transcription factor E2F1 and to the NFkB pathway subunits RelA and RelB. The AhR can also act as a ubiquitin ligase. Accordingly, signaling via the AhR comprises multiple pathways, including constitutive and non-constitutive AhR signaling pathways or signaling activity, as those terms are defined herein. As used herein, "constitutive AhR signaling" refers to one or more signaling pathways mediated or regulated by the AhR that are activated or driven by one or more endogenous AhR ligands, or one or more environmental ligands, such as toxins or pollutants, that cause constitutive or long-term translocation of the AhR to the nucleus, and activation or modulation of one or more AhR battery genes involved in unregulated cell growth and proliferation, tumor cell invasiveness, or a combination thereof. As used herein, "non-constitutive AhR signaling" refers to one or more signaling pathways mediated or induced by the AhR that does not cause constitutive or long-term translocation of the AhR to the nucleus, nor activation or modulation of one or more AhR battery genes involved in unregulated cell growth, tumor cell invasiveness, or a combination thereof. In some embodiments, non-constitutive AhR signaling does not cause upregulation of expression of CYP1A1, CYP1B1, or a combination thereof. Accordingly, an "AhR modulator," as the term is used herein refers to an agent, such as a compound of Formula (I), that modulates or causes or facilitates a qualitative or quantitative change, alteration, or modification in one or more processes, mechanisms, effects, responses, functions, activities or pathways mediated by the AhR receptor. Such changes mediated by an AhR modulator, such as an antagonist of the AhR described herein, can refer to a decrease in, inhibition of, or diversion of, constitutive activity of the AhR. The term "expression," refers to the cellular processes involved in producing RNA and proteins and as appropriate, secreting proteins, including where applicable, but not limited to, for example, transcription, translation, folding, modification and processing. "Expression products" include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene. The term "modulate" in reference to an Ahr modulator is used consistently with its use in the art, e.g., meaning to cause or facilitate a qualitative or quantitative change, alteration, or modification in one or more biological processes, mechanisms, effects, responses, functions, activities, pathways, or other phenomena of interest. Accordingly, as used herein, modulate refers to a qualitative or quantitative change, alteration, or modification in one or more processes, mechanisms, effects, responses, functions, activities or pathways mediated by the AhR receptor. The term "agent" as used herein in reference to an AhR modulator means any compound or substance such as, but not limited to, a small molecule, nucleic acid, polypeptide, peptide, drug, ion, etc. An "agent" can be any chemical, entity, or moiety, including, without limitation, synthetic and naturally-occurring proteinaceous and non-proteinaceous entities. In some embodiments, an agent is a nucleic acid, a nucleic acid analogue, a protein, an antibody, a peptide, an aptamer, an oligomer of nucleic acids, an amino acid, or a carbohydrate, and includes, without limitation, proteins, oligonucleotides, ribozymes, DNAzymes, glycoproteins, siRNAs, lipoproteins, aptamers, and modifications and combinations thereof etc. In certain embodiments, as described herein, agents are small molecules having a chemical moiety. For example, chemical moieties include unsubstituted or substituted alkyl, aromatic, or heterocyclyl moieties. Compounds can be known to have a desired activity and / or property, e.g., modulate AhR activity, or can be selected from a library of diverse compounds, using, for example, the screening methods described herein. In some embodiments, an AhR modulator selectively binds to the AhR. As used herein, "selectively binds" or "specifically binds" refers to the ability of an AhR antagonist, described herein to bind to a target, such as the AhR, with a K<com:Sub>D< / com:Sub> 10<com:Sup>-5< / com:Sup> M (10000 nM) or less, e.g., 10<com:Sup>-6< / com:Sup> M or less, 10<com:Sup>-7< / com:Sup> M or less, 10<com:Sup>-8< / com:Sup> M or less, 10<com:Sup>-9< / com:Sup> M or less, 10<com:Sup>-10< / com:Sup> M or less, 10<com:Sup>-11< / com:Sup> M or less, or 10<com:Sup>-12< / com:Sup> M or less. For example, if an antagonist described herein binds to the AhR with a K<com:Sub>D< / com:Sub> of 10<com:Sup>-5< / com:Sup> M or lower, but not to other molecules, or a related homologue, then the agent is said to specifically bind the AhR. Specific binding can be influenced by, for example, the affinity and avidity of the antagonist and the concentration of the antagonist used. The person of ordinary skill in the art can determine appropriate conditions under which the antagonists described herein selectively bind using any suitable methods, such as titration of an AhR antagonist in a suitable cell binding assay, such as those described herein. In some aspects of the compositions and methods described herein, AhR modulators are AhR antagonists having the chemical structures of Formula (I), described herein. As used herein, the AhR is an "AhR antagonist." An AhR antagonist refers to an AhR inhibitor that does not provoke a biological response itself upon specifically binding to the AhR, but blocks or dampens agonist-mediated or ligand-mediated responses, i.e., an AhR antagonist can bind but does not activate the AhR, and the binding disrupts the interaction, displaces an AhR agonist, and / or inhibits the function of an AhR agonist. Thus, as used herein, an AhR antagonist does not function as an inducer of AhR activity when bound to the AhR, i.e., they function as pure AhR inhibitors. In some embodiments, an AhR antagonist selectively binds to the AhR. In some embodiments of these aspects, the AhR antagonists described herein, such as the compounds of Formula (I) block constitutive AhR effector functions that mediate growth and progression of established tumors. In other embodiments, the small molecule AhR antagonists of Formula (I), described herein act as chemopreventatives by blocking AhR-mediated CYP1A1 induction and mutagen production on exposure to environmental ligands. In some embodiments of these aspects, the AhR antagonists of Formula (I), described herein inhibit the early contributions of constitutively active AhR in driving malignant transformation. In some embodiments, the compunds of Formula (I) described herein inhibit constitutive AhR signaling-mediated cancer or tumor cell growth. In some embodiments, the compounds of Formula (I), described herein inhibit constitutive AhR signaling-mediated tumor invasion in driving malignant transformation. Accordingly, provided for use in the various aspects described herein are AhR antagonist of Formula (I): An aspect of the present inventionrelates to novel compounds that can modulate human aryl hydrocarbon receptor (AhR). These compounds bind specifically to AhR. In some embodiments, the compound has the structure of formula (I), or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (I) wherein: <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> are each independently <com:Math><semantics>CR2<annotation encoding="application / x-tex">CR^2< / annotation>< / semantics>< / com:Math>, N or <com:Math><semantics>NR3<annotation encoding="application / x-tex">NR^3< / annotation>< / semantics>< / com:Math>; Ar<com:Sup>1< / com:Sup> and Ar<com:Sup>2< / com:Sup> are each independently selected from substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl, substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl; D is H, halo, cyano, hydroxy, amino, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heteroaryl, E is absent(direct bond), amino, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, mono- or bicyclic C<com:Sub>3-10< / com:Sub> heteroaryl, or D and E, together with the atoms to which they are attached, are combined to form substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring; G is absent(direct bond), H, halo, cyano, hydroxy, amino, nitro, ether(-O-), thioether(-S- ), sulfinyl(-SO-), sulfonyl(-SO<com:Sub>2< / com:Sub>-), sulfonylamido(-SO<com:Sub>2< / com:Sub>NR<com:Sup>4< / com:Sup>-), aminosulfonyl(-NR<com:Sup>4< / com:Sup>SO<com:Sub>2< / com:Sub>-), carbonyl(-(CO)-), amido(-(CO)NR<com:Sup>4< / com:Sup>-), reverse amido(-NR<com:Sup>4< / com:Sup>(CO)-), ester(-(CO)O-), substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> heterocycloalkyl, substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl; R<com:Sup>1< / com:Sup> is absent, H, halo, cyano, hydroxy, amino, N(R<com:Sup>5< / com:Sup>)<com:Sub>2< / com:Sub>, OR<com:Sup>5< / com:Sup>, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>1-5< / com:Sub> alkenylhydroxy, C<com:Sub>1-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>1-5< / com:Sub> alkenylamine, C<com:Sub>1-5< / com:Sub> alkynylamine, substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> heterocycloalkyl and substituted or unsubstituted mono- or bicyclic <com:Math><semantics>C5−10<annotation encoding="application / x-tex">C_{5-10}< / annotation>< / semantics>< / com:Math> heteroaryl; R<com:Sup>2< / com:Sup> is H, halo, cyano, hydroxy and C<com:Sub>1-3< / com:Sub> alkyl; R<com:Sup>3< / com:Sup> is H, halo, cyano, hydroxyl and amino; and R<com:Sup>4< / com:Sup> is H, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkoxy and substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid; and R<com:Sup>5< / com:Sup> is H, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkoxy and substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid; In a preferred embodiment, the Ar<com:Sup>1< / com:Sup> may be substituted or unsubstituted monocyclic C<com:Sub>5-7< / com:Sub> heteroaryl comprising one or more hetero atoms selected from the group consisting of N, O and S. More preferably, the <com:Math><semantics>Ar1<annotation encoding="application / x-tex">Ar^1< / annotation>< / semantics>< / com:Math> may be monocyclic <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> heteroaryl comprising one or two hetero atoms selected from the group consisting of N, O and S, which may be unsubstituted or substituted with <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl. Far more preferably, the <com:Math><semantics>Ar1<annotation encoding="application / x-tex">Ar^1< / annotation>< / semantics>< / com:Math> may be pyrazole or pyridine which may be unsubstituted or substituted with methyl. In a preferred embodiment, the <com:Math><semantics>Ar2<annotation encoding="application / x-tex">Ar^2< / annotation>< / semantics>< / com:Math> may be mono- or bicyclic <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl comprising one or more hetero atoms selected from the group consisting of N, O and S, which is unsubstituted or substituted with halo. More preferably, the Ar<com:Sup>2< / com:Sup> may be phenyl which may be unsubstituted or substituted with chloro. In a preferred embodiment, the D may be H or C<com:Sub>1-3< / com:Sub> alkyl. In a preferred embodiment, the E may absent(direct bond), amino, substituted or unsubstituted C<com:Sub>1-4< / com:Sub> alkyl, mono- or bicyclic C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-4< / com:Sub> alkylhydroxy, C<com:Sub>1-4< / com:Sub> alkenylhydroxy, C<com:Sub>1-4< / com:Sub> alkynylhydroxy, C<com:Sub>1-4< / com:Sub> alkylamine, C<com:Sub>1-4< / com:Sub> alkenylamine, C<com:Sub>1-4< / com:Sub> alkynylamine, mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl, mono- or bicyclic C<com:Sub>3-8< / com:Sub> heteroaryl, wherein the mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl and mono- or bicyclic C<com:Sub>3-8< / com:Sub> heteroaryl comprises one or more, preferably one or two heteroatoms selected from the group consisting of N, O and S. In a preferred embodiment, the D and E, together with the atoms to which they are attached, may be combined to form substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring one or more hetero atoms selected from the group consisting of N, O and S. More preferably, said mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring may be unsubstituted or substituted pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, or octahydropyranopyridine. In a preferred embodiment, G is absent(direct bond), H, halo, cyano, hydroxy, amino, nitro, ether(-O-), thioether(-S-), sulfinyl(-SO-), sulfonyl(-SO<com:Sub>2< / com:Sub>-), sulfonylamido(-SO<com:Sub>2< / com:Sub>NR<com:Sup>4< / com:Sup>-), aminosulfonyl(-NR<com:Sup>4< / com:Sup>SO<com:Sub>2< / com:Sub>-), carbonyl(-(CO)-), amido(-(CO)NR<com:Sup>4< / com:Sup>-), reverse amido(-NR<com:Sup>4< / com:Sup>(CO)-), ester(-(CO)O-), substituted or unsubstituted mono- or bicyclic C<com:Sub>3-8< / com:Sub> cycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl, wherein the mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl and mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl comprises one or more, preferably one or two heteroatoms selected from the group consisting of N, O and S. In a preferred embodiment, R<com:Sup>1< / com:Sup> is absent, H, halo, cyano, hydroxy, amino, N(R<com:Sup>5< / com:Sup>)<com:Sub>2< / com:Sub>, OR<com:Sup>5< / com:Sup>, substituted or unsubstituted C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-4< / com:Sub> alkylhydroxy, C<com:Sub>1-4< / com:Sub> alkenylhydroxy, C<com:Sub>1-4< / com:Sub> alkynylhydroxy, C<com:Sub>1-4< / com:Sub> alkylamine, C<com:Sub>1-4< / com:Sub> alkenylamine, C<com:Sub>1-4< / com:Sub> alkynylamine, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl and substituted or unsubstituted mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl, phosphate, substituted or unsubstituted C<com:Sub>1-3< / com:Sub> alkyl phosphate, wherein the mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl and mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl comprises one or more, preferably one or two heteroatoms selected from the group consisting of N, O and S. Further, in a more specific embodiment, the compound of the Formula I may be one selected from the group consisting of Compounds 1 to 276, as shown below: 1. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-1-ol 2. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 3. (S)-2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)amino)propan-1-ol 4. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-2-methylpropan-1-ol 5. 2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)amino)-2-methylpropan-1-ol 6. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)ethan-1-ol 7. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 8. (S)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-2-ol 9. (R)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-2-ol 10. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane-1,2-diol 11. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 12. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1-ol 13. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1- ol 14. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1- ol 15. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-1-ol 16. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane-1,3-diol 17. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1-phenylethan-1- ol 18. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1-phenylethan-1- ol 19. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-((tetrahydro-2H-pyran-4- yl)methyl)pyrimidin-4-amine 20. N<com:Sup>1< / com:Sup>-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N<com:Sup>3< / com:Sup>,N<com:Sup>3< / com:Sup>-dimethylpropane-1,3- diamine 21. 6-(4-chlorophenyl)-N-ethyl-2-(pyridin-3-yl)pyrimidin-4-amine 22. 6-(4-chlorophenyl)-N-propyl-2-(pyridin-3-yl)pyrimidin-4-amine 23. N-butyl-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 24. 1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 25. 6-(4-chlorophenyl)-N-(cyclopropylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 26. 6-(4-chlorophenyl)-N-cyclopentyl-2-(pyridin-3-yl)pyrimidin-4-amine 27. 4-(4-chlorophenyl)-6-(4-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 28. N-(tert-butyl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 29. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-ol 30. (1S,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-ol 31. 6-(4-chlorophenyl)-N-(pyridin-2-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 32. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine 33. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-4-ylmethyl)pyrimidin-4-amine 34. trans-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1-ol 35. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1-ol 36. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)methanol 37. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)ethan-1-ol 38. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-ol 39. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-ol 40. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 41. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-ol 42. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanol 43. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)ethan-1-ol 44. 3-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)propan-1-ol 45. 4-(4-chlorophenyl)-6-(4-methoxypiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 46. 4-(4-chlorophenyl)-6-(piperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 47. 4-(4-chlorophenyl)-6-(2-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 48. 4-(4-chlorophenyl)-6-(3-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 49. 4-(4-chlorophenyl)-6-(2,6-dimethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 50. 4-(4-chlorophenyl)-6-(3,5-dimethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 51. 4-(4-chlorophenyl)-6-(3,3-difluoropiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 52. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(3-(trifluoromethyl)piperidin-1-yl)pyrimidine 53. 4-(4-chlorophenyl)-6-(3-ethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 54. 6-(4-chlorophenyl)-N-(piperidin-4-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 55. 6-(4-chlorophenyl)-N-(piperidin-3-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 56. 6-(4-chlorophenyl)-N-(piperidin-4-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 57. 6-(4-chlorophenyl)-N-(1-methylpiperidin-4-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 58. 6-(4-chlorophenyl)-N-(2-(piperidin-4-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 59. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)methanamine 60. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-amine 61. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-amine 62. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanamine 63. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanamine 64. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-amine 65. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanamine 66. (1R,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-ol 67. (1S,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-ol 68. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan-1-ol 69. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1- ol 70. cis-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-2,6-dimethylmorpholine 71. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)morpholine 72. 6-(4-chlorophenyl)-N-(morpholin-2-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 73. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)morpholine 74. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)thiomorpholine 75. 6-(4-chlorophenyl)-N-(3-morpholinopropyl)-2-(pyridin-3-yl)pyrimidin-4-amine 76. (R)-4-(4-chlorophenyl)-6-(2-methylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 77. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3-methylpiperazin-1- yl)(phenyl)methanone 78. methyl (R)-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2- carboxylate 79. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-yl)methanol 80. 4-(4-chlorophenyl)-6-(4-(2,3-dichlorophenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 81. 4-(4-chlorophenyl)-6-(4-(2,5-dimethoxybenzyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 82. 2-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1-yl)ethan-1-ol 83. 4-(4-chlorophenyl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 84. 4-(4-chlorophenyl)-6-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 85. 4-(4-chlorophenyl)-6-(4-(2-fluorophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 86. (4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1-yl)(furan-2- yl)methanone 87. 4-(4-chlorophenyl)-6-(4-phenethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 88. 6-(4-chlorophenyl)-N-(2-(piperazin-1-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 89. 4-(4-chlorophenyl)-6-(4-(pyridin-2-yl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 90. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrimidine 91. 4-(2-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1- yl)ethyl)morpholine 92. 4-(4-chlorophenyl)-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(pyridin-3- yl)pyrimidine 93. trans-4-(4-chlorophenyl)-6-(4-cinnamylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 94. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-one 95. 4-(4-chlorophenyl)-6-(4-phenylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 96. 4-(4-chlorophenyl)-6-(4-propylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 97. 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-6-(4-chlorophenyl)-2-(pyridin- 3-y1)pyrimidine 98. (S)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-yl)methanol 99. 4-(4-chlorophenyl)-6-(4-(4-fluorophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 100. 6-(4-chlorophenyl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2-(pyridin-3- yl)pyrimidin-4-amine 101. 6-(4-chlorophenyl)-N-(piperidin-3-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 102. 4-(4-chlorophenyl)-6-(piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 103. Trans-4-(4-chlorophenyl)-6-(2,5-dimethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 104. Cis-4-(4-chlorophenyl)-6-(3,5-dimethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 105. 4-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 106. 4-(4-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 107. 4-(4-chlorophenyl)-6-(4-(methylsulfonyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 108. 1-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1-yl)ethan-1-one 109. 4-(4-chlorophenyl)-6-(3-ethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 110. ethyl 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-1- carboxylate 111. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2-carboxylic acid 112. methyl 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2- carboxylate 113. (S)-4-(4-chlorophenyl)-6-(2-phenylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 114. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(o-tolyl)piperazin-1-yl)pyrimidine 115. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(p-tolyl)piperazin-1-yl)pyrimidine 116. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(m-tolyl)piperazin-1-yl)pyrimidine 117. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(3-(trifluoromethyl)phenyl)piperazin-1- yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine 121. 4-(4-chlorophenyl)-6-(4-(4-nitrophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 122. 4-(4-chlorophenyl)-6-(3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine 123. 4-(4-benzhydrylpiperazin-1-yl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidine 124. 4-(4-chlorophenyl)-6-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine 125. 1'-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)spiro[indene-1,4'-piperidine] 126. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin-4-amine 127. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin-4-amine 128. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-ylmethyl)pyrimidin-4- amine 129. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrimidin-4-amine 130. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(3-(pyrrolidin-1-yl)propyl)pyrimidin-4- amine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine 132. N-(1-benzylpyrrolidin-3-yl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 133. (3R,4S)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)pyrrolidin-3- ol 134. (3S,4R)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)pyrrolidin-3- ol 135. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(pyrrolidin-1-yl)pyrimidine 136. 4-(4-chlorophenyl)-6-(2-methylpyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidine 137. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-ol 138. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)methanol 139. (R)-4-(4-chlorophenyl)-6-(3-fluoropyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidine 140. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-amine 141. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N-methylpyrrolidin-3-amine 142. methyl (6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)prolinate 143. N-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)acetamide 144. (2R,3R)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 145. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 146. 1-(4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)piperidin-1- yl)ethan-1-one 147. (R)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 148. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 149. 6-(4-chlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 150. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidine-4-carbonitrile 151. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-4-(3- (trifluoromethyl)phenyl)piperidin-4-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-ol [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] oxopropanoate [Image disponible dans le document PDF, Image available in the PDF document] yl)acetate [Image disponible dans le document PDF, Image available in the PDF document] 1-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] amine [Image disponible dans le document PDF, Image available in the PDF document] dimethylethan-1-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)acetate [Image disponible dans le document PDF, Image available in the PDF document] trifluoroacetate [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclopentan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)propan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] carbonitrile [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-3-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclopentan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)butan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclohexan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] c]pyridine [Image disponible dans le document PDF, Image available in the PDF document] c]pyridin-4-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)morpholine [Image disponible dans le document PDF, Image available in the PDF document] one [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] amine [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)pyrrolidine-2-carboxylate [Image disponible dans le document PDF, Image available in the PDF document] 2-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] isopropylpyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1-o1 [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclohexyl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] hydroxyethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] methoxyacetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1(2H)-yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] hydroxypropanamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxyacetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-yl acetate [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperazine-1-carboxylate [Image disponible dans le document PDF, Image available in the PDF document] yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)methanesulfonamide [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3,4-diol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] one [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)morpholin-3-one [Image disponible dans le document PDF, Image available in the PDF document] acid [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] morpholinophenyl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] acid [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] 316. (S)-1-(6-(4-chloro-2-hydroxyphenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- ol 317. (S)-3-(6-(3-hydroxypyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyridin-2-ol 318. (1-(6-(6-fluoropyridin-3-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanol 319. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azetidin-3-ol 320. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azetidin-3-yl)methanol 321. 4-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-6-(4-(methylsulfonyl)piperazin- 1-yl)pyrimidine 322. (S)-1-(6-(4-chlorophenyl)-2-(3-hydroxyphenyl)pyrimidin-4-yl)pyrrolidin-3-ol formate) 322. (S)-1-(6-(4-chlorophenyl)-2-(3-hydroxyphenyl)pyrimidin-4-yl)pyrrolidin-3-ol 323. (S)-1-(6-(4-chlorophenyl)-2-(5-fluoropyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-ol 324. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-4-yl)pyrimidin-4-yl)pyrrolidin-3-ol 325. 4-(4-chlorophenyl)-2-(5-fluoropyridin-3-yl)-6-(4-(methylsulfonyl)piperazin-1- yl)pyrimidine 326. 4-(4-chlorophenyl)-6-(4-(methylsulfonyl)piperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 327. (S)-1-(2-(5-fluoropyridin-3-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-4- yl)pyrrolidin-3-ol 328. 4-(4-chlorophenyl)-6-(4-(cyclopropylsulfonyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 329. (S)-1-(6-(4-chlorophenyl)-2-(pyridazin-4-yl)pyrimidin-4-yl)pyrrolidin-3-ol 330. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azepan-4-ol 331. 2-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-5-(methylsulfonyl)-2,5- diazabicyclo[2.2.1]heptane [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3,4-diol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] hydroxypropan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)piperazin-1-yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] 4-01 [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (dimethylamino)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)ethanol [Image disponible dans le document PDF, Image available in the PDF document] hydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)propan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] dihydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] dihydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)morpholin-3-one [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)propane-1,2-diol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)propane-1,2-diol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)morpholin-3-one [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol, and [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol. Single stereochemical isomers, enantiomers, diastereomers, and pharmaceutically acceptable salts of the above exemplified compounds are also within the scope of the present disclosure. Pharmaceutically acceptable salts may be, for example, derived from suitable inorganic and organic acids and bases. Acid addition salts can be prepared by reacting the purified compound in its free-based form, if possible, with a suitable organic or inorganic acid and isolating the salt thus formed. Examples of pharmaceutically acceptable acid addition salts include, without limitations, salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Base addition salts can be prepared by reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Such salts include, without limitations, alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and <com:Math><semantics>N+(C1−4alkyl)4<annotation encoding="application / x-tex">N^+(C_{1-4}alkyl)_4< / annotation>< / semantics>< / com:Math> salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate salts. In addition, the compounds represented by Formula I according to the present invention include, but are not limited thereto, not only pharmaceutically acceptable salts thereof, but also all solvates or hydrates and all possible stereoisomers that can be prepared therefrom. All stereoisomers of the present compounds (e.g., those which may exist due to asymmetric carbons on various substituents), including enantiomeric forms and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the present invention may, for example, be substantially free of other isomers (e.g., as a pure or substantially pure optical isomer having a specified activity), or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the compounds of the present invention may have the S or R configuration as defined by the IUPAC 1974 Recommendations. The racemic forms can be analyzed by physical methods, such as fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates by any suitable method, including without limitation, salt formation with an optically active acid followed by crystallization. The solvate and stereoisomer of the compound represented by Formula I may be prepared from the compound represented by Formula I using methods known in the art. Furthermore, the compounds represented by Formula I according to the present invention may be prepared either in a crystalline form or in a non-crystalline form, When the compound is prepared in a crystalline form, it may be optionally hydrated or solvated. In the present invention, the compound of Formula I may not only include a stoichiometric hydrate, but also include a compound containing various amounts of water. The solvate of the compound of Formula I according to the present invention includes both stoichiometric solvates and non- stoichiometric solvates. The compounds of the present inventionmay be synthesized by methods known in the art or by methods illustrated in Examples 1-376 below. Pharmaceutical compositions, Methods and Use In a specific embodiment, the pharmaceutical composition and the method provided herein comprises the compound of Formula (I). The subject may be a mammal including human or a mammalian cell; for example, a mammal (e.g., human) suffering from the disease, disorder, or condition associated with AhR activity as described above or a mammalian cell isolated therefrom. The compound as an active ingredient or the pharmaceutical composition may be administered orally or parenterally. For example, the parenteral administration may be performed by any one of intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration, and the like. The effective amount may refer to pharmaceutically and / or therapeutically effective amount, and may be prescribed depending on factors such as a type of preparation (formulation), administration route, the patient's age, body weight, gender, and / or pathologic conditions, and the like. A pharmaceutically acceptable salt of the compound of Formula (I) may include addition salts formed by inorganic acids such as hydrochloride, sulfate, phosphate, hydrobromide, hydroiodide, nitrate, pyrosulfate, or metaphosphate, addition salts formed by organic acids such as citrate, oxalate, benzoate, acetate, trifluoroacetate, propionate, succinate, fumarate, lactate, maleate, tartrate, glutarate, or sulfonate, or metal salts such as lithium salt, sodium salt, potassium salt, magnesium salt and calcium salt, but is not limited thereto. The pharmaceutical composition according to the present invention can be formulated into a suitable form together with a commonly used pharmaceutically acceptable carrier. The "pharmaceutically acceptable" refers to being physiologically acceptable, and not usually causing an allergic reaction or a similar reaction such as gastrointestinal disorders and dizziness when administered to humans. Further, the pharmaceutical composition of the present invention may be used after being formulated into an oral preparation, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, etc., and a parental preparation, such as epidermal formulations, suppositories, or sterile injection solutions, in accordance with a conventional method. Examples of carriers, excipients and diluents that can be included in the composition, may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, arabic gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. When formulated into a preparation, a diluting agent or an excipient, such as commonly-used fillers, stabilizing agents, binding agents, disintegrating agents, and surfactants can be used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations may be prepared by mixing the compound of the present invention with at least one excipient, for example, starch, microcrystalline cellulose, sucrose, lactose, low-substituted hydroxypropyl cellulose, hypromellose or the like. In addition to the simple excipient, a lubricant such as magnesium stearate and talc are also used. Liquid preparations for oral administration include a suspension, a liquid for internal use, an emulsion, a syrup, etc. In addition to a commonly used simple diluent such as water and liquid paraffin, various excipients such as a humectant, a sweetener, an aromatic, a preservative, etc. may also be contained. Formulations for parenteral administration include a sterilized aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized formulation and a suppository. The non-aqueous solution or suspension may contain propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethyl oleate, etc. As a base of the suppository, witepsol, macrogol, tween<com:Sup>TM< / com:Sup> 61, cocoa butter, laurin butter, glycerogelatin, etc. may be used. In order to formulate the formulation for parenteral administration, the compound of Formula I or a pharmaceutically acceptable salt thereof may be mixed in water together with sterilized and / or contain adjuvants such as preservatives, stabilizers, auxiliary agents such as wettable powder or emulsifying accelerators, salt for controlling osmotic pressure and / or buffers and the like, and other therapeutically useful substances, to prepare a solution or suspension, which is then manufactured in the form of an ampoule or vial unit administration. The pharmaceutical composition including the compound of Formula I disclosed herein as an active ingredient may be administered to mammals such as mice, livestock, and humans by various routes for the modulation of AhR activity, or the prevention or treatment of a disease, disorder, or condition associated with AhR activity. In some embodiment, the disease, disorder, or condition associated with AhR activity. may be a cancer, cancerous condition, tumor, fibrotic dieases, immune related disease or other disease related with AhR signaling. In some embodiment, the diseases related with dysregulated immune response associated with AhR signaling are selected from the group consisting of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, inflammatory skin disorders and inflammatory eye disorders, autoimmune diseases, such as rheumatoid diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). In some embodiment, the fibrotic disorders are selected from the group consisting of fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders. In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitroretinopathy and disorders of the connective tissue (for example sarcoidosis). In some embodiments of the cancer, cancerous condition, or tumor particularly suitable for treatment with an AHR antagonist of the present invention are liquid and solid tumours, such as a breast cancer, squamous cell cancer, lung cancer, a cancer of the peritoneum, a hepatocellular cancer, a gastric cancer, a pancreatic cancer, a glioblastoma, a cervical cancer, an ovarian cancer, a liver cancer, a bladder cancer, a hepatoma, a colon cancer, a colorectal cancer, an endometrial or uterine carcinoma, a salivary gland carcinoma, a kidney or renal cancer, a prostate cancer, a vulval cancer, a thyroid cancer, a head and neck cancer, a B-cell lymphoma, a chronic lymphocytic leukemia (CLL); an acute lymphoblastic leukemia (ALL), a Hairy cell leukemia, or a chronic myeloblastic leukemia. In some embodiments, the pharmaceutical composition of the preset invention can be used together with one or more additional anti-cancer therapies. In some such embodiments, the additional anti-cancer therapy comprises surgery, radiation therapy, biotherapy, immunotherapy, chemotherapy, or any combination thereof. In some embodiments, the pharmaceutical composition of the preset invention can be used together with anti-cancer therapeutic agents. In some such embodiments, the anti-cancer therapeutic agent is a chemotherapeutic agent, a growth inhibitor agent, an anti-angiogenesis agent, a cytotoxic agent, an anti-hormonal agent, a prodrug, or a cytokine. Examples of other disorders associated with aberrant AhR signaling inflammation are vaccination for infection & cancer, viral infections, obesity and diet-induced obesity, adiposity, metabolic disorders, hepatic steatosis and uterine fibroids (uterine leiomyoma or uterine myoma) in women, chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropaties, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer, and Creutzfeld-Jakob. Also provided herein, in other aspects, are pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), and pharmaceutically acceptable excipients. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in for modulating constitutive AhR activity in a subject in need thereof. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in treating a cancer or a cancerous condition by modulating AhR activity. In some aspects, pharmaceutical compositions comprising an AhR modulator, such as an AhR antagonist of Formula (I), are provided for use in inhibiting proliferation, tissue invasion, metastasis and angiogenesis of cancer cells in a subject having a cancer, a cancerous condition, or a tumor. In some embodiment, the pharmaceutical composition of the present invention may be for use in inhibiting proliferation, tissue invasion, metastasis and angiogenesis of cancer cells in a subject having a cancer, a cancerous condition, or a tumor. Pharmaceutical formulations described herein are administrable to a subject in a variety of by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, rectal, enfometrial or cerebrovascular injection), intranasal, buccal, topical or transdermal administration routes. In some embodiments, the compounds of Chemical Formula I are administered orally. Another aspect of the present invention relates to a method of stimulating the immune system in a patient in need thereof, e.g., in a patient suffering from cancer or an infection (e.g., a viral, bacterial, or parasitic infection). The method includes administering to the patient a therapeutically effective amount of one or a combination of the compounds described herein. In some embodiments, the patient has an increased count of white blood cells, T and / or B lymphocytes, macrophases, dendritic cells, neutrophils, natural killer (NK) cells, and / or platelets after the administering step. In some embodiments, the compound decreases IL-21 level in the patient. The patient may have cancer, or may be immune-compromised. "Treat", "treating" and "treatment" refer to a method of alleviating or abrogating a biological disorder and / or at least one of its attendant symptoms. As used herein, to "alleviate" a disease, disorder or condition means reducing the severity and / or occurrence frequency of the symptoms of the disease, disorder, or condition. Further, references herein to "treatment" include references to curative, palliative and prophylactic treatment. Treatment of cancer encompasses inhibiting cancer growth (including causing partial or complete cancer regression), inhibiting cancer progression or metastasis, preventing cancer recurrence or residual disease, and / or prolonging the patient's survival. "A therapeutically effective amount" is an amount of the medication that can achieve the desired curative, palliative, or prophylactic effect for the treated condition. In some embodiments, the effective dose range of a compound is determined by measuring the patient's blood concentration of the compound under a specified dosing regimen to establish a concentration-time profile, consulting with an established correlation between the concentration-time profiles and effects on cancer inhibition or eradication obtained during a trial, and balancing the therapeutic effects achievable with possible toxicity to the patient, with further consideration of the health condition or physical durability of the patient. The dosing frequency of the compound may be determined similarly. The dosing may be continued until the patiunlessent is free from the cancer. In some embodiments, an effective amount for tumor therapy may be measured by its ability to stabilize disease progression and / or ameliorate symptoms in a patient, and preferably to reverse disease progression, e.g., by reducing tumor size. In some embodiments, a maintenance dosing may be provided after the patient is free of cancer to ensure its complete elimination or eradication, or prevention of residual disease. The duration of the maintenance dosing can be determined based on clinical trial data. In some embodiments, a compound may be administered in combination with one or more other cancer therapeutic agents that also target AhR or target molecules other than AhR. Compounds can be formulated either separately from, or together with, the other cancer therapeutic agents. Compounds can be administered either at the same schedule as, or at a different schedule from, the other cancer therapeutic agents. The proportion of a compound relative to other cancer therapeutic agents may be determined by clinical trials. Combining the compounds with the other cancer therapeutic agents may further enhance the efficacy of one another. For example, a compound of the present invention can be administered with an immune checkpoint inhibitor, such as an inhibitor of PD-1, PD-L1 or PD-L2 (e.g., pembrolizumab, nivolumab, or atezolizumab), or administered with CAR-T therapy (e.g., axicabtagene ciloleucel), to achieve additive or synergistic anti-cancer effect. Dosage regimens may be adjusted to provide the optimum desired response. Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages for the patients / subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the embodied composition. Further, the dosage regimen with the compositions of this invention may be based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular antibody employed. Thus, the dosage regimen can vary widely, but can be determined routinely using standard methods. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical effects such as toxic effects and / or laboratory values. It is contemplated that a suitable dose of a compound of the present invention may be in the range of 0.001-200 mg / kg per day, and preferably from about 0.01 mg / kg to about 20 mg / kg body weight per day, such as about 0.5-50 mg / kg, e.g., about 1-20 mg / kg. The compound may for example be administered in a dosage of at least 0.25 mg / kg, e.g., at least 0.5 mg / kg, such as at least 1 mg / kg, e.g., at least 1.5 mg / kg, such as at least 2 mg / kg, e.g., at least 3 mg / kg, such as at least 4 mg / kg, e.g., at least 5 mg / kg; and e.g., up to at most 50 mg / kg, such as up to at the most 30 mg / kg, e.g., up to at the most 20 mg / kg, such as up to at the most 15 mg / kg. Administration will normally be repeated at suitable intervals, e.g., twice a day, thrice a day, once a day, once every week, once every two weeks, or once every three weeks, and for as long as deemed appropriate by the responsible doctor, who may optionally increase or decrease the dosage as necessary. General Synthetic Methods The compounds of Formlua (I) of the presnet invention can be prepared in accordance with one or more of schemes discussed below. These methods can be used either directly or with obvious variations to trained chemists to prepare key intermediates and certain compounds of this invention. Suitable synthetic sequences are readily selected per specific structures of this invention, but within the art known to individuals practicing organic synthesis, such as methods summarized in available chemistry data bases, as in CAS Scifinder and Elesevier Reaxys. Based on these general methods, the enablement for making the compounds of this invention is straightforward and can be practiced within a common professional knowledge. Some general synthetic methods to prepare the compounds of this invention are illustrated below in Schemes 1-5(general procedure A~E). One general approach to the compounds of this invention is illustrated in general Scheme 1. [Image disponible dans le document PDF, Image available in the PDF document] Scheme 1. General procedure A. a) 1. CH<com:Sub>3< / com:Sub>ONa, MeOH, 2. ammonia solution in MeOH; b) Diethyl malonate, CH<com:Sub>3< / com:Sub>ONa, MeOH; c) POCl<com:Sub>3< / com:Sub>; d) Ar<com:Sup>2< / com:Sup>-B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H<com:Sub>2< / com:Sub>O (4 / 1) heat, microwave; e) RNH2 or (R)2NH(primary or secondary amine), TEA, THF, heat; f) Hydrochloric acid in ethanol, Ammonium acetate 1M solution. * R¹s mean boc-deprotected forms of R moieties. Another general approach to the compounds of this invention is illustrated in general Scheme 2. [Image disponible dans le document PDF, Image available in the PDF document] Scheme 2. General procedure B. a) 1. HCl, MeOH, 2. ammonia solution in MeOH; b) NaH, THF, reflux; c) CH<com:Sub>3< / com:Sub>ONa, MeOH heat; d) POCl<com:Sub>3< / com:Sub>, heat; e) RNH<com:Sub>2< / com:Sub> or (R)<com:Sub>2< / com:Sub>NH(primary or secondary amine), TEA, THF, heat; f) Hydrochloric acid in ethanol, Ammonium acetate 1M solution. * R¹s mean boc-deprotected forms of R moieties. Another general approach to the compounds of this invention is illustrated in general Scheme 3. [Image disponible dans le document PDF, Image available in the PDF document] Scheme 3. General procedure C. a) Ar<com:Sup>2< / com:Sup>-B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H2O(4 / 1) heat, microwave; b) RNH<com:Sub>2< / com:Sub> or (R)<com:Sub>2< / com:Sub>NH(primary or secondary amine), TEA, THF, heat; c) Ar<com:Sup>1< / com:Sup>-B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H2O(4 / 1) heat, microwave; d) Hydrochloric acid in ethanol, Ammonium acetate 1M solution. * R¹s mean boc-deprotected forms of R moieties. Another general approach to the compounds of this invention is illustrated in general Scheme 4. [Image disponible dans le document PDF, Image available in the PDF document] Scheme 4. General procedure D. a) 1. CH<com:Sub>3< / com:Sub>ONa, MeOH, 2. ammonia solution in MeOH; b) Diethyl malonate, CH<com:Sub>3< / com:Sub>ONa, MeOH; c) POCl<com:Sub>3< / com:Sub>; d) RNH<com:Sub>2< / com:Sub> or (R)<com:Sub>2< / com:Sub>NH(primary or secondary amine), TEA, THF, heat; e) Ar<com:Sup>2< / com:Sup>- B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H<com:Sub>2< / com:Sub>O (4 / 1) heat, microwave; f) Hydrochloric acid in ethanol, Ammonium acetate 1M solution. * R¹s mean boc-deprotected forms of R moieties. Another general approach to the compounds of this invention is illustrated in general Scheme 5. [Image disponible dans le document PDF, Image available in the PDF document] Scheme 5. General procedure E. a) RNH<com:Sub>2< / com:Sub> or (R)<com:Sub>2< / com:Sub>NH(primary or secondary amine), TEA, THF, heat; b) Ar<com:Sup>2< / com:Sup>-B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H<com:Sub>2< / com:Sub>O (4 / 1) heat, microwave; c) Ar<com:Sup>1< / com:Sup>-B(OH)<com:Sub>2< / com:Sub> or its pinacol ester, Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, THF / H<com:Sub>2< / com:Sub>O (4 / 1) heat, microwave. * R¹s mean boc-deprotected forms of R moieties. [Mode for Invention] Examples Embodiments of the present invention are described in the following examples, which are meant to illustrate and not limit the scope of this invention. Common abbreviations well known to those with ordinary skills in the synthetic art used throughout. All chemical reagents were commercially available. Flash column chromatography means silica gel chromatography unless specified otherwise, which was performed on Teledyne Combiflash<com:Sup>TM< / com:Sup>-RF200 System. <com:Sup>1< / com:Sup>H NMR spectra (δ, ppm) are recorded on 400 MHz or 600 MHz instrument. Mass spectroscopy data for a positive ionization method are provided. Preparative HPLC was performed on Agilent technologies G1361A and Gilson Preparative HPLC System. Example 1. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan- 1-01 Scheme for the preparation of the Compound of Example 1: [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 1. Nicotinimidamide hydrochloride To a suspension of 3-Cyanopyridine (5 g, 48.03 mmol) in 50 mL of MeOH was added Sodium methoxide 30 wt % in MeOH (4 mL) and the mixture was stirred at room temperature for 24 hr. After adding NH<com:Sub>4< / com:Sub>C1 (16.5 g, 0.31 mol), the mixture was heated at reflux for 6 h and then cooled. The solvent was removed in vacuo and then EtOH (60 mL) was added and the mixture was heated to reflux for 30min. After the reaction mixture was cooled to room temperature, solids were filtered off and the filtrate was concentrated in vacuo. The suspension of reaction mixture in 3 mL of EtOH was filtered and the solid product was dried to afford 4.9 g of the title compound. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 9.43 (bs, 4H), 8.98 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.6 Hz, 1H), 8.74 <com:Math><semantics>(dd,J=4.8 Hz,J=1.2 Hz,1H),8.20−8.23 (m, 1H),7.64−7.67 (m, 1H);MS(ESI,m / z):122.1<annotation encoding="application / x-tex">(dd, J = 4.8 \text{ Hz}, J = 1.2 \text{ Hz}, 1\text{H}), 8.20-8.23 \text{ (m, 1H)}, 7.64-7.67 \text{ (m, 1H)}; MS (ESI, m / z): 122.1< / annotation>< / semantics>< / com:Math> <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Intermediate 2. 2-Pyridin-3-yl-pyrimidine-4,6-diol ; To a solution of 3-pyridyl amidine hydrochloride (4.8 g, 30.46 mmol) in MeOH (120 mL) was added diethyl malonate (4.63 mL, 30.46 mmol) followed by a solution of sodium methoxide 30 wt % in MeOH (20 mL) at 0 °C. The resulting mixture was stirred for 24 h at room temperature. The solvents were removed in vacuo. The resulting residue was used without further purification. MS (ESI, m / z): <com:Math><semantics>190.0[M+H]+<annotation encoding="application / x-tex">190.0 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Intermediate 3. 4,6-Dichloro-2-pyridin-3-yl-pyrimidine To a solution of 2-pyridin-3-yl-pyrimidine-4,6-diol (crude 5.0 g of previous step) in POCl<com:Sub>3< / com:Sub> (10 mL) was added dimethylamino aniline (4.77 g, 35.03 mmol) and the reaction mixture was heated at 120 °C for 4 h. The residue was cooled to room temperature, extracted with 500 mL of EtOAc and concentrated in vacuo. The crude product was purified by silicagel column chromatography to give 4.45 g of the title compound. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 7.36 (s, 1H), 7.49 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 4.8 Hz, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.6 Hz, 1H), 8.80-8.72 (m, 2H), 9.64 (br, 1H); MS (ESI, m / z): 226.0 [M+H]<com:Sup>+< / com:Sup> Intermediate 4. 4-chloro-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidine To a mixture of 4,6-Dichloro-2-pyridin-3-yl-pyrimidine (1.03 g, 4.6 mmol), (4- chlorophenyl)boronic acid (0.66 g, 4.2 mmol) and sodium carbonate (1.01 g, 9.5 mmol) in 50 mL of tetrahydrofuran / H<com:Sub>2< / com:Sub>O (4 / 1) was added Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub> (203 mg, 0.18 mmol). The mixture is heated under microwave at 80 °C for 20 minutes, cooled to room temperature and extracted three times with EtOAc (50 mL). The organic layer was dried over anhydrous MgSO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The crude product was purified by silicagel column chromatography to give 1.02 g of the title compound. [Image disponible dans le document PDF, Image available in the PDF document] 2H), 9.02 (d, 1H), 9.12 (d, 1H), 10.16 (s, 1H); MS (ESI, m / z): 302.0 [M+H]<com:Sup>+< / com:Sup> Example 1. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan- 1-ol To a solution of 4-chloro-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidine (45 mg, 0.15 mmol) in tetrahydrofuran (6 mL) was added triethylamine (0.3 mL, 2.15 mmol) followed by (R)- 2-aminobutan-1-ol (27 mg, 0.30 mmol) at room temperature. The reaction mixture in sealed tube was heated at 120 °C for 4 h. and cooled to room temperature. The residue was filtered, evaporated in vacuo and isolated by Preparative HPLC to give 50 mg of the title compound. [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.70 (d, 2H), 4.39 (br, 1H), 6.96 (s, 1H), 7.50 (d, 2H), 8.10-8.13 (m, 3H), 8.90 (d, 1H), 9.44 <com:Math><semantics>(d,1H),9.69(d,1H);MS(ESI,m / z):355.1[M+H]+<annotation encoding="application / x-tex">(d, 1H), 9.69 (d, 1H); MS (ESI, m / z): 355.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 2 and 3. (S)-2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2- yl)amino)propan-1-ol and (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)propan-1-ol Scheme for the preparation of the Compound of Example 2 and 3: [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 5. 2,4-dichloro-6-(4-chlorophenyl)pyrimidine To a solution of 2,4,6-trichloropyrimidine (813.5 mg, 4.43 mmol), (4- chlorophenyl)boronic acid (329.2 mg, 2.11 mmol) and sodium carbonate (314.6 mg, 2.97 mmol) in 20 mL of tetrahydrofuran / H<com:Sub>2< / com:Sub>O (4 / 1) was added Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub> (253.7 mg, 0.22 mmol). The mixture is heated to 80 °C for overnight, cooled to room temperature and extracted three times with EtOAc (150 mL) two times. The organic layer was washed with brine, dried over anhydrous MgSO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography(silica gel, hexane / ethyl acetate, gradient) to give 510.0 mg of the title compound. <com:Sup>1< / com:Sup>H NMR (600 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 7.52 (d, 2H), 7.67 (s, 1H), 8.05 (d, 2H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 258.0 [M+H]<com:Sup>+< / com:Sup> Intermediate 6 and 7. (S)-2-((2-chloro-6-(4-chlorophenyl)pyrimidin-4- yl)amino)propan-1-ol and (S)-2-((4-chloro-6-(4-chlorophenyl)pyrimidin-2- yl)amino)propan-1-ol To a solution of 2,4-dichloro-6-(4-chlorophenyl)pyrimidine (intermediate 5, 76.2 mg, 0.294 mmol) in tetrahydrofuran (6 mL) was added triethylamine (0.1 mL, 0.712 mmol) followed by (S)-2-aminopropan-1-ol (28.95 mg, 0.385 mmol) at room temperature. The reaction mixture was stirred at RT for overnight. The reaction mixture was filtered, evaporated in vacuo and isolated by flash chromatography(silica gel, hexane / ethyl acetate, gradient) to give 54.0 mg and 30.1 mg of the intermediate 6 and 7 respectively. intermediate 6 <com:Sup>1< / com:Sup>H NMR (600 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.28 (d, 3H), 3.61-3.65 (m, 1H), 3.78-3.81 (m, 1H), 4.15 (br, 1H), 5.48 (br, 1H), 6.59 (s, 1H), 7.41 (d, 2H), 7.86 (d, 2H); MS (ESI, m / z): 298.0 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> intermediate 7 <com:Sup>1< / com:Sup>H NMR (600 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.28 (d, 3H), 3.61-3.66 (m, 1H), 3.79-3.83 (m, 1H), 4.27 (br, 1H), 5.58 (br, 1H), 6.93 (s, 1H), 7.42 (d, 2H), 7.88 (d, 2H); MS (ESI, m / z): 298.0 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 2. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)propan-1-ol To a solution (S)-2-((2-chloro-6-(4-chlorophenyl)pyrimidin-4-yl)amino)propan-1-ol (60 mg, 0.201 mmol), 3-pyridylboronic acid (80 mg, 0.651 mmol), sodium carbonate (90 mg, 0.849 mmol) in 10 mL of tetrahydrofuran / H<com:Sub>2< / com:Sub>O (4 / 1) was added Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub> (80 mg, 0.069 mmol). The mixture is heated under microwave at 130 °C for 15 minutes, cooled to room temperature and extracted three times with EtOAc (30 mL). The organic layer was washed with brine, dried over anhydrous MgSO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography(silica gel, hexane / ethyl acetate, gradient) to give 32 mg of the title compound (Scheme 3. General procedure C.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.25 (d, 3H), 3.56-3.59 (m, 1H), 3.63-3.66 (m, 1H), 4.35 (br, 1H), 6.73 (s, 1H), 7.36 (d, 2H), 7.45-7.49 (m, 1H), 7.98 (d, 2H), 8.56 (br, 1H), 8.71 (d, 1H), 9.48 (br, 1H); MS (ESI, m / z): 341.1 [M+H]<com:Sup>+< / com:Sup> Example 3. (S)-2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2- yl)amino)propan-1-ol To a solution (S)-2-((4-chloro-6-(4-chlorophenyl)pyrimidin-2-yl)amino)propan-1-ol (25 mg, 0.084 mmol), 3-pyridylboronic acid (31 mg, 0.252 mmol), sodium carbonate (35 mg, 0.336 mmol) in 5 mL of tetrahydrofuran / H<com:Sub>2< / com:Sub>O (4 / 1) was added Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>4< / com:Sub> (34 mg, 0.029 mmol). The mixture is heated under microwave at 130 °C for 15 minutes, cooled to room temperature and extracted three times with EtOAc (30 mL). The organic layer was washed with brine, dried over anhydrous MgSO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel, hexane / ethyl acetate, gradient) to give 17.6 mg of the title compound (Scheme 3. General procedure C.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.34 (d, 3H), 3.64-3.66 (m, 1H), 3.73-3.76 (m, 1H), 4.33-4.36 (m, 1H), 7.49 (d, 2H), 7.57-7.59 (m, 1H), 7.60 (s, 1H), 8.17 (d, 2H), 8.58 (d, 1H), 8.67 (s, 1H), 9.34 (s, 1H); MS (ESI, m / z): <com:Math><semantics>341.1[M+H]+<annotation encoding="application / x-tex">341.1 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 4. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-2- methylpropan-1-ol Using 2-amino-2-methylpropan-1-ol, the title compound was obtained as described for the example 2 (Scheme 3. General procedure C.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.53 (s, 6H), 3.91 (s, 2H), 7.01 (s, 1H), 7.53 (d, 2H), 8.11 (d, 2H), 8.05-8.15 (m, 1H), 8.90 (br, 1H), 9.33 (d, 1H), 9.68 (br, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 5. 2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)amino)-2- methylpropan-1-ol Using 2-amino-2-methylpropan-1-ol, the title compound was obtained as described for the example 3 (Scheme 3. General procedure C.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.55 (s, 6H), 3.84 (s, 2H), 7.12 (d, 1H), 7.40 (s, 1H), 7.44-7.48 (m, 1H), 7.54 (d, 2H), 7.98 (d, 2H), 8.03 (d, 1H), 8.82 (br, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 6. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)ethan-1-ol Using 2-aminoethan-1-ol, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.80 (t, 2H), 4.10 (t, 2H), 6.84 (s, 1H), 7.45 (d, 2H), 7.50-7.52 (m, 1H), 8.07 (d, 2H), 8.59 (d, 1H), 8.79 (d, 1H), 9.52 (s, 1H); MS (ESI, m / z): Example 7. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1- ol Using 3-aminopropan-1-ol, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 6.89 (s, 1H), 7.82 (d, 2H), 7.56-7.58 (m, 1H), 8.15 (d, 2H), 8.63 (d, 1H), 8.87 (d, 1H), 9.58 (s, 1H); MS (ESI, m / z): 341.1 [M+H]<com:Sup>+< / com:Sup> Example 8. (S)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)propan-2-ol Using (S)-1-aminopropan-2-ol, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.15 (m, 1H), 5.63 (br, 1H), 6.65 (s, 1H), 7.43 (d, 2H), 7.39-7.45 (m, 1H), 8.00 (d, 2H), 8.66 (br, 1H), 8.72 (d, 1H), 9.64 (br, 1H); MS (ESI, m / z): 341.1 [M+H]<com:Sup>+< / com:Sup> Example 9. (R)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)propan-2-ol Using (R)-1-aminopropan-2-ol, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.31 (d, 3H), 3.41 (br, 1H), 3.70 (br, 1H), 4.12- 4.15 (m, 1H), 5.63 (br, 1H), 6.65 (s, 1H), 7.43 (d, 2H), 7.39-7.45 (m, 1H), 8.00 (d, 2H), 8.66 (br, 1H), 8.72 (d, 1H), 9.64 (br, 1H); MS (ESI, m / z): 341.1 [M+H]<com:Sup>+< / com:Sup> Example 10. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane- 1,2-diol Using 3-aminopropane-1,2-diol, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). MS (ESI, m / z): <com:Math><semantics>357.1[M+H]+<annotation encoding="application / x-tex">357.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 11. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)propan-1-ol Using (R)-2-aminopropan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.) <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.31 (d, 3H), 3.61-3.64 (m, 1H), 3.67-3.70 (m, 1H), 4.50 (br, 1H), 6.95 (s, 1H), 7.52 (d, 2H), 8.01-8.19 (m, 1H), 8.12 (d, 2H), 8.85 (br, 1H), 9.38 (d, 1H), 9.71 (br, 1H); MS (ESI, m / z): 341.1 [M+H]<com:Sup>+< / com:Sup> Example 12. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3- methylbutan-1-ol Using 2-amino-3-methylbutan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.06 (d, 3H), 1.09 (d, 3H), 2.10 (br, 1H), 3.73- 3.76 (m, 1H), 3.80-3.83 (m, 1H), 4.41 (br, 1H), 7.02 (s, 1H), 7.54 (d, 2H), 8.06 (br, 1H), 8.14 (d, 2H), 8.88 (br, 1H), 9.38 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 369.2 [M+H]<com:Sup>+< / com:Sup> Example 13. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3- methylbutan-1-ol Using (S)-2-amino-3-methylbutan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.06 (d, 3H), 1.09 (d, 3H), 2.10 (br, 1H), 3.73- 3.76 (m, 1H), 3.80-3.83 (m, 1H), 4.41 (br, 1H), 7.02 (s, 1H), 7.54 (d, 2H), 8.06 (br, 1H), 8.14 (d, 2H), 8.88 (br, 1H), 9.38 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 369.2 [M+H]<com:Sup>+< / com:Sup> Example 14. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3- methylbutan-1-ol Using (R)-2-amino-3-methylbutan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.06 (d, 3H), 1.09 (d, 3H), 2.10 (br, 1H), 3.73- 3.76 (m, 1H), 3.80-3.83 (m, 1H), 4.41 (br, 1H), 7.02 (s, 1H), 7.54 (d, 2H), 8.06 (br, 1H), 8.14 (d, 2H), 8.88 (br, 1H), 9.38 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 369.2 [M+H]<com:Sup>+< / com:Sup> Example 15. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-1- ol Using 2-aminobutan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.70 (d, 2H), 4.39 (br, 1H), 6.96 (s, 1H), 7.50 (d, 2H), 8.10-8.13 (m, 3H), 8.90 (d, 1H), 9.44 (d, 1H), 9.69 (d, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 16. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane- 1,3-diol Using 2-aminopropane-1,3-diol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.81 (d, 4H), 4.54 (br, 1H), 7.02 (s, 1H), 7.51 (d, 2H), 8.06 (br, 1H), 8.13 (d, 2H), 8.87 (br, 1H), 9.43 (d, 1H), 9.70 (br, 1H); MS (ESI, m / z): 357.1 [M+H]<com:Sup>+< / com:Sup> Example 17. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1- phenylethan-1-ol Using (R)-2-amino-1-phenylethan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.77 (br, 1H), 3.91 (br, 1H), 4.95 (br, 1H), 6.95 (s, 1H), 7.25 (t, 1H), 7.35 (t, 2H), 7.47 (d, 2H), 7.53 (d, 2H), 8.00 (br, 1H), 8.13 (d, 2H), 8.86 (br, 1H), 9.28 (d, 1H), 9.68 (br, 1H); MS (ESI, m / z): 403.1 [M+H]<com:Sup>+< / com:Sup> Example 18. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1- phenylethan-1-ol Using (S)-2-amino-1-phenylethan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.77 (br, 1H), 3.91 (br, 1H), 4.95 (br, 1H), 6.95 (s, 1H), 7.25 (t, 1H), 7.35 (t, 2H), 7.47 (d, 2H), 7.53 (d, 2H), 8.00 (br, 1H), 8.13 (d, 2H), 8.86 (br, 1H), 9.28 (d, 1H), 9.68 (br, 1H); MS (ESI, m / z): 403.1 [M+H]<com:Sup>+< / com:Sup> Example 19. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-((tetrahydro-2H-pyran-4- yl)methyl)pyrimidin-4-amine Using (tetrahydro-2H-pyran-4-yl)methanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.44 (t, 2H), 3.54 (br, 2H), 3.98 (d, 2H), 6.95 (s, 1H), 7.54 (d, 2H), 8.06 (br, 1H), 8.14 (d, 2H), 8.87 (br, 1H), 9.36 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 20. N<com:Sup>1< / com:Sup>-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N<com:Sup>3< / com:Sup>,N<com:Sup>3< / com:Sup>- dimethylpropane-1,3-diamine Using N<com:Sup>1< / com:Sup>,N<com:Sup>1< / com:Sup>-dimethylpropane-1,3-diamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.23-3.26 (m, 1H), 3.74 (br, 2H), 7.02 (s, 1H), 7.56 (d, 2H), 8.08 (br, 1H), 8.19 (d, 2H), 8.90 (br, 1H), 9.44 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): 368.2 [M+H]<com:Sup>+< / com:Sup> Example 21. 6-(4-chlorophenyl)-N-ethyl-2-(pyridin-3-yl)pyrimidin-4-amine Using ethanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (d, 2H), 7.97 (br, 1H), 8.14 (d, 2H), 8.85 (br, 1H), 9.27 (d, 1H), 9.71 (br, 1H); MS (ESI, m / z): 311.1 [M+H]<com:Sup>+< / com:Sup> Example 22. 6-(4-chlorophenyl)-N-propyl-2-(pyridin-3-yl)pyrimidin-4-amine Using propan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.05 (t, 3H), 1.74 (q, 2H), 3.56 (br, 2H), 6.93 (s, 1H), 7.53 (d, 2H), 8.01 (br, 1H), 8.13 (d, 2H), 8.84 (br, 1H), 9.32 (d, 1H), 9.69 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 325.1 [M+H]<com:Sup>+< / com:Sup> Example 23. N-butyl-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine Using butan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.01 (t, 3H), 1.45-1.54 (m, 2H), 1.66-1.73 (m, 2H), 3.58 (br, 2H), 6.89 (s, 1H), 7.52 (d, 2H), 7.90 (br, 1H), 8.12 (d, 2H), 8.84 (br, 1H), 9.18 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 339.1 [M+H]<com:Sup>+< / com:Sup> Example 24. 1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2- ol Using 1-aminobutan-2-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.01 (t, 3H), 1.45-1.54 (m, 2H), 1.66-1.73 (m, 2H), 3.58 (br, 2H), 6.89 (s, 1H), 7.52 (d, 2H), 7.90 (br, 1H), 8.12 (d, 2H), 8.84 (br, 1H), 9.18 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 25. 6-(4-chlorophenyl)-N-(cyclopropylmethyl)-2-(pyridin-3-yl)pyrimidin- 4-amine Using cyclopropylmethanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 0.32-0.36 (m, 2H), 0.57-0.61 (m, 2H), 1.14- 1.26 (m, 1H), 3.46 (br, 2H), 6.93 (s, 1H), 7.53 (d, 2H), 8.05 (br, 1H), 8.13 (d, 2H), 8.97 (br, 1H), 9.29 (d, 1H), 9.82 (br, 1H); MS (ESI, m / z): 337.1 [M+H]<com:Sup>+< / com:Sup> Example 26. 6-(4-chlorophenyl)-N-cyclopentyl-2-(pyridin-3-yl)pyrimidin-4-amine Using cyclopentanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.89 (m, 2H), 2.12-2.20 (m, 2H), 4.59 (br, 1H), 6.93 (s, 1H), 7.54 (d, 2H), 8.08 (br, 1H), 8.13 (d, 2H), 8.89 (br, 1H), 9.38 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 351.1 [M+H]<com:Sup>+< / com:Sup> Example 27. 4-(4-chlorophenyl)-6-(4-methylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 4-methylpiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.02 (d, 3H), 1.18-1.31 (m, 2H), 1.74-1.92 (m, 3H), 3.09 (t, 2H), 3.33-3.38 (m, 2H), 7.23 (s, 1H), 7.53 (d, 2H), 8.09 (br, 1H), 8.20 (d, 2H), 8.94 (br, 1H), 9.38 (d, 1H), 9.76 (br, 1H); MS (ESI, m / z): 365.2 [M+H]<com:Sup>+< / com:Sup> Example 28. N-(tert-butyl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine Using 2-methylpropan-2-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 4.64 (s, 9H), 7.63 (d, 2H), 7.66 (br, 1H), 8.10 (s, 1H), 8.36 (d, 2H), 8.75 (br, 1H), 8.94 (d, 1H), 9.67 (br, 1H); MS (ESI, m / z): 339.1 [M+H]<com:Sup>+< / com:Sup> Example 29. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1R,2R)-2-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.07 (m, 1H), 2.27-2.35 (m, 1H), 4.16 (br, 1H), 4.44 (br, 1H), 6.97 (s, 1H), 7.53 (d, 2H), 8.07 (br, 1H), 8.14 (d, 2H), 8.88 (br, 1H), 9.45 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 30. (1S,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1S,2R)-2-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.07 (m, 1H), 2.13 (br, 1H), 4.37 (br, 1H), 4.49 (br, 1H), 7.04 (s, 1H), 7.53 (d, 2H), 7.70 (br, 3H), 8.86 (br, 1H), 9.35 (d, 1H), 9.67 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 31. 6-(4-chlorophenyl)-N-(pyridin-2-ylmethyl)-2-(pyridin-3-yl)pyrimidin- 4-amine Using pyridin-2-ylmethanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 5.16 (s, 2H), 7.24 (s, 1H), 7.54 (d, 2H), 7.88 (t, 1H), 8.07-8.11 (m, 2H), 8.20 (d, 2H), 8.49 (t, 1H), 8.76 (d, 1H), 8.88 (d, 1H), 9.32 (d, 1H), 9.57 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 374.1 [M+H]<com:Sup>+< / com:Sup> Example 32. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-3-ylmethyl)pyrimidin- 4-amine Using pyridin-3-ylmethanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 5.04 (s, 2H), 7.15 (s, 1H), 7.53 (d, 2H), 8.06 (br, 1H), 8.14 (br, 1H), 8.19 (d, 2H), 8.67 (d, 1H), 8.79 (br, 1H), 8.97 (br, 2H), 9.43 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): <com:Math><semantics>374.1[M+H]+<annotation encoding="application / x-tex">374.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 33. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-4-ylmethyl)pyrimidin- 4-amine Using pyridin-4-ylmethanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 5.12 (s, 2H), 7.23 (s, 1H), 7.55 (d, 2H), 8.09 (br, 1H), 8.13 (d, 2H), 8.21 (d, 2H), 8.79 (d, 2H), 8.88 (br, 1H), 9.34 (d, 1H), 9.59 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 374.1 [M+H]<com:Sup>+< / com:Sup> Example 34. trans-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexan-1-ol Using trans-4-aminocyclohexan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.39-1.46 (m, 2H), 1.48-1.54 (m, 2H), 2.02- 2.07 (m, 2H), 2.14-2.19 (m, 2H), 3.62-3.67 (m, 1H), 4.14 (br, 1H), 6.90 (s, 1H), 7.53 (d, 2H), 7.99 (br, 1H), 8.13 (d, 2H), 8.83 (br, 1H), 9.28 (d, 1H), 9.66 (br, 1H); MS (ESI, m / z): 381.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 35. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexan-1-ol Using trans-2-aminocyclohexan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.16 (m, 2H), 3.55 (br, 1H), 4.19 (br, 1H), 6.95 (s, 1H), 7.53 (d, 2H), 8.08 (br, 1H), 8.12 (d, 2H), 8.89 (br, 1H), 9.37 (d, 1H), 9.67 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 36. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2- yl)methanol Using piperidin-2-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.92 (m, 1H), 1.98-2.05 (m, 1H), 3.11-3.21 (m, 1H), 3.79-3.91 (m, 2H), 4.21-4.40 (m, 1H), 4.70 (br, 1H), 7.26 (s, 1H), 7.53 (d, 2H), 8.12 (br, 1H), 8.19 (d, 2H), 8.92 (br, 1H), 9.45 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): <com:Math><semantics>381.1[M+H]+<annotation encoding="application / x-tex">381.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 37. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2- yl)ethan-1-ol Using 2-(piperidin-2-yl)ethan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.76 (m, 1H), 1.78-1.90 (m, 4H), 1.90-1.97 (m, 1H), 2.07-2.16 (m, 1H), 3.10-3.20 (m, 1H), 3.57- 3.69 (m, 2H), 7.31 (s, 1H), 7.54 (d, 2H), 8.03 (br, 1H), 8.20 (d, 2H), 8.87 (br, 1H), 9.37 (d, 1H), 9.71 (br, 1H); MS (ESI, m / z): 395.2 [M+H]<com:Sup>+< / com:Sup> Example 38. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- ol Using (R)-piperidin-3-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.09 (m, 1H), 4.47 (dd, 1H), 3.63 (br, 1H), 3.77-3.82 (m, 1H), 4.04 (br, 1H), 4.29 (br, 1H), 7.21 (s, 1H), 7.50 (d, 2H), 8.13 (br, 1H), 8.17 (d, 2H), 8.95 (br, 1H), 9.43 (d, 1H), 9.73 (br, 1H); MS <com:Math><semantics>(ESI,m / z):367.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 367.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 39. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-ol Using piperidin-3-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.09 (m, 1H), 4.47 (dd, 1H), 3.63 (br, 1H), 3.77-3.82 (m, 1H), 4.04 (br, 1H), 4.29 (br, 1H), 7.21 (s, 1H), 7.50 (d, 2H), 8.13 (br, 1H), 8.17 (d, 2H), 8.95 (br, 1H), 9.43 (d, 1H), 9.73 (br, 1H); MS <com:Math><semantics>(ESI,m / z):367.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 367.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 40. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanol Using piperidin-3-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.35-1.46 (m, 1H), 1.56-1.68 (m, 1H), 1.78- 1.95 (m, 4H), 3.02 (dd, 1H), 3.23 (dd, 1H), 3.63 (br, 1H), 3.38-3.46 (m, 1H), 3.47-3.61 (m, 2H), 7.24 (s, 1H), 7.52 (d, 2H), 8.10 (dd, 1H), 8.19 (d, 2H), 8.89 (br, 1H), 9.45 (d, 1H), 9.71 (br, 1H); <com:Math><semantics>MS(ESI,m / z):381.1[M+H]+<annotation encoding="application / x-tex">MS (ESI, m / z): 381.1 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 41. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-ol Using piperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.53 (m, 2H), 3.93-3.99 (m, 2H), 4.36 (br, 2H), 7.23 (s, 1H), 7.50 (d, 2H), 8.10 (br, 1H), 8.18 (d, 2H), 8.89 (br, 1H), 9.43 (d, 1H), 9.70 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 42. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)methanol Using piperidin-4-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.24-1.34 (m, 2H), 1.82-1.94 (m, 3H), 3.08 (t, 2H), 3.47 (d, 2H), 4.77 (br, 2H), 7.21 (s, 1H), 7.50 (d, 2H), 8.11 (br, 1H), 8.17 (d, 2H), 8.90 (br, 1H), 9.43 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 43. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)ethan-1-ol Using 2-(piperidin-4-yl)ethan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.22-1.32 (m, 2H), 1.51-1.56 (m, 2H), 1.81- 1.93 (m, 3H), 3.07 (t, 2H), 3.67 (t, 2H), 4.72 (br, 2H), 7.20 (s, 1H), 7.51 (d, 2H), 8.10 (br, 1H), 8.17 (d, 2H), 8.89 (br, 1H), 9.41 (d, 1H), 9.68 (br, 1H); MS (ESI, m / z): 395.2 [M+H]<com:Sup>+< / com:Sup> Example 44. 3-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)propan-1-ol Using 3-(piperidin-4-yl)propan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.18-1.29 (m, 2H), 1.34-1.39 (m, 2H), 1.58- 1.73 (m, 3H), 1.93 (d, 2H), 3.07 (t, 2H), 3.57 (t, 2H), 4.75 (br, 2H), 7.22 (s, 1H), 7.52 (d, 2H), 8.11 (br, 1H), 8.18 (d, 2H), 8.90 (br, 1H), 9.42 (d, 1H), 9.70 (br, 1H); MS (ESI, m / z): 409.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 45. 4-(4-chlorophenyl)-6-(4-methoxypiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 4-methoxypiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.60-1.68 (m, 2H), 1.98-2.05 (m, 2H), 3.42 (s, 3H), 3.57-3.65 (m, 3H), 4.21 (br, 2H), 7.22 (s, 1H), 7.50 (d, 2H), 8.09 (br, 1H), 8.18 (d, 2H), 8.89 (br, 1H), 9.41 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 46. 4-(4-chlorophenyl)-6-(piperidin-1-yl)-2-(pyridin-3-yl)pyrimidine Using piperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.71 (br, 4H), 1.78 (br, 2H), 3.90 (br, 4H), 7.21 (s, 1H), 7.53 (d, 2H), 8.03 (br, 1H), 8.19 (d, 2H), 8.88 (br, 1H), 9.33 (d, 1H), 9.69 (br, 1H); MS <com:Math><semantics>(ESI,m / z):351.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 351.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 47. 4-(4-chlorophenyl)-6-(2-methylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 2-methylpiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 5H), 3.14-3.21 (m, 1H), 4.60 (br, 1H), 5.06 (br, 1H), 7.20 (s, 1H), 7.53 (d, 2H), 8.13 (br, 1H), 8.19 (d, 2H), 8.96 (br, 1H), 9.39 (d, 1H), 9.75 (br, 1H); MS (ESI, m / z): 365.2 [M+H]<com:Sup>+< / com:Sup> Example 48. 4-(4-chlorophenyl)-6-(3-methylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 3-methylpiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.04 (d, 3H), 1.28-1.35 (m, 1H), 1.56-1.76 (m, 2H), 1.83-1.96 (m, 2H), 2.81 (dd, 1H), 3.12 (dd, 1H), 4.59 (br, 2H), 7.23 (s, 1H), 7.53 (d, 2H), 8.11 (br, 1H), 8.19 (d, 2H), 8.91 (br, 1H), 9.42 (d, 1H), 9.70 (br, 1H), 9.75 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 365.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 49. 4-(4-chlorophenyl)-6-(2,6-dimethylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 2,6-dimethylpiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Math><semantics>MS<annotation encoding="application / x-tex">MS< / annotation>< / semantics>< / com:Math> (ESI, m / z): 379.2 [M+H]<com:Sup>+< / com:Sup> Example 50. 4-(4-chlorophenyl)-6-(3,5-dimethylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 3,5-dimethylpiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.91 (d, 1H), 2.51 (t, 2H), 4.68 (br, 1H), 7.21 (s, 1H), 7.51 (d, 2H), 8.11 (br, 1H), 8.18 (d, 2H), 8.94 (br, 1H), 9.39 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): 379.2 [M+H]<com:Sup>+< / com:Sup> Example 51. 4-(4-chlorophenyl)-6-(3,3-difluoropiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 3,3-difluoropiperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.87-1.93 (m, 2H), 2.14-2.24 (m, 2H), 3.92 (br, 2H), 4.23 (t, 2H), 7.32 (s, 1H), 7.51 (d, 2H), 8.06 (br, 1H), 8.23 (d, 2H), 8.87 (br, 1H), 9.40 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 387.1 [M+H]<com:Sup>+< / com:Sup> Example 52. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(3-(trifluoromethyl)piperidin-1- yl)pyrimidine Using 3-(trifluoromethyl)piperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.59-1.82 (m, 2H), 1.94-1.97 (m, 1H), 2.12- 2.15 (m, 1H), 2.44-2.56 (m, 1H), 3.19-3.27 (m, 2H), 4.48 (br, 1H), 4.95 (br, 1H), 7.28 (s, 1H), 7.52 (d, 2H), 8.07 (br, 1H), 8.23 (d, 2H), 8.88 (br, 1H), 9.37 (d, 1H), 9.70 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 419.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 53. 4-(4-chlorophenyl)-6-(3-ethylpiperidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 3-(trifluoromethyl)piperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). MS (ESI, m / z): <com:Math><semantics>379.2[M+H]+<annotation encoding="application / x-tex">379.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 54. 6-(4-chlorophenyl)-N-(piperidin-4-yl)-2-(pyridin-3-yl)pyrimidin-4- amine To a solution of 4-chloro-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidine (15 mg, 0.05 mmol) in tetrahydrofuran (2 mL) was added triethylamine (0.06 mL, 0.43 mmol) followed by tert-butyl 4-aminopiperidine-1-carboxylate (20 mg, 0.10 mmol) at room temperature. The reaction mixture in sealed tube was heated at 120 °C for 4 h. and cooled to room temperature. The residue was filtered, evaporated in vacuo. To a solution of the reaction mixture in ethanol(1) mL) was added 1M hydrochloric acid ethanol solution (2 mL). The reaction mixture was stirred at 50 °C for overnight, evaporated in vacuo and quenched with 1M ammonium acetate methanol solution (2mL). The residue was filtered and purified by Preparative HPLC to give 7.6 mg of the title compound (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.52 (d, 2H), 4.47 (br, 1H), 7.00 (s, 1H), 7.54 (d, 2H), 8.07 (br, 1H), 8.16 (d, 2H), 8.88 (br, 1H), 9.43 (d, 1H), 9.76 (br, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 55. 6-(4-chlorophenyl)-N-(piperidin-3-ylmethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 3-(aminomethyl)piperidine-1-carboxylate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 2.26 (br, 1H), 2.83 (t, 1H), 2.94 (t, 1H), 3.37 (d, 1H), 3.50 (d, 1H), 3.62 (br, 2H), 6.99 (s, 1H), 7.53 (d, 2H), 8.06 (br, 1H), 8.16 (d, 2H), 8.88 (br, 1H), 9.41 (d, 1H), 9.75 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 56. 6-(4-chlorophenyl)-N-(piperidin-4-ylmethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 4-(aminomethyl)piperidine-1-carboxylate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4H), 2.91 (d, 2H), 2.98-3.14 (m, 2H), 3.45 (d, 1H), 7.26 (s, 1H), 7.52 (d, 2H), 8.10 (br, 1H), 8.21 (d, 2H), 8.89 (br, 1H), 9.42 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 57. 6-(4-chlorophenyl)-N-(1-methylpiperidin-4-yl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 1-methylpiperidin-4-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3H), 3.10-3.24 (m, 2H), 3.42-3.54 (m, 2H), 3.63 (br, 1H), 6.97 (s, 1H), 7.53 (d, 2H), 8.06 (br, 1H), 8.15 (d, 2H), 8.88 (br, 1H), 9.42 (d, 1H), 9.75 (br, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 58. 6-(4-chlorophenyl)-N-(2-(piperidin-4-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 2.98 (t, 2H), 3.40 (d, 2H), 3.68 (br, 2H), 6.94 (s, 1H), 7.54 (d, 2H), 8.00 (br, 1H), 8.14 (d, 2H), 8.86 (br, 1H), 9.32 (d, 1H), 9.69 (br, 1H); MS (ESI, m / z): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 59. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2- yl)methanamine Using tert-butyl (piperidin-2-ylmethyl)carbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.63 (br, 2H), 1.76-1.91 (m, 5H), 3.24-3.33 (m, 2H), 3.61 (t, 2H), 4.47 (br, 1H), 5.50 (br, 1H), 7.37 (s, 1H), 7.55 (d, 2H), 8.07 (br, 1H), 8.27 (d, 2H), 8.89 (br, 1H), 9.47 (d, 1H), 9.81 (br, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 60. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- amine Using tert-butyl (R)-piperidin-3-ylcarbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.26 (m, 1H), 3.40-3.46 (m, 1H), 3.51-3.57 (m, 1H), 3.62-3.67 (m, 1H), 4.18 (d, 1H), 4.71 (d, 1H), 7.33 (s, 1H), 7.51 (d, 2H), 8.05 (br, 1H), 8.25 (d, 2H), 8.89 (br, 1H), 9.42 (d, 1H), 9.80 (br, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 61. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- amine Using tert-butyl (S)-piperidin-3-ylcarbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.72-1.88 (m, 2H), 1.93-1.99 (m, 1H), 2.19- 2.26 (m, 1H), 3.40-3.46 (m, 1H), 3.51-3.57 (m, 1H), 3.62-3.67 (m, 1H), 4.18 (d, 1H), 4.71 (d, 1H), 7.33 (s, 1H), 7.51 (d, 2H), 8.05 (br, 1H), 8.25 (d, 2H), 8.89 (br, 1H), 9.42 (d, 1H), 9.80 (br, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 62. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanamine Using tert-butyl (piperidin-3-ylmethyl)carbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.44-1.53 (m, 1H), 1.61-1.71 (m, 1H), 1.91- 2.07 (m, 3H), 2.92-3.09 (m, 3H), 3.15-3.24 (m, 1H), 4.57 (br, 1H), 4.77 (br, 1H), 7.30 (s, 1H), 7.53 (d, 2H), 8.09 (br, 1H), 8.23 (d, 2H), 8.90 (br, 1H), 9.46 (d, 1H), 9.79 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 63. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanamine Using tert-butyl (R)-(piperidin-3-ylmethyl)carbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.44-1.53 (m, 1H), 1.61-1.71 (m, 1H), 1.91- 2.07 (m, 3H), 2.92-3.09 (m, 3H), 3.15-3.24 (m, 1H), 4.57 (br, 1H), 4.77 (br, 1H), 7.30 (s, 1H), 7.53 (d, 2H), 8.09 (br, 1H), 8.23 (d, 2H), 8.90 (br, 1H), 9.46 (d, 1H), 9.79 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 64. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- amine Using tert-butyl piperidin-4-ylcarbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.47-3.56 (m, 1H), 4.83-4.94 (m, 2H), 7.33 (s, 1H), 7.54 (d, 2H), 7.98 (br, 1H), 8.25 (d, 2H), 8.84 (br, 1H), 9.32 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 65. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)methanamine Using tert-butyl (piperidin-4-ylmethyl)carbamate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 2.91 (d, 2H), 3.13 (t, 2H), 4.81-4.95 (m, 2H), 7.29 (s, 1H), 7.54 (d, 2H), 8.00 (br, 1H), 8.23 (d, 2H), 8.85 (br, 1H), 9.34 (d, 1H), 9.71 (br, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 66. (1R,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1R,2S)-2-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.07 (m, 1H), 2.27-2.35 (m, 1H), 4.16 (br, 1H), 4.43 (br, 1H), 6.96 (s, 1H), 7.53 (d, 2H), 8.02 (br, 1H), 8.14 (d, 2H), 8.86 (br, 1H), 9.38 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 67. (1S,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1S,2S)-2-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.07 (m, 1H), 2.27-2.35 (m, 1H), 4.16 (br, 1H), 4.43 (br, 1H), 6.96 (s, 1H), 7.53 (d, 2H), 8.02 (br, 1H), 8.14 (d, 2H), 8.86 (br, 1H), 9.38 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 68. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using trans-2-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.07 (m, 1H), 2.27-2.35 (m, 1H), 4.16 (br, 1H), 4.43 (br, 1H), 6.96 (s, 1H), 7.53 (d, 2H), 8.02 (br, 1H), 8.14 (d, 2H), 8.86 (br, 1H), 9.38 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 69. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexan-1-ol Using (1R,2R)-2-aminocyclohexan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.16 (m, 2H), 3.52-3.57 (m, 1H), 4.16 (br, 1H), 6.95 (s, 1H), 7.52 (d, 2H), 8.03 (br, 1H), 8.12 (d, 2H), 8.86 (br, 1H), 9.32 (d, 1H), 9.66 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 70. cis-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-2,6- dimethylmorpholine Using cis-2,6-dimethylmorpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.56 (br, 2H), 7.23 (s, 1H), 7.51 (d, 2H), 8.05 (br, 1H), 8.22 (d, 2H), 8.88 (br, 1H), 9.38 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 71. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)morpholine Using morpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 8.12 (br, 1H), 8.21 (d, 2H), 8.88 (br, 1H), 9.41 (d, 1H), 9.83 (br, 1H); MS (ESI, m / z): 353.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 72. 6-(4-chlorophenyl)-N-(morpholin-2-ylmethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 2-(aminomethyl)morpholine-4-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 8.15 (br, 1H), 8.33 (d, 2H), 8.89 (br, 1H), 9.41 (d, 1H), 9.73 (br, 1H); MS (ESI, m / z): 382.9 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 73. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- yl)morpholine Using 4-(pyrrolidin-3-yl)morpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.43 (br, 1H), 2.68 (br, 1H), 3.50 (br, 4H), 3.69 (br, 1H), 3.86-4.40 (m, 8H), 7.05 (s, 1H), 7.53 (d, 2H), 8.14 (br, 1H), 8.25 (d, 2H), 8.92 (br, 1H), 9.52 (d, 1H), 9.79 (br, 1H); MS (ESI, m / z): 422.2 [M+H]<com:Sup>+< / com:Sup> Example 74. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)thiomorpholine Using thiomorpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.74-7.76 (m, 4H), 4.24 (br, 4H), 7.25 (s, 1H), 7.52 (d, 2H), 8.12 (br, 1H), 8.22 (d, 2H), 8.91 (br, 1H), 9.45 (d, 1H), 9.73 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 422.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 75. 6-(4-chlorophenyl)-N-(3-morpholinopropyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 3-morpholinopropan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 3.51 (br, 2H), 3.72 (br, 4H), 4.03 (br, 2H), 6.98 (s, 1H), 7.53 (d, 2H), 8.00 (br, 1H), 8.15 (d, 2H), 8.85 (br, 1H), 9.35 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 410.2 [M+H]<com:Sup>+< / com:Sup> Example 76. (R)-4-(4-chlorophenyl)-6-(2-methylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using tert-butyl (R)-3-methylpiperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 3.51 (br, 2H), 3.72 (br, 4H), 4.03 (br, 2H), 6.98 (s, 1H), 7.53 (d, 2H), 8.00 (br, 1H), 8.15 (d, 2H), 8.85 (br, 1H), 9.35 (d, 1H), 9.72 (br, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 77. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3- methylpiperazin-1-yl)(phenyl)methanone Using (R)-(3-methylpiperazin-1-yl)(phenyl)methanone and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Math><semantics>MS<annotation encoding="application / x-tex">MS< / annotation>< / semantics>< / com:Math> (ESI, m / z): 470.2 [M+H]<com:Sup>+< / com:Sup> Example 78. methyl (R)-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)piperazine-2-carboxylate Using 1-(tert-butyl) 2-methyl (R)-piperazine-1,2-dicarboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 4.01 (br, 1H), 4.46 (br, 1H), 4.55 (br, 1H), 5.35 (br, 1H), 7.43 (s, 1H), 7.56 (d, 2H), 7.74 (br, 1H), 8.29 (d, 2H), 8.74 (br, 1H), 9.06 (d, 1H), 9.67 (br, 1H); MS (ESI, m / z): 410.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 79. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2- yl)methanol Using tert-butyl (R)-2-(hydroxymethyl)piperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.85 (m, 2H), 3.94-3.98 (m, 2H), 4.82-4.85 (m, 1H), 7.44 (s, 1H), 7.56 (d, 2H), 8.03 (br, 1H), 8.30 (d, 2H), 8.87 (br, 1H), 9.40 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): 410.1 [M+H]<com:Sup>+< / com:Sup> Example 80. 4-(4-chlorophenyl)-6-(4-(2,3-dichlorophenyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-(2,3-dichlorophenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.21 (br, 4H), 4.10 (br, 4H), 7.13-7.17 (m, 1H), 7.28 (d, 2H), 7.34 (s, 1H), 7.55 (d, 2H), 8.12 (br, 1H), 8.26 (d, 2H), 8.91 (br, 1H), 9.50 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): 496.1 [M+H]<com:Sup>+< / com:Sup> Example 81. 4-(4-chlorophenyl)-6-(4-(2,5-dimethoxybenzyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-(2,5-dimethoxybenzyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.54 (br, 8H), 3.80 (s, 3H), 3.90 (s, 3H), 4.43 (s, 2H), 7.09 (s, 3H), 7.42 (s, 1H), 7.55 (d, 2H), 8.14 (br, 1H), 8.28 (d, 2H), 8.92 (br, 1H), 9.54 (d, 1H), 9.81 (br, 1H); MS (ESI, m / z): 502.2 [M+H]<com:Sup>+< / com:Sup> Example 82. 2-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1- yl)ethan-1-ol Using 2-(piperazin-1-yl)ethan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.38 (t, 2H), 3.52 (br, 8H), 3.96 (t, 2H), 7.42 (s, 1H), 7.55 (d, 2H), 8.00 (br, 1H), 8.28 (d, 2H), 8.86 (br, 1H), 9.37 (d, 1H), 9.76 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 396.2 [M+H]<com:Sup>+< / com:Sup> Example 83. 4-(4-chlorophenyl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)-2-(pyridin- 3-yl)pyrimidine Using 1-(2-methoxyphenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (dd, 1H), 7.15 (d, 1H), 7.26-7.32 (m, 2H), 7.37 (s, 1H), 7.53 (d, 2H), 8.12 (br, 1H), 8.26 (d, 2H), 8.91 (br, 1H), 9.50 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): 458.2 [M+H]<com:Sup>+< / com:Sup> Example 84. 4-(4-chlorophenyl)-6-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(2-ethoxyphenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 7.01 (dd, 1H), 7.10 (d, 1H), 7.19-7.25 (m, 2H), 7.38 (s, 1H), 7.55 (d, 2H), 8.11 (br, 1H), 8.26 (d, 2H), 8.90 (br, 1H), 9.49 (d, 1H), 9.78 (br, 1H); MS (ESI, m / z): 472.2 [M+H]<com:Sup>+< / com:Sup> Example 85. 4-(4-chlorophenyl)-6-(4-(2-fluorophenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(2-fluorophenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 7.31 (s, 1H), 7.52 (d, 2H), 8.12 (br, 1H), 8.23 (d, 2H), 8.90 (br, 1H), 9.46 (d, 1H), 9.75 (br, 1H); <com:Math><semantics>MS<annotation encoding="application / x-tex">MS< / annotation>< / semantics>< / com:Math> (ESI, m / z): 446.2 [M+H]<com:Sup>+< / com:Sup> Example 86. (4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1- yl)(furan-2-yl)methanone Using furan-2-yl(piperazin-1-yl)methanone and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 4.02 (br, 8H), 6.64 (dd, 1H), 7.14 (d, 1H), 7.29 (s, 1H), 7.53 (d, 2H), 7.74 (d, 1H), 8.06 (dd, 1H), 8.25 (d, 2H), 8.87 (br, 1H), 9.43 (d, 1H), 9.74 (br, 1H); MS (ESI, m / z): <com:Math><semantics>446.1[M+H]+<annotation encoding="application / x-tex">446.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 87. 4-(4-chlorophenyl)-6-(4-phenethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-phenethylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 8H), 7.26-7.38 (m, 5H), 7.44 (s, 1H), 7.54 (d, 2H), 8.16 (br, 1H), 8.28 (d, 2H), 8.94 (br, 1H), 9.54 (d, 1H), 9.81 (br, 1H); MS (ESI, m / z): <com:Math><semantics>456.2[M+H]+<annotation encoding="application / x-tex">456.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 88. 6-(4-chlorophenyl)-N-(2-(piperazin-1-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 4H), 7.37 (s, 1H), 7.52 (d, 2H), 8.11 (br, 1H), 8.25 (d, 2H), 8.91 (br, 1H), 9.48 (d, 1H), 9.78 (br, 1H); MS (ESI, m / z): 395.2 [M+H]<com:Sup>+< / com:Sup> Example 89. 4-(4-chlorophenyl)-6-(4-(pyridin-2-yl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(pyridin-2-yl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.98 (br, 4H), 4.20 (br, 4H), 7.06 (t, 1H), 7.30 (s, 1H), 7.44 (d, 1H), 7.54 (d, 2H), 8.04 (d, 1H), 8.08-8.16 (m, 2H), 8.27 (d, 2H), 8.93 (br, 1H), 9.53 (d, 1H), 9.80 (br, 1H); MS (ESI, m / z): 429.2 [M+H]<com:Sup>+< / com:Sup> Example 90. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(pyrimidin-2-yl)piperazin-1- yl)pyrimidine Using 1-(pyridin-2-yl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 4.04 (br, 8H), 6.72 (t, 1H), 7.36 (s, 1H), 7.55 (d, 2H), 8.04 (d, 1H), 8.19 (br, 1H), 8.28 (d, 2H), 8.43 (d, 2H), 8.93 (br, 1H), 9.59 (d, 1H), 9.81 (br, 1H); MS (ESI, m / z): 429.2 [M+H]<com:Sup>+< / com:Sup> Example 91. 4-(2-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin- 1-yl)ethyl)morpholine Using 4-(2-(piperazin-1-yl)ethyl)morpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.27 (br, 4H), 3.35 (br, 4H), 3.41 (t, 2H), 3.55 (t, 2H), 3.95 (br, 4H), 4.18 (br, 4H), 7.39 (s, 1H), 7.54 (d, 2H), 8.16 (br, 1H), 8.26 (d, 2H), 8.93 (br, 1H), 9.54 (d, 1H), 9.79 (br, 1H); MS (ESI, m / z): 429.2 [M+H]<com:Sup>+< / com:Sup> Example 92. 4-(4-chlorophenyl)-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-methyl-4-(piperidin-4-yl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.69-1.79 (m, 2H), 2.53 (d, 2H), 2.93 (s, 3H), 3.14 (t, 2H), 3.44 (br, 4H), 3.52 (br, 4H), 3.63 (br, 2H), 4.29 (br, 1H), 7.34 (s, 1H), 7.54 (d, 2H), 8.14 (br, 1H), 8.24 (d, 2H), 8.92 (br, 1H), 9.51 (d, 1H), 9.76 (br, 1H); MS (ESI, m / z): 449.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 93. trans-4-(4-chlorophenyl)-6-(4-cinnamylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using trans-1-cinnamylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.58 (br, 8H), 4.04 (d, 2H), 6.35-6.43 (m, 1H), 6.96 (d, 1H), 7.32-7.40 (m, 3H), 7.44 (s, 1H), 7.50-7.55 (m, 4H), 8.16 (br, 1H), 8.28 (d, 2H), 8.93 (br, 1H), 9.56 (d, 1H), 9.82 (br, 1H); MS (ESI, m / z): 468.2 [M+H]<com:Sup>+< / com:Sup> Example 94. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-one Using piperazin-2-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.53 (t, 2H), 4.10 (br, 2H), 4.46 (s, 2H), 7.29 (s, 1H), 7.54 (d, 2H), 8.11 (br, 1H), 8.28 (d, 2H), 8.89 (br, 1H), 9.49 (d, 1H), 9.77 (br, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 95. 4-(4-chlorophenyl)-6-(4-phenylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-phenylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.43 (t, 4H), 4.13 (br, 4H), 7.02 (t, 1H), 7.14 (d, 2H), 7.34 (t, 3H), 7.53 (d, 2H), 8.14-8.17 (m, 1H), 8.25 (d, 2H), 8.92 (br, 1H), 9.54 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): <com:Math><semantics>428.2[M+H]+<annotation encoding="application / x-tex">428.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 96. 4-(4-chlorophenyl)-6-(4-propylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-propylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.06 (t, 3H), 1.80-1.90 (m, 2H), 3.17-3.21 (m, 2H), 3.54 (br, 8H), 7.43 (s, 1H), 7.55 (d, 2H), 8.03 (t, 1H), 8.28 (d, 2H), 8.87 (br, 1H), 9.41 (d, 1H), 9.77 (br, 1H); MS (ESI, m / z): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 97. 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-6-(4- chlorophenyl)-2-(pyridin-3-yl)pyrimidine Using 1-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 7.03 (d, 1H), 7.05 (s, 1H), 7.42 (s, 1H), 7.54 (d, 2H), 8.11-8.14 (m, 1H), 8.28 (d, 2H), 8.92 (br, 1H), 9.51 (d, 1H), 9.80 (br, 1H); MS (ESI, m / z): 486.2 [M+H]<com:Sup>+< / com:Sup> Example 98. (S)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2- yl)methanol Using tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.55 (br, 1H), 3.45-3.59 (m, 4H), 3.62-3.67 (m, 1H), 3.72-3.77 (m, 1H), 3.82-3.87 (m, 1H), 3.95-4.00 (m, 1H), 7.50 (s, 1H), 7.56 (d, 2H), 8.25- 8.28 (m, 1H), 8.33 (d, 2H), 8.99 (d, 1H), 9.69 (d, 1H), 9.88 (s, 1H); MS (ESI, m / z): 382.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 99. 4-(4-chlorophenyl)-6-(4-(4-fluorophenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(4-fluorophenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 4.09 (br, 8H), 7.02-7.07 (m, 2H), 7.10-7.13 (m, 2H), 7.32 (s, 1H), 7.52 (d, 2H), 8.14-8.17 (m, 1H), 8.23 (d, 2H), 8.92 (d, 1H), 9.53 (d, 1H), 9.76 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 446.2 [M+H]<com:Sup>+< / com:Sup> Example 100. 6-(4-chlorophenyl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2- (pyridin-3-yl)pyrimidin-4-amine Using 1,2,2,6,6-pentamethylpiperidin-4-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.55 (s, 6H), 1.68 (s, 6H), 1.86 (t, 1H), 2.43 (d, 4H), 2.92 (s, 3H), 7.00 (s, 1H), 7.54 (d, 2H), 8.06-8.09 (m, 1H), 8.16 (d, 2H), 8.89 (d, 1H), 9.41 (d, 1H), 9.73 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 436.2 [M+H]<com:Sup>+< / com:Sup> Example 101. 6-(4-chlorophenyl)-N-(piperidin-3-yl)-2-(pyridin-3-yl)pyrimidin-4- amine Using tert-butyl 3-aminopiperidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.74-1.83 (m, 1H), 1.92-2.03 (m, 1H), 2.12- 2.23 (m, 2H), 2.96-3.11 (m, 2H), 3.40 (d, 1H), 3.71 (d, 1H), 4.55 (br, 1H), 7.03 (s, 1H), 7.53 (d, 2H), 8.10 (br, 1H), 8.16 (d, 2H), 8.91 (br, 1H), 9.49 (d, 1H), 9.83 (br, 1H); MS (ESI, m / z): 366.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 102. 4-(4-chlorophenyl)-6-(piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine Using tert-butyl piperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.41 (br, 4H), 4.19 (br, 4H), 7.41 (s, 1H), 7.55 (d, 2H), 8.04 (t, 1H), 8.28 (d, 2H), 8.87 (d, 1H), 9.41 (d, 1H), 9.77 (s, 1H); MS (ESI, m / z): 352.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 103. Trans-4-(4-chlorophenyl)-6-(2,5-dimethylpiperazin-1-yl)-2-(pyridin- 3-yl)pyrimidine Using tert-butyl trans-2,5-dimethylpiperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.91 (br, 1H), 4.67 (d, 1H), 5.17 (br, 1H), 7.35 (s, 1H), 7.56 (d, 2H), 8.02-8.05 (m, 1H), 8.28 (d, 2H), 8.87 (d, 1H), 9.41 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 104. Cis-4-(4-chlorophenyl)-6-(3,5-dimethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using tert-butyl cis-2,6-dimethylpiperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 5.04 (br, 2H), 7.47 (s, 1H), 7.55 (d, 2H), 8.08-8.12 (m, 1H), 8.30 (d, 2H), 8.91 (d, 1H), 9.50 (d, 1H), 9.81 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 105. 4-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-methylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (s, 1H), 7.56 (d, 2H), 7.97-8.00 (m, 1H), 8.29 (d, 2H), 8.86 (d, 1H), 9.36 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 106. 4-(4-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-ethylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 4H), 7.43 (s, 1H), 7.56 (d, 2H), 7.97-8.01 (m, 1H), 8.29 (d, 2H), 8.86 (d, 1H), 9.36 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): <com:Math><semantics>380.2[M+H]+<annotation encoding="application / x-tex">380.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 107. 4-(4-chlorophenyl)-6-(4-(methylsulfonyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(methylsulfonyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.90 (s, 3H), 3.40 (br, 4H), 4.06 (br, 4H), 7.35 (s, 1H), 7.55 (d, 2H), 8.02 (br, 1H), 8.27 (d, 2H), 8.85 (br, 1H), 9.38 (d, 1H), 9.76 (br, 1H); MS <com:Math><semantics>(ESI,m / z):430.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 430.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 108. 1-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1- yl)ethan-1-one Using 1-(piperazin-1-yl)ethan-1-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.19 (s, 3H), 3.73-3.78 (m, 4H), 3.93 (br, 2H), 3.99 (br, 2H), 7.28 (s, 1H), 7.54 (d, 2H), 7.96-7.99 (m, 1H), 8.25 (d, 2H), 8.83 (d, 1H), 9.34 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): 394.1 [M+H]<com:Sup>+< / com:Sup> Example 109. 4-(4-chlorophenyl)-6-(3-ethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using tert-butyl 2-ethylpiperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.19 (t, 3H), 1.73-1.90 (m, 3H), 3.25-3.35 (m, 4H), 3.49-3.59 (m, 2H), 7.45 (s, 1H), 7.56 (d, 2H), 8.07-8.10 (m, 1H), 8.30 (d, 2H), 8.90 (d, 1H), 9.46 (d, 1H), 9.78 (s, 1H); MS (ESI, m / z): <com:Math><semantics>380.2[M+H]+<annotation encoding="application / x-tex">380.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 110. ethyl 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)piperazine-1-carboxylate Using ethyl piperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.31 (t, 3H), 3.66 (br, 4H), 3.94 (br, 4H), 4.19 (q, 2H), 7.29 (s, 1H), 7.53 (d, 2H), 8.02-8.06 (m, 1H), 8.24 (d, 2H), 8.86 (d, 1H), 9.41 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 424.2 [M+H]<com:Sup>+< / com:Sup> Example 111. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2- carboxylic acid Using 1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Math><semantics>MS(ESI,m / z):396.1[M+H]+<annotation encoding="application / x-tex">MS (ESI, m / z): 396.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 112. methyl 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)piperazine-2-carboxylate Using 1-(tert-butyl) 3-methyl piperazine-1,3-dicarboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.83 (br, 1H), 4.07 (br, 1H), 4.10 (br, 1H), 7.43 (s, 1H), 7.55 (d, 2H), 7.80-7.84 (m, 1H), 8.28 (d, 2H), 8.77 (d, 1H), 9.16 (d, 1H), 9.68 (s, 1H); MS (ESI, m / z): 410.1 [M+H]<com:Sup>+< / com:Sup> Example 113. (S)-4-(4-chlorophenyl)-6-(2-phenylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using tert-butyl (S)-3-phenylpiperazine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.60 (m, 2H), 5.09-5.12 (m, 1H), 7.47 (s, 1H), 7.53-7.63 (m, 7H), 7.79-7.82 (m, 1H), 8.29 (d, 2H), 8.76 (d, 1H), 9.15 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 428.2 [M+H]<com:Sup>+< / com:Sup> Example 114. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(0-tolyl)piperazin-1- yl)pyrimidine Using 1-(o-tolyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 7.08 (d, 1H), 7.31 (s, 1H), 7.53 (d, 2H), 7.59 (d, 1H), 8.11-8.14 (m, 1H), 8.24 (d, 2H), 8.42 (t, 1H), 8.91 (d, 1H), 9.50 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 442.2 [M+H]<com:Sup>+< / com:Sup> Example 115. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(p-tolyl)piperazin-1- yl)pyrimidine Using 1-(p-tolyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.31 (s, 3H), 3.44 (t, 4H), 4.17 (br, 4H), 7.14 (d, 2H), 7.20 (d, 2H), 7.37 (s, 1H), 7.54 (d, 2H), 8.11-8.14 (m, 1H), 8.26 (d, 2H), 8.91 (d, 1H), 9.52 (d, 1H), 9.78 (s, 1H); MS (ESI, m / z): 442.2 [M+H]<com:Sup>+< / com:Sup> Example 116. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(m-tolyl)piperazin-1- yl)pyrimidine Using 1-(m-tolyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.34 (s, 3H), 3.43 (t, 4H), 4.13 (br, 4H), 6.87 (d, 1H), 6.98 (d, 1H), 7.01 (s, 1H), 7.22 (t, 1H), 7.35 (s, 1H), 7.54 (d, 2H), 8.12-8.15 (m, 1H), 8.26 (d, 2H), 8.91 (d, 1H), 9.52 (d, 1H), 9.77 (s, 1H); MS (ESI, m / z): 442.2 [M+H]<com:Sup>+< / com:Sup> Example 117. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(3- (trifluoromethyl)phenyl)piperazin-1-yl)pyrimidine Using 1-(3-(trifluoromethyl)phenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.42 (t, 4H), 4.08 (br, 4H), 7.13 (d, 1H), 7.25 (s, 1H), 7.26 (d, 1H), 7.31 (s, 1H), 7.44 (t, 1H), 7.53 (d, 2H), 8.10-8.14 (m, 1H), 8.24 (d, 2H), 8.90 (d, 1H), 9.50 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): <com:Math><semantics>496.1 [M+H]+<annotation encoding="application / x-tex">496.1 \text{ [M+H]}^{+}< / annotation>< / semantics>< / com:Math> Example 118. 4-(4-chlorophenyl)-6-(4-(2,3-dimethylphenyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-(2,3-dimethylphenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.29 (s, 3H), 2.33 (s, 3H), 3.03 (br, 4H), 4.08 (br, 4H), 6.94 (t, 2H), 7.06 (t, 1H), 7.32 (s, 1H), 7.54 (d, 2H), 8.10-8.13 (m, 1H), 8.25 (d, 2H), 8.90 (d, 1H), 9.49 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 456.2 [M+H]<com:Sup>+< / com:Sup> Example 119. 4-(4-chlorophenyl)-6-(4-(3,4-dichlorophenyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-(3,4-dichlorophenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.39 (t, 4H), 4.09 (br, 4H), 6.96 (d, 1H), 6.99 (d, 1H), 7.35 (d, 2H), 7.55 (d, 2H), 8.10-8.14 (m, 1H), 8.27 (d, 2H), 8.90 (d, 1H), 9.51 (d, 1H), 9.77 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 496.1 [M+H]<com:Sup>+< / com:Sup> Example 120. 4-(4-chlorophenyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-(4-methoxyphenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.57 (t, 4H), 3.83 (s, 3H), 4.27 (br, 4H), 7.04 (d, 2H), 7.39 (d, 2H), 7.44 (s, 1H), 7.57 (d, 2H), 8.13-8.16 (m, 1H), 8.30 (d, 2H), 8.93 (d, 1H), 9.54 <com:Math><semantics>(d,1H),9.81(s,1H);MS(ESI,m / z):458.2[M+H]+<annotation encoding="application / x-tex">(d, 1H), 9.81 (s, 1H); MS (ESI, m / z): 458.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 121. 4-(4-chlorophenyl)-6-(4-(4-nitrophenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 1-(4-nitrophenyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.73 (t, 4H), 4.13 (br, 4H), 7.05 (d, 2H), 7.32 (s, 1H), 7.56 (d, 2H), 8.03-8.07 (m, 1H), 8.17 (d, 2H), 8.28 (d, 2H), 8.87 (d, 1H), 9.42 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): <com:Math><semantics>473.1[M+H]+<annotation encoding="application / x-tex">473.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 122. 4-(4-chlorophenyl)-6-(3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 1-methyl-4-(pyrrolidin-3-yl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.02 (br, 2H), 2.41 (br, 2H), 2.93 (s, 3H), 2.97 (br, 2H), 3.28 (br, 2H), 3.38 (br, 4H), 3.62 (br, 2H), 4.16 (br, 1H), 6.99 (s, 1H), 7.54 (d, 2H), 8.10-8.13 (m, 1H), 8.23 (d, 2H), 8.91 (d, 1H), 9.49 (d, 1H), 9.77 (s, 1H); MS (ESI, m / z): 435.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 123. 4-(4-benzhydrylpiperazin-1-yl)-6-(4-chlorophenyl)-2-(pyridin-3- yl)pyrimidine Using 1-benzhydrylpiperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.35 (br, 4H), 4.22 (br, 4H), 5.41 (s, 1H), 7.31 (t, 2H), 7.37 (s, 1H), 7.43-7.55 (m, 8H), 7.69 (d, 2H), 8.00-8.04 (m, 1H), 8.26 (d, 2H), 8.86 (d, 1H), 9.40 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): 518.2 [M+H]<com:Sup>+< / com:Sup> Example 124. 4-(4-chlorophenyl)-6-(4-((4-chlorophenyl)(phenyl)methyl)piperazin- 1-yl)-2-(pyridin-3-yl)pyrimidine Using 1-((4-chlorophenyl)(phenyl)methyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.29 (br, 4H), 4.21 (br, 4H), 5.36 (s, 1H), 7.30- 7.34 (m, 1H), 7.36 (s, 1H), 7.42-7.54 (m, 7H), 7.67-7.71 (m, 3H), 8.07-8.11 (m, 1H), 8.25 (d, 2H), 8.90 (br, 1H), 9.47 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 552.2 [M+H]<com:Sup>+< / com:Sup> Example 125. 1'-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)spiro[indene- 1,4'-piperidine Using spiro[indene-1,4'-piperidine] and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.17-2.24 (m, 4H), 3.53-3.59 (m, 4H), 6.89 (d, 1H), 7.12 (d, 1H), 7.17 (t, 1H), 7.23 (t, 1H), 7.35 (d, 2H), 7.37 (s, 1H), 7.55 (d, 2H), 8.09-8.13 (m, 1H), 8.25 (d, 2H), 8.90 (d, 1H), 9.49 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 451.2 [M+H]<com:Sup>+< / com:Sup> Example 126. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin-4- amine Using tert-butyl 3-aminopyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.16 (br, 1H), 2.50 (br, 1H), 3.18-3.23 (m, 1H), 3.38-3.46 (m, 1H), 3.52-3.59 (m, 1H), 3.70-3.75 (m, 1H), 4.04-4.11 (m, 1H), 7.00 (s, 1H), 7.53 (d, 2H), 7.70-7.74 (m, 1H), 8.16 (d, 2H), 8.72 (d, 1H), 9.06 (d, 1H), 9.63 (s, 1H); MS (ESI, m / z): 352.1 [M+H]<com:Sup>+< / com:Sup> Example 127. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin- 4-amine Using tert-butyl (R)-3-aminopyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.11-2.24 (m, 1H), 2.46-2.56 (m, 1H), 3.37- 3.46 (m, 1H), 3.48-3.61 (m, 2H), 3.71-3.81 (m, 1H), 4.05-4.12 (m, 1H), 7.06 (s, 1H), 7.53 (d, 2H), 8.02-8.06 (m, 1H), 8.18 (d, 2H), 8.88 (d, 1H), 9.41 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 352.1 [M+H]<com:Sup>+< / com:Sup> Example 128. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3- ylmethyl)pyrimidin-4-amine Using tert-butyl (S)-3-(aminomethyl)pyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.85-1.94 (m, 1H), 2.22-2.32 (m, 1H), 2.79- 2.87 (m, 1H), 3.00-3.15 (m, 2H), 3.40-3.46 (m, 1H), 3.47-3.57 (m, 1H), 3.73 (br, 2H), 7.00 (s, 1H), 7.53 (d, 2H), 8.05-8.08 (m, 1H), 8.16 (d, 2H), 8.88 (d, 1H), 9.43 (d, 1H), 9.75 (s, 1H); MS <com:Math><semantics>(ESI,m / z):366.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 366.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 129. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(2-(pyrrolidin-1- yl)ethyl)pyrimidin-4-amine Using 2-(pyrrolidin-1-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 4H), 7.06 (s, 1H), 7.54 (d, 2H), 8.02-8.05 (m, 1H), 8.18 (d, 2H), 8.88 (d, 1H), 9.41 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): <com:Math><semantics>380.2[M+H]+<annotation encoding="application / x-tex">380.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 130. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(3-(pyrrolidin-1- yl)propyl)pyrimidin-4-amine Using 3-(pyrrolidin-1-yl)propan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.00-2.18 (br, 6H), 3.03-3.13 (br, 6H), 3.69 (br, 2H), 6.98 (s, 1H), 7.52 (d, 2H), 7.95-7.98 (m, 1H), 8.15 (d, 2H), 8.84 (d, 1H), 9.31 (d, 1H), 9.71 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 131. 6-(4-chlorophenyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 2-(1-methylpyrrolidin-2-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.89-2.00 (m, 2H), 2.02-2.18 (m, 2H), 2.35- 2.43 (m, 1H), 2.93 (s, 3H), 3.03-3.07 (m, 2H), 3.11-3.20 (m, 1H), 3.34-3.44 (m, 1H), 3.72 (br, 2H), 6.96 (s, 1H), 7.52 (d, 2H), 7.87-7.90 (m, 1H), 8.15 (d, 2H), 8.80 (d, 1H), 9.21 (d, 1H), 9.67 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 132. N-(1-benzylpyrrolidin-3-yl)-6-(4-chlorophenyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 1-benzylpyrrolidin-3-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.48 (s, 2H), 7.03 (s, 1H), 7.47-7.49 (m, 3H), 7.52-7.56 (m, 4H), 8.10-8.14 (m, 1H), 8.16 (d, 2H), 8.87 (d, 1H), 9.36 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 442.2 [M+H]<com:Sup>+< / com:Sup> Example 133. (3R,4S)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)pyrrolidin-3-ol Using tert-butyl (3S,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 2H), 7.09 (s, 1H), 7.53 (d, 2H), 7.65-7.70 (m, 1H), 8.17 (d, 2H), 8.69 (d, 1H), 9.01 (d, 1H), 9.62 (s, 1H); MS (ESI, m / z): 368.1 [M+H]<com:Sup>+< / com:Sup> Example 134. (3S,4R)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)pyrrolidin-3-ol Using tert-butyl (3R,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 9.62 (s, 1H); MS (ESI, m / z): 368.1 [M+H]<com:Sup>+< / com:Sup> Example 135. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(pyrrolidin-1-yl)pyrimidine Using pyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (s, 1H), 7.54 (d, 2H), 8.05-8.08 (m, 1H), 8.20 (d, 2H), 8.88 (d, 1H), 9.40 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 337.1 [M+H]<com:Sup>+< / com:Sup> Example 136. 4-(4-chlorophenyl)-6-(2-methylpyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 2-methylpyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 2H), 4.63 (br, 1H), 6.91 (s, 1H), 7.53 (d, 2H), 8.04-8.07 (m, 1H), 8.18 (d, 2H), 8.88 (d, 1H), 9.37 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 351.1 [M+H]<com:Sup>+< / com:Sup> Example 137. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin- 3-01 Using (S)-pyrrolidin-3-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 6.95 (s, 1H), 7.52 (d, 2H), 8.07-8.11 (m, 1H), 8.19 (d, 2H), 8.89 (d, 1H), 9.43 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 353.1 [M+H]<com:Sup>+< / com:Sup> Example 138. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- yl)methanol Using pyrrolidin-3-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.92 (br, 1H), 2.21 (br, 1H), 2.60 (br, 1H), 3.52-3.59 (m, 2H), 3.60-3.71 (m, 3H), 3.97 (br, 1H), 6.91 (s, 1H), 7.52 (d, 2H), 8.04-8.08 (m, 1H), 8.18 (d, 2H), 8.88 (d, 1H), 9.39 (d, 1H), 9.68 (s, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 139. (R)-4-(4-chlorophenyl)-6-(3-fluoropyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using (R)-3-fluoropyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.25 (br, 1H), 2.45 (br, 1H), 3.71 (br, 1H), 3.79 (br, 2H), 3.88 (br, 1H), 4.17 (br, 1H), 7.00 (s, 1H), 7.53 (d, 2H), 8.07-8.10 (m, 1H), 8.23 (d, 2H), 8.88 (d, 1H), 9.46 (d, 1H), 9.72 (s, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 140. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- amine Using tert-butyl pyrrolidin-3-ylcarbamate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.31 (br, 1H), 2.57 (br, 1H), 3.87 (br, 2H), 4.06 (br, 2H), 4.14 (br, 1H), 7.04 (s, 1H), 7.54 (d, 2H), 8.06-8.09 (m, 1H), 8.25 (d, 2H), 8.89 (d, 1H), 9.45 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): <com:Math><semantics>352.1 [M+H]+<annotation encoding="application / x-tex">352.1 \text{ [M+H]}^+< / annotation>< / semantics>< / com:Math> Example 141. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N- methylpyrrolidin-3-amine Using tert-butyl methyl(pyrrolidin-3-yl)carbamate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 3.89 (br, 1H), 4.05 (br, 3H), 7.04 (s, 1H), 7.53 (d, 2H), 8.08-8.12 (m, 1H), 8.25 (d, 2H), 8.90 (d, 1H), 9.47 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 142. methyl (6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)prolinate Using methyl prolinate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.80 (m, 5H), 4.76-4.79 (m, 1H), 7.06 (s, 1H), 7.52 (d, 2H), 8.05-8.08 (m, 1H), 8.23 (d, 2H), 8.88 (d, 1H), 9.32 (d, 1H), 9.59 (s, 1H); MS (ESI, m / z): 395.1 [M+H]<com:Sup>+< / com:Sup> Example 143. N-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- yl)acetamide Using N-(pyrrolidin-3-yl)acetamide and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 3.72 (br, 1H), 3.89 (br, 1H), 4.02 (br, 1H), 4.52 (br, 1H), 6.97 (s, 1H), 7.53 (d, 2H), 8.13-8.16 (m, 1H), 8.21 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 394.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 144. (2R,3R)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)butan-2-ol Using (2R,3R)-3-aminobutan-2-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.23 (d, 3H), 1.30 (d, 3H), 3.94 (br, 1H), 4.51 (br, 1H), 7.01 (s, 1H), 7.55 (d, 2H), 8.07-8.10 (m, 1H), 8.15 (d, 2H), 8.89 (d, 1H), 9.44 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): <com:Math><semantics>355.1[M+H]+<annotation encoding="application / x-tex">355.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 145. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2- ol Using 3-aminobutan-2-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.27 (d, 3H), 1.31 (d, 3H), 3.90-3.94 (m, 1H), 4.46 (br, 1H), 7.00 (s, 1H), 7.55 (d, 2H), 8.13-8.20 (m, 3H), 8.92 (d, 1H), 9.48 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 146. 1-(4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)piperidin-1-yl)ethan-1-one Using 1-(4-aminopiperidin-1-yl)ethan-1-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3H), 4.49 (br, 1H), 6.99 (s, 1H), 7.57 (d, 2H), 8.14-8.19 (m, 3H), 8.93 (d, 1H), 9.52 (d, 1H), 9.77 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 408.2 [M+H]<com:Sup>+< / com:Sup> Example 147. (R)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin- 3-yl)methanol Using (R)-piperidin-3-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.84 (m, 1H), 1.86-1.92 (m, 2H), 3.03 (t, 1H), 3.24 (t, 1H), 3.35 (d, 1H), 3.50 (dd, 1H), 3.60 (dd, 1H), 4.58 (br, 1H), 7.27 (s, 1H), 7.54 (d, 2H), 8.13-8.15 (m, 1H), 8.21 (d, 2H), 8.92 (d, 1H), 9.50 <com:Math><semantics>(d,1H),9.73(s,1H);MS(ESI,m / z):381.1[M+H]+<annotation encoding="application / x-tex">(d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 381.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 148. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanol Using (S)-piperidin-3-ylmethanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.84 (m, 1H), 1.86-1.92 (m, 2H), 3.03 (t, 1H), 3.24 (t, 1H), 3.35 (d, 1H), 3.50 (dd, 1H), 3.60 (dd, 1H), 4.58 (br, 1H), 7.27 (s, 1H), 7.54 (d, 2H), 8.13-8.15 (m, 1H), 8.21 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 149. 6-(4-chlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 2-(piperidin-1-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 3.05 (t, 2H), 3.48 (t, 2H), 3.72 (d, 2H), 4.05 (br, 2H), 7.08 (s, 1H), 7.57 (d, 2H), 8.10-8.12 (m, 1H), 8.21 (d, 2H), 8.92 (d, 1H), 9.48 (d, 1H), 9.80 (s, 1H); MS (ESI, m / z): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 150. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidine-4- carbonitrile Using piperidine-4-carbonitrile and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.20 (m, 1H), 3.76-3.80 (m, 2H), 4.24 (br, 2H), 7.32 (s, 1H), 7.54 (d, 2H), 8.11-8.13 (m, 1H), 8.25 (d, 2H), 8.90 (d, 1H), 9.50 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 376.1 [M+H]<com:Sup>+< / com:Sup> Example 151. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-4-(3- (trifluoromethyl)phenyl)piperidin-4-ol Using 4-(3-(trifluoromethyl)phenyl)piperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.70 (br, 2H), 7.33 (s, 1H), 7.53 (d, 2H), 7.53-7.59 (m, 2H), 7.76 (d, 1H), 7.88 (s, 1H), 8.13-8.15 (m, 1H), 8.22 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): 511.1 [M+H]<com:Sup>+< / com:Sup> Example 152. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(pyrrolidin-1-yl)piperidin-1- yl)pyrimidine Using 4-(pyrrolidin-1-yl)piperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.71-1.78 (m, 2H), 2.03 (br, 2H), 2.18 (br, 2H), 2.34 (d, 2H), 3.13 (t, 2H), 3.22 (br, 2H), 3.31 (br, 2H), 3.52-3.56 (m, 1H), 3.70 (br, 2H), 7.36 (s, 1H), 7.54 (d, 2H), 8.16-8.18 (m, 1H), 8.25 (d, 2H), 8.94 (d, 1H), 9.55 (d, 1H), 9.78 (s, 1H); MS <com:Math><semantics>(ESI,m / z)<annotation encoding="application / x-tex">(ESI, m / z)< / annotation>< / semantics>< / com:Math>: 420.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 153. 4-(4-chlorophenyl)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin- 4-yl)piperidin-4-ol Using 4-(4-chlorophenyl)piperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.90 (d, 2H), 2.08-2.13 (m, 2H), 3.58 (br, 2H), 4.66 (br, 2H), 7.32 (s, 1H), 7.33 (d, 2H), 7.51 (d, 2H), 7.53 (d, 2H), 8.13-8.15 (m, 1H), 8.22 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): 477.1 [M+H]<com:Sup>+< / com:Sup> Example 154. 1-(4-(((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)methyl)piperidin-1-yl)ethan-1-one Using 1-(4-(aminomethyl)piperidin-1-yl)ethan-1-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.08-3.13 (m, 4H), 4.79 (br, 2H), 7.28 (s, 1H), 7.54 (d, 2H), 8.14-8.16 (m, 1H), 8.22 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 422.2 [M+H]<com:Sup>+< / com:Sup> Example 155. 1-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-4- phenylpiperidin-4-yl)ethan-1-one Using 1-(4-phenylpiperidin-4-yl)ethan-1-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.99 (s, 3H), 2.14-2.19 (m, 2H), 2.58 (d, 2H), 3.60 (t, 2H), 4.27 (br, 2H), 7.24 (s, 1H), 7.30-7.34 (m, 1H), 7.42 (d, 4H), 7.51 (d, 2H), 8.10-8.12 (m, 1H), 8.20 (d, 2H), 8.90 (d, 1H), 9.46 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): 469.2 [M+H]<com:Sup>+< / com:Sup> Example 156. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)morpholine Using 4-(piperidin-4-yl)morpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.75-1.82 (m, 2H), 2.35 (d, 2H), 3.14 (t, 2H), 3.24 (t, 2H), 3.55 (d, 2H), 3.60-3.66 (m, 2H), 3.80 (t, 2H), 4.10 (d, 2H), 5.00 (br, 2H), 7.37 (s, 1H), 7.54 (d, 2H), 8.17-8.19 (m, 1H), 8.26 (d, 2H), 8.94 (d, 1H), 9.56 (d, 1H), 9.79 (s, 1H); MS <com:Math><semantics>(ESI,m / z)<annotation encoding="application / x-tex">(ESI, m / z)< / annotation>< / semantics>< / com:Math>: 436.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 157. 4-(4-chlorophenyl)-6-(4-(3,5-dichlorophenyl)piperidin-1-yl)-2- (pyridin-3-yl)pyrimidine Using 4-(3,5-dichlorophenyl)piperidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.20 (t, 2H), 4.95 (br, 2H), 7.27 (s, 2H), 7.29 (s, 1H), 7.35 (s, 1H), 7.55 (d, 2H), 8.15-8.18 (m, 1H), 8.25 (d, 2H), 8.93 (d, 1H), 9.54 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 495.1 [M+H]<com:Sup>+< / com:Sup> Example 158. 6-(4-chlorophenyl)-N-((1-cyclohexylpiperidin-3-yl)methyl)-2- (pyridin-3-yl)pyrimidin-4-amine Using (1-cyclohexylpiperidin-3-yl)methanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.72 (m, 3H), 1.93 (d, 2H), 2.08 (d, 3H), 2.15 (d, 2H), 3.07 (t, 2H), 3.14-3.19 (m, 1H), 3.54 (d, 2H), 3.59 (br, 1H), 4.87-4.91 (m, 2H), 6.99 (s, 1H), 7.53 (d, 2H), 8.14-8.16 (m, 3H), 8.93 (d, 1H), 9.51 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): <com:Math><semantics>462.2[M+H]+<annotation encoding="application / x-tex">462.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 159. N-((1-benzylpiperidin-4-yl)methyl)-6-(4-chlorophenyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using (1-benzylpiperidin-4-yl)methanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.05 (t, 2H), 3.56 (d, 2H), 3.59 (br, 1H), 4.30 (s, 2H), 7.00 (s, 1H), 7.49 (s, 5H), 7.54 (d, 2H), 8.13-8.15 (m, 3H), 8.94 (d, 1H), 9.51 (d, 1H), 9.77 (s, 1H); MS (ESI, m / z): 470.2 [M+H]<com:Sup>+< / com:Sup> Example 160. ethyl 3-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)piperidin-4-yl)-3-oxopropanoate Using ethyl 3-oxo-3-(piperidin-4-yl)propanoate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.24 (t, 3H), 1.60-1.71 (m, 4H), 2.18-2.24 (m, 1H), 3.20-3.29 (m, 2H), 3.70 (s, 2H), 4.69 (br, 4H), 7.26 (s, 1H), 7.53 (d, 2H), 8.06-8.08 (m, 1H), 8.22 (d, 2H), 8.88 (d, 1H), 9.42 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): 465.2 [M+H]<com:Sup>+< / com:Sup> Example 161. ethyl 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)piperidin-4-yl)acetate Using ethyl 2-(piperidin-4-yl)acetate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.28 (t, 3H), 1.95 (d, 2H), 2.15-2.23 (m, 1H), 2.35 (d, 2H), 3.13 (t, 2H), 3.80 (br, 2H), 4.17 (q, 2H), 4.78 (br, 2H), 7.27 (s, 1H), 7.55 (d, 2H), 8.16-8.18 (m, 1H), 8.22 (d, 2H), 8.94 (d, 1H), 9.51 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): 437.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 162. (1S,3R)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1S,3R)-3-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.22 (m, 1H), 2.42-2.49 (m, 1H), 4.34-4.39 (m, 1H), 4.60 (br, 1H), 6.92 (s, 1H), 7.50 (d, 2H), 8.08-8.14 (m, 3H), 8.91 (d, 1H), 9.44 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 163. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- ol Using (S)-piperidin-3-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.59-1.66 (m, 1H), 1.67-1.72 (m, 1H), 1.93- 1.99 (m, 1H), 2.04-2.08 (m, 1H), 3.51 (q, 1H), 3.65 (br, 1H), 3.80-3.82 (m, 1H), 4.06 (br, 1H), 4.30 (br, 1H), 7.26 (s, 1H), 7.53 (d, 2H), 8.14-8.16 (m, 1H), 8.20 (d, 2H), 8.92 (d, 1H), 9.50 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 367.1 [M+H]<com:Sup>+< / com:Sup> Example 164. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N,N- dimethylpyrrolidin-3-amine Using N,N-dimethylpyrrolidin-3-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 3.94 (br, 1H), 4.13 (br, 2H), 4.33 (br, 1H), 7.08 (s, 1H), 7.54 (d, 2H), 8.15-8.18 (m, 1H), 8.27 (d, 2H), 8.94 (d, 1H), 9.57 (d, 1H), 9.81 (s, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 165. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-2- yl)-N,N-dimethylethan-1-amine Using N,N-dimethyl-2-(pyrrolidin-2-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.08-2.15 (m, 2H), 2.39-2.45 (m, 2H), 2.88 (s, 6H), 3.08-3.13 (m, 2H), 3.26-3.31 (m, 2H), 3.50-3.59 (m, 2H), 3.92-3.96 (m, 1H), 7.31 (s, 1H), 7.56 (d, 2H), 8.20-8.22 (m, 1H), 8.26 (d, 2H), 8.95 (d, 1H), 9.58 (d, 1H), 9.80 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 408.2 [M+H]<com:Sup>+< / com:Sup> Example 166. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-one Using piperidin-4-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.85-1.90 (m, 4H), 3.93 (br, 2H), 3.99 (br, 2H), 7.31 (s, 1H), 7.54 (d, 2H), 8.12-8.14 (m, 1H), 8.23 (d, 2H), 8.91 (d, 1H), 9.49 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): 365.1 [M+H]<com:Sup>+< / com:Sup> Example 167. 6-(4-chlorophenyl)-N-methyl-N-(piperidin-4-yl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl 4-(methylamino)piperidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.05 (d, 2H), 2.14-2.21 (m, 2H), 3.17 (s, 3H), 3.34-3.36 (m, 2H), 3.59 (d, 2H), 5.26 (br, 1H), 7.23 (s, 1H), 7.55 (d, 2H), 8.16-8.18 (m, 1H), 8.27 (d, 2H), 8.94 (d, 1H), 9.59 (d, 1H), 9.85 (s, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 168. 6-(4-chlorophenyl)-N-(2-(1-methylpiperidin-2-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 2-(1-methylpiperidin-2-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.90-1.96 (m, 4H), 2.30 (d, 1H), 2.41-2.46 (m, 1H), 2.92 (s, 3H), 3.05-3.10 (m, 1H), 3.52-3.57 (m, 2H), 3.73 (br, 2H), 3.77 (br, 2H), 7.01 (s, 1H), 7.54 (d, 2H), 8.13-8.15 (m, 1H), 8.17 (d, 2H), 8.93 (d, 1H), 9.49 (d, 1H), 9.76 (s, 1H); MS <com:Math><semantics>(ESI,m / z):408.2[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 408.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 169. 6-(4-chlorophenyl)-N-(1-(1-methylpiperidin-4-yl)ethyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 1-(1-methylpiperidin-4-yl)ethan-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.32 (d, 3H), 1.39-1.45 (m, 2H), 1.62-1.67 (m, 1H), 1.94 (br, 2H), 2.11-2.18 (m, 1H), 3.85 (s, 3H), 2.97-3.13 (m, 2H), 3.48-3.63 (m, 2H), 7.29 (s, 1H), 7.54 (d, 2H), 7.94-7.97 (m, 1H), 8.23 (d, 2H), 8.83 (d, 1H), 9.30 (d, 1H), 9.70 (s, 1H); MS (ESI, m / z): 408.2 [M+H]<com:Sup>+< / com:Sup> Example 170. 6-(4-chlorophenyl)-N-((1-(2-methoxyethyl)piperidin-4-yl)methyl)-2- (pyridin-3-yl)pyrimidin-4-amine Using (1-(2-methoxyethyl)piperidin-4-yl)methanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.65 (br, 2H), 2.12 (br, 2H), 3.02 (br, 2H), 3.40 (s, 3H), 3.48 (br, 1H), 3.60 (br, 1H), 3.64-3.72 (m, 2H), 4.51 (br, 1H), 4.90-4.97 (m, 4H), 6.97 (s, 1H), 7.54 (d, 2H), 7.94-7.98 (m, 1H), 8.16 (d, 2H), 8.83 (d, 1H), 9.29 (d, 1H), 9.70 (s, 1H); MS <com:Math><semantics>(ESI,m / z):438.2[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 438.2 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 171. methyl 2-(4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)piperidin-1-yl)acetate Using methyl 2-(4-aminopiperidin-1-yl)acetate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.97 (br, 4H), 2.43 (br, 4H), 3.89 (s, 3H), 4.23 (s, 2H), 4.47 (br, 1H), 6.97 (s, 1H), 7.54 (d, 2H), 7.81-7.84 (m, 1H), 8.16 (d, 2H), 8.77 (d, 1H), 9.16 (d, 1H), 9.66 (s, 1H); MS (ESI, m / z): <com:Math><semantics>438.2 [M+H]+<annotation encoding="application / x-tex">438.2 \text{ [M+H]}^+< / annotation>< / semantics>< / com:Math> Example 172. 1-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4- yl)ethyl 2,2,2-trifluoroacetate Using 1-(piperidin-4-yl)ethyl 2,2,2-trifluoroacetate and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 3.05 (br, 4H), 3.53-3.59 (m, 1H), 7.26 (s, 1H), 7.54 (d, 2H), 8.02-8.05 (m, 1H), 8.21 (d, 2H), 8.86 (d, 1H), 9.37 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 491.1 [M+H]<com:Sup>+< / com:Sup> Example 173. 6-(4-chlorophenyl)-N-(1-methylpiperidin-3-yl)-2-(pyridin-3- yl)pyrimidin-4-amine Using 1-methylpiperidin-3-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.26 (m, 2H), 2.79 (t, 1H), 2.96 (s, 3H), 3.57-3.62 (m, 1H), 3.88-3.93 (m, 1H), 4.62 (br, 1H), 7.00 (s, 1H), 7.55 (d, 2H), 7.97-8.00 (m, 1H), 8.17 (d, 2H), 8.86 (d, 1H), 9.38 (d, 1H), 9.79 (s, 1H); MS (ESI, m / z): 380.2 [M+H]<com:Sup>+< / com:Sup> Example 174. (1S,2R)-2-((6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4- yl)pyrimidin-4-yl)amino)cyclopentan-1-ol Scheme for the preparation of the Compound of Example 174: [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 8. methyl 1-methyl-1H-pyrazole-4-carbimidate A suspension of 1-methyl-1H-pyrazole-4-carbonitrile (3.0 g, 28.04 mmol) in Hydrogen chloride-methanol solution (4 M HCl gas in MeOH, 30 mL) was stirred at room temperature for 16 hr. The solvent was removed in vacuo and the residue was purified via silica gel column chromatography (DCM / MeOH = <com:Math><semantics>20 / 1<annotation encoding="application / x-tex">20 / 1< / annotation>< / semantics>< / com:Math>; V / V) to afford 1.7 g of the title compound. <com:Math><semantics>MS<annotation encoding="application / x-tex">MS< / annotation>< / semantics>< / com:Math> (ESI, m / z): 140.1 [M+H]<com:Sup>+< / com:Sup> Intermediate 9. 1-methyl-1H-pyrazole-4-carboximidamide A solution of methyl 1-methyl-1H-pyrazole-4-carbimidate (2.7 g, 19.4 mmol) in 30 mL of ammonia-MeOH solution (7.0 M NH<com:Sub>3< / com:Sub> in MeOH) was stirred at room temperature for 16 hr. The solvent was removed in vacuo and the residue was purified via reverse phase column chromatography (<com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> / <com:Math><semantics>MeOH=10<annotation encoding="application / x-tex">MeOH = 10< / annotation>< / semantics>< / com:Math> / 1; V / V) to afford 1.8 g of the title compound as a white solid. MS (ESI, m / z): <com:Math><semantics>125.1[M+H]+<annotation encoding="application / x-tex">125.1 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Intermediate 10. methyl 3-(4-chlorophenyl)-3-oxopropanoate To a solution of 1-(4-chlorophenyl)ethan-1-one (2.4 g, 15.5 mmol) in tetrahydrofuran (25 mL) was added sodium hydride (60 %, 0.62 g, 15.5 mmol) at room temperature. A solution of dimethyl carbonate (0.7 g, 7.76 mmol) in tetrahydrofuran (5 mL) was added to the above reaction mixture during 5 minutes. The reaction mixture was heated at 70 °C for 2 hr. The reaction mixture was cooled to room temperature and quenched by saturated ammonium chloride aqueous solution. The mixture was acidified to <com:Math><semantics>pH=6.0<annotation encoding="application / x-tex">pH = 6.0< / annotation>< / semantics>< / com:Math> and the residue was extracted with dichloromethane (20 mL x 3), dried over anhydrous sodium sulfate. The solids was filtered off and the filtrate was concentrated in vacuo. The residue was purified via silica gel column chromatography (Petroleum ether / EtOAc = <com:Math><semantics>20 / 1<annotation encoding="application / x-tex">20 / 1< / annotation>< / semantics>< / com:Math>; V / V) to afford 2.3 g of the title compound as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.77 (s, 1H), 3.83 (s, 3H), 4.03 (s, 1H), 5.73 (s, 1H), 7.68 (d, <com:Math><semantics>J=8.3<annotation encoding="application / x-tex">J = 8.3< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.76 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 8.06 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 8.06 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 8.06 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 8.06 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 8.06 (d, <com:Math><semantics>J=8.<annotation encoding="application / x-tex">J = 8.< / annotation>< / semantics>< / com:Math> 8.1 Hz, 1H), 12.48 (s, 1H); MS (ESI, m / z): 213.1 [M+H]<com:Sup>+< / com:Sup> Intermediate 11. 6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-ol To a solution of methyl 3-(4-chlorophenyl)-3-oxopropanoate (1.7 g, 8.13 mmol) in MeOH (20 mL) was added 1-methyl-1H-pyrazole-4-carboximidamide (1.0 g, 8.13 mmol) and sodium methoxide (527 mg, 9.576 mmol) at room temperature. The reaction mixture was heated at 80 °C under nitrogen for 16 hr. The residue was cooled to room temperature and acidified to <com:Math><semantics>pH=6.0<annotation encoding="application / x-tex">pH = 6.0< / annotation>< / semantics>< / com:Math>. A white solid was formed. The solid was collected by filtration and dried in vacuo to give 1.1 g of the title compound as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.93 (s, 3H), 6.85 (s, 1H), 7.85 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.3 Hz, 2H), 8.29 (s, 1H), 8.59 (s, 1H), 8.36 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 12.70 (s, 1H); MS (ESI, m / z): 287.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Intermediate 12. 4-chloro-6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4- yl)pyrimidine A solution of 6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-ol (1.0 g, 3.43 mmol) in 10 mL of phosphorus oxychloride was heated at reflux for 13 hr. The mixture was concentrated in vacuo. The residue was poured into water and extracted with EtOAc (20 mL x 2), washed with brine, dried and concentrated in vacuo. The residue was purified via column chromatography (DCM / MeOH = <com:Math><semantics>10 / 1<annotation encoding="application / x-tex">10 / 1< / annotation>< / semantics>< / com:Math>; V / V) to afford 950 mg of the title compound. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 3.94 (s, 3H), 7.93 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.3 Hz, 2H), 8.14 (d, <com:Math><semantics>J=5.5 Hz<annotation encoding="application / x-tex">J = 5.5 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 2H), 8.53 (d, <com:Math><semantics>J=8.2 Hz<annotation encoding="application / x-tex">J = 8.2 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 2H), 8.56 (s, 1H); MS (ESI, m / z): 305.1 [M+H]<com:Sup>+< / com:Sup> Example 174. (1S,2R)-2-((6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4- yl)pyrimidin-4-yl)amino)cyclopentan-1-ol To a solution of 4-chloro-6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidine (28 mg, 0.09 mmol) in tetrahydrofuran (4 mL) was added triethylamine (0.2 mL, 1.43 mmol) followed by (1S,2R)-2-aminocyclopentan-1-ol (20 mg, 0.20 mmol) at room temperature. The reaction mixture in sealed tube was heated at 120 °C for 4 h. and cooled to room temperature. The residue was filtered, evaporated in vacuo and isolated by Preparative HPLC to give 15 mg of the title compound. <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.95 (br, 1H), 2.05 (br, 1H), 3.41 (br, 3H), 3.49 (br, 3H), 4.03 (s, 3H), 6.98 (s, 1H), 7.67 (d, 2H), 7.90 (d, 2H), 8.33 (s, 1H), 8.59 (s, 1H); MS <com:Math><semantics>(ESI,m / z):370.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 370.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 175. (R)-1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-3-ol Using (R)-piperidin-3-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] (d, 2H), 3.89 (br, 1H), 3.93 (br, 2H), 4.01 (s, 3H), 7.08 (s, 1H), 7.64 (d, 2H), 7.88 (d, 2H), 8.32 (s, 1H), 8.58 (s, 1H); MS (ESI, m / z): 370.1 [M+H]<com:Sup>+< / com:Sup> Example 176. 1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-4-ol Using piperidin-4-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 4.01 (s, 3H), 4.01-4.07 (m, 1H), 4.36 (br, 2H), 7.10 (s, 1H), 7.63 (d, 2H), 7.89 (d, 2H), 8.31 (s, 1H), 8.57 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 370.1 [M+H]<com:Sup>+< / com:Sup> Example 177. (1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-4-yl)methanol Using piperidin-4-ylmethanol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 3.28 (m, 1H), 3.48 (d, 2H), 4.01 (s, 3H), 7.08 (s, 1H), 7.64 (d, 2H), 7.88 (d, 2H), 8.30 (s, 1H), 8.56 (s, 1H); MS (ESI, m / z): 384.2 [M+H]<com:Sup>+< / com:Sup> Example 178. 2-(1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-4-yl)ethan-1-ol Using 2-(piperidin-4-yl)ethan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 4H), 3.25 (br, 1H), 3.67 (t, 2H), 4.01 (s, 3H), 7.08 (s, 1H), 7.64 (d, 2H), 7.87 (d, 2H), 8.31 (s, 1H), 8.58 (s, 1H); MS (ESI, m / z): 398.2 [M+H]<com:Sup>+< / com:Sup> Example 179. 3-(1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-4-yl)propan-1-ol Using 3-(piperidin-4-yl)propan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 1.80 (m, 1H), 1.98 (d, 2H), 3.21 (t, 2H), 3.57 (t, 2H), 4.00 (s, 3H), 4.83 (br, 2H), 7.05 (s, 1H), 7.63 (d, 2H), 7.88 (d, 2H), 8.29 (s, 1H), 8.55 (s, 1H); MS (ESI, m / z): 412.2 [M+H]<com:Sup>+< / com:Sup> Example 180. 4-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-6-(4- methylpiperidin-1-yl)pyrimidine Using 4-methylpiperidine, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 2H), 8.31 (s, 1H), 8.58 (s, 1H); MS (ESI, m / z): 368.2 [M+H]<com:Sup>+< / com:Sup> Example 181. 4-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-6-(4- methylpiperazin-1-yl)pyrimidine Using 1-methylpiperazine, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 182. 2-(4-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperazin-1-yl)ethan-1-ol Using 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 3H), 4.34 (br, 4H), 7.22 (s, 1H), 7.63 (d, 2H), 7.96 (d, 2H), 8.33 (s, 1H), 8.59 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 399.2 [M+H]<com:Sup>+< / com:Sup> Example 183. (S)-1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)pyrrolidin-3-ol Using (S)-pyrrolidin-3-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 4.03 (br, 1H), 4.63 (d, 1H), 6.83 (s, 1H), 7.65 (d, 2H), 7.90 (d, 2H), 8.30 (s, 1H), 8.55 (s, 1H); MS (ESI, m / z): 356.1 [M+H]<com:Sup>+< / com:Sup> Example 184. 1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidine-4-carbonitrile Using piperidine-4-carbonitrile, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 3.25 (m, 1H), 3.84-3.90 (m, 2H), 4.01 (s, 3H), 4.31 (br, 2H), 7.12 (s, 1H), 7.63 (d, 2H), 7.91 (d, 2H), 8.31 (s, 1H), 8.56 (s, 1H); MS (ESI, m / z): 379.1 [M+H]<com:Sup>+< / com:Sup> Example 185. (R)-(1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)piperidin-3-yl)methanol Using (R)-piperidin-3-ylmethanol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 1.93 (d, 2H), 3.18 (br, 1H), 3.39 (t, 1H), 3.48-3.52 (m, 1H), 3.58-3.62 (m, 1H), 4.01 (s, 3H), 4.59 (br, 2H), 7.08 (s, 1H), 7.63 (d, 2H), 7.88 (d, 2H), 8.31 (s, 1H), 8.57 (s, 1H); MS (ESI, m / z): 384.2 [M+H]<com:Sup>+< / com:Sup> Example 186. (R)-1-(6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)pyrrolidin-3-ol Using (R)-pyrrolidin-3-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 4.03 (br, 1H), 4.63 (d, 1H), 6.83 (s, 1H), 7.65 (d, 2H), 7.90 (d, 2H), 8.30 (s, 1H), 8.55 (s, 1H); MS (ESI, m / z): 356.1 [M+H]<com:Sup>+< / com:Sup> Example 187. (1S,3R)-3-((6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4- yl)pyrimidin-4-yl)amino)cyclopentan-1-ol Using (1S,3R)-3-aminocyclopentan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 4.37 (br, 1H), 6.97 (s, 1H), 7.65 (d, 2H), 7.88 (d, 2H), 8.32 (s, 1H), 8.58 (s, 1H); MS (ESI, m / z): 370.1 [M+H]<com:Sup>+< / com:Sup> Example 188. (R)-2-((6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4- yl)amino)butan-1-ol Using (R)-2-aminobutan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.69-3.73 (m, 2H), 4.02 (s, 3H), 6.97 (s, 1H), 7.65 (d, 2H), 7.89 (d, 2H), 8.32 (s, 1H), 8.56 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 358.1 [M+H]<com:Sup>+< / com:Sup> Example 189. Trans-4-((6-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4- yl)pyrimidin-4-yl)amino)cyclohexan-1-ol Using Trans-4-aminocyclohexan-1-ol, the title compound was obtained as described for the example 174 (Scheme 2. General procedure B.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.43 (br, 4H), 3.63 (br, 1H), 4.02 (s, 3H), 6.97 (s, 1H), 7.65 (d, 2H), 7.89 (d, 2H), 8.31 (s, 1H), 8.56 (s, 1H); MS (ESI, m / z): 384.2 [M+H]<com:Sup>+< / com:Sup> Example 190. 7-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)octahydro-2H- pyrano[2,3-c]pyridine Using octahydro-2H-pyrano[2,3-c]pyridine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 1.85 (d, 1H), 1.95 (d, 1H), 2.10-2.20 (m, 1H), 2.98-3.08 (m, 2H), 3.20 (d, 1H), 3.53 (t, 2H), 3.92 (d, 1H), 7.17 (s, 1H), 7.46 (d, 2H), 8.06-8.09 (m, 1H), 8.11 (d, 2H), 8.87 (d, 1H), 9.37 (d, 1H), 9.63 (s, 1H); MS (ESI, m / z): <com:Math><semantics>407.2[M+H]+<annotation encoding="application / x-tex">407.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 191. 7-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)octahydro-2H- pyrano[2,3-c]pyridin-4-ol Using octahydro-2H-pyrano[2,3-c]pyridin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1.83 (m, 1H), 1.88-1.92 (m, 1H), 1.94-2.04 (m, 1H), 2.14-2.21 (m, 1H), 2.99-3.11 (m, 1H), 3.18- 3.27 (m, 1H), 3.51 (t, 1H), 3.61-3.73 (m, 1H), 3.78-3.86 (m, 1H), 3.88-4.00 (m, 2H), 7.23 (s, 1H), 7.50 (d, 2H), 8.12-8.19 (m, 3H), 8.91 (d, 1H), 9.47 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 423.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 192. (2R,3R)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)pentan-2-ol Using (2R,3R)-3-aminopentan-2-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.02 (t, 3H), 1.21 (d, 3H), 1.58-1.68 (m, 2H), 1.79-1.85 (m, 1H), 2.01-2.05 (m, 1H), 4.00 (br, 1H), 4.36 (br, 1H), 7.02 (s, 1H), 7.54 (d, 2H), 7.98-8.02 (m, 1H), 8.14 (d, 2H), 8.84 (d, 1H), 9.34 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 369.1 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 193. 6-(4-chlorophenyl)-N-((1-methylpiperidin-4-yl)methyl)-2-(pyridin-3- yl)pyrimidin-4-amine Using (1-methylpiperidin-4-yl)methanamine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2H), 2.86 (s, 3H), 3.01 (t, 1H), 3.13 (t, 1H), 3.57 (br, 2H), 3.81-3.93 (m, 1H), 7.00 (s, 1H), 7.54 (d, 2H), 8.12-8.16 (m, 1H), 8.24 (d, 2H), 8.92 (d, 1H), 9.49 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 394.2 [M+H]<com:Sup>+< / com:Sup> Example 194. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin- 3-01 Using (R)-pyrrolidin-3-ol) and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.17 (br, 2H), 3.70 (br, 2H), 3.86 (br, 2H), 4.59 (br, 1H), 6.95 (s, 1H), 7.52 (d, 2H), 8.07-8.11 (m, 1H), 8.19 (d, 2H), 8.89 (d, 1H), 9.43 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): <com:Math><semantics>353.1 [M+H]+<annotation encoding="application / x-tex">353.1 \text{ [M+H]}^+< / annotation>< / semantics>< / com:Math> Example 195. (S)-6-(4-chlorophenyl)-N-(2-(methoxymethyl)pyrrolidin-1-yl)-2- (pyridin-3-yl)pyrimidin-4-amine Using (S)-2-(methoxymethyl)pyrrolidin-1-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.60 (br, 1H), 1.80-1.87 (m, 1H), 1.89-1.97 (m, 1H), 2.02-2.10 (m, 1H), 2.17-2.21 (m, 1H), 2.82-2.89 (m, 1H), 3.07 (br, 1H), 3.24 (s, 3H), 3.44 (t, 2H), 7.42 (s, 1H), 7.56 (d, 2H), 8.08-8.12 (m, 1H), 8.21 (d, 2H), 8.89 (d, 1H), 9.45 (d, 1H), 9.71 (s, 1H); MS (ESI, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 396.2 [M+H]<com:Sup>+< / com:Sup> Example 196. (S)-4-(4-chlorophenyl)-6-(3-fluoropyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using (S)-3-fluoropyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 6.98 (s, 1H), 7.53 (d, 2H), 8.03-8.06 (m, 1H), 8.23 (d, 2H), 8.86 (d, 1H), 9.40 (d, 1H), 9.71 (s, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 197. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(2-(trifluoromethyl)pyrrolidin- 1-yl)pyrimidine Using 2-(trifluoromethyl)pyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 1H), 7.20 (s, 1H), 7.56 (d, 2H), 8.02-8.06 (m, 1H), 8.28 (d, 2H), 8.87 (d, 1H), 9.40 (d, 1H), 9.74 (s, 1H); MS (ESI, m / z): <com:Math><semantics>405.1[M+H]+<annotation encoding="application / x-tex">405.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 198. 4-(4-chlorophenyl)-6-(3,3-difluoropyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine Using 3,3-difluoropyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 7.06 (s, 1H), 7.55 (d, 2H), 8.04-8.07 (m, 1H), 8.28 (d, 2H), 8.87 (d, 1H), 9.44 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 373.1 [M+H]<com:Sup>+< / com:Sup> Example 199. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- yl)morpholine Using 4-(pyrrolidin-3-yl)morpholine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.44 (br, 1H), 2.68 (br, 1H), 3.52 (br, 4H), 3.70 (br, 2H), 3.99 (br, 5H), 4.14 (br, 2H), 7.06 (s, 1H), 7.54 (d, 2H), 8.16-8.19 (m, 1H), 8.25 (d, 2H), 8.94 (d, 1H), 9.57 (d, 1H), 9.80 (s, 1H); MS (ESI, m / z): 422.2 [M+H]<com:Sup>+< / com:Sup> Example 200. 5-(((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)methyl)pyrrolidin-2-one Using 5-(aminomethyl)pyrrolidin-2-one and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 4.04 (br, 1H), 7.01 (s, 1H), 7.54 (d, 2H), 8.07-8.10 (m, 1H), 8.17 (d, 2H), 8.88 (d, 1H), 9.46 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 380.1 [M+H]<com:Sup>+< / com:Sup> Example 201. Trans-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(4-(pyrrolidin-1- yl)tetrahydrofuran-3-yl)pyrimidin-4-amine Using Trans-4-(pyrrolidin-1-yl)tetrahydrofuran-3-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 4.19-4.21 (m, 2H), 4.43-4.47 (m, 1H), 5.31 (br, 1H), 7.06 (s, 1H), 7.55 (d, 2H), 8.00-8.03 (m, 1H), 8.18 (d, 2H), 8.88 (d, 1H), 9.36 (d, 1H), 9.73 (s, 1H); MS (ESI, m / z): 422.2 [M+H]<com:Sup>+< / com:Sup> Example 202. 6-(4-chlorophenyl)-N-((3S,4S)-4-methoxy-1-methylpyrrolidin-3-yl)-2- (pyridin-3-yl)pyrimidin-4-amine Using (3S,4S)-4-methoxy-1-methylpyrrolidin-3-amine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.59 (br, 1H), 1.90 (br, 1H), 2.02 (br, 1H), 3.06 (s, 3H), 3.55 (s, 3H), 3.72 (br, 1H), 3.84 (br, 2H), 7.10 (s, 1H), 7.53 (d, 2H), 8.18 (d, 2H), 8.19 8.27 (m, 1H), 8.95 (d, 1H), 9.55 (d, 1H), 9.78 (s, 1H); MS (ESI, m / z): 396.2 [M+H]<com:Sup>+< / com:Sup> Example 203. (R)-6-(4-chlorophenyl)-N-(piperidin-3-yl)-2-(pyridin-3-yl)pyrimidin- 4-amine Using tert-butyl (R)-3-aminopiperidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.15 (m, 1H), 2.17-2.23 (m, 1H), 2.96-3.01 (m, 1H), 3.04-3.11 (m, 1H), 3.37-3.43 (m, 1H), 3.69- 3.73 (m, 1H), 4.56 (br, 1H), 7.03 (s, 1H), 7.54 (d, 2H), 8.02-8.06 (m, 1H), 8.17 (d, 2H), 8.88 (d, 1H), 9.44 (d, 1H), 9.82 (s, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 204. 6-(4-chlorophenyl)-N-(piperidin-3-yl)-2-(pyridin-3-yl)pyrimidin-4- amine Using tert-butyl 3-aminopiperidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.15 (m, 1H), 2.17-2.23 (m, 1H), 2.96-3.01 (m, 1H), 3.04-3.11 (m, 1H), 3.37-3.43 (m, 1H), 3.69- 3.73 (m, 1H), 4.56 (br, 1H), 7.03 (s, 1H), 7.54 (d, 2H), 8.02-8.06 (m, 1H), 8.17 (d, 2H), 8.88 (d, 1H), 9.44 (d, 1H), 9.82 (s, 1H); MS (ESI, m / z): 366.1 [M+H]<com:Sup>+< / com:Sup> Example 205. 6-(4-chlorophenyl)-N-((3R,4R)-3-fluoropiperidin-4-yl)-2-(pyridin-3- yl)pyrimidin-4-amine Using tert-butyl (3R,4R)-4-amino-3-fluoropiperidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] (br, 5H), 7.08 (s, 1H), 7.55 (d, 2H), 8.08-8.11 (m, 1H), 8.20 (d, 2H), 8.90 (d, 1H), 9.41 (d, 1H), 9.70 (s, 1H); MS (ESI, m / z): <com:Math><semantics>384.1[M+H]+<annotation encoding="application / x-tex">384.1 [M+H]^{+}< / annotation>< / semantics>< / com:Math> Example 206. (S)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3- ylmethyl)pyrimidin-4-amine Using tert-butyl (R)-3-(aminomethyl)pyrrolidine-1-carboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.87 (m, 1H), 3.10-3.15 (m, 1H), 3.41-3.48 (m, 1H), 3.50-3.55 (m, 1H), 3.75 (br, 2H), 7.01 (s, 1H), 7.54 (d, 2H), 8.09-8.13 (m, 1H), 8.17 (d, 2H), 8.91 (d, 1H), 9.48 (d, 1H), 9.77 (s, 1H); MS <com:Math><semantics>(ESI,m / z):366.1[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 366.1 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 207. methyl (2R,4R)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)pyrrolidine-2-carboxylate Using 1-(tert-butyl) 2-methyl (2R,4R)-4-aminopyrrolidine-1,2-dicarboxylate and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Math><semantics>MS<annotation encoding="application / x-tex">MS< / annotation>< / semantics>< / com:Math> (ESI, m / z): 410.1 [M+H]<com:Sup>+< / com:Sup> Example 208. (2R,4S)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)pyrrolidine-2-carboxylic acid Using (2R,4S)-4-amino-1-(tert-butoxy carbonyl)pyrrolidine-2-carboxylic acid and separation method of PREP. HPLC, the title compound was obtained as described for the example 54 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.61 (br, 2H), 2.04 (br, 2H), 2.20 (t, 1H), 3.35 (br, 1H), 7.01 (s, 1H), 7.55 (d, 2H), 7.78-7.81 (m, 1H), 8.18 (d, 2H), 8.76 (d, 1H), 9.12 (d, 1H), 9.66 (s, 1H); MS (ESI, m / z): 396.1 [M+H]<com:Sup>+< / com:Sup> Example 209. Trans-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)- 1-isopropylpyrrolidin-3-ol Using Trans-4-amino-1-isopropylpyrrolidin-3-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.43 (t, 6H), 1.61 (br, 1H), 1.90 (br, 1H), 2.02 (br, 1H), 2.19 (t, 1H), 3.55 (br, 1H), 3.72 (br, 1H), 3.84 (br, 1H), 7.06 (s, 1H), 7.55 (d, 2H), 7.95- 7.80 (m, 1H), 8.19 (d, 2H), 8.85 (d, 1H), 9.36 (d, 1H), 9.75 (s, 1H); MS (ESI, m / z): 410.2 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math> Example 210. (R)-4-(3-(chloromethyl)pyrrolidin-1-yl)-6-(4-chlorophenyl)-2- (pyridin-3-yl)pyrimidine Using (R)-3-(chloromethyl)pyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.98 (br, 1H), 2.28 (br, 1H), 2.79 (br, 1H), 3.54 (br, 1H), 3.68-3.78 (m, 4H), 4.02 (br, 1H), 6.88 (s, 1H), 7.50 (d, 2H), 8.08-8.11 (m, 1H), 8.18 (d, 2H), 8.89 (d, 1H), 9.43 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 385.1 [M+H]<com:Sup>+< / com:Sup> Example 211. (S)-4-(3-(chloromethyl)pyrrolidin-1-yl)-6-(4-chlorophenyl)-2- (pyridin-3-yl)pyrimidine Using (S)-3-(chloromethyl)pyrrolidine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.98 (br, 1H), 2.28 (br, 1H), 2.79 (br, 1H), 3.54 (br, 1H), 3.68-3.78 (m, 4H), 4.02 (br, 1H), 6.88 (s, 1H), 7.50 (d, 2H), 8.08-8.11 (m, 1H), 8.18 (d, 2H), 8.89 (d, 1H), 9.43 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 385.1 [M+H]<com:Sup>+< / com:Sup> Example 212. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidine-3- carbonitrile Using pyrrolidine-3-carbonitrile and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 2.44 (br, 1H), 2.53 (br, 1H), 3.57 (br, 1H), 3.84 (br, 2H), 4.06 (br, 2H), 7.06 (s, 1H), 7.55 (d, 2H), 8.08-8.12 (m, 1H), 8.27 (d, 2H), 8.89 (d, 1H), 9.49 (d, 1H), 9.76 (s, 1H); MS (ESI, m / z): 362.1 [M+H]<com:Sup>+< / com:Sup> Example 213. (R)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)butan-2-ol Using (R)-1-aminobutan-2-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR: (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 1.05 (t, 3H), 1.48-1.59 (m, 1H), 1.61-1.70 (m, 1H), 3.55 (br, 1H), 3.72 (br, 1H), 3.76 (br, 1H), 6.99 (s, 1H), 7.51 (d, 2H), 8.09-8.13 (m, 3H), 8.90 (d, 1H), 9.44 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 355.1 [M+H]<com:Sup>+< / com:Sup> Example 214. (1R,3S)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclopentan-1-ol Using (1R,3S)-3-aminocyclopentan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.23 (m, 1H), 2.43-2.50 (m, 1H), 4.34-4.38 (m, 1H), 4.62 (br, 1H), 6.94 (s, 1H), 7.53 (d, 2H), 8.06-8.10 (m, 1H), 8.12 (d, 2H), 8.89 (d, 1H), 9.41 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 367.1 Example 215. Cis-(4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexyl)methanol Using Cis-4-aminocyclohexan-1-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 1H), 3.92 (br, 1H), 4.24 (br, 1H), 6.96 (s, 1H), 7.53 (d, 2H), 8.01-8.05 (m, 1H), 8.12 (d, 2H), 8.86 (d, 1H), 9.34 (d, 1H), 9.67 (s, 1H); MS (ESI, m / z): 381.1 [M+H]<com:Sup>+< / com:Sup> Example 216. Cis-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexan-1-ol Using Cis-(4-aminocyclohexyl)methanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.05 (m, 1H), 3.71-3.74 (m, 1H), 3.84-8.37 (m, 1H), 4.46 (br, 1H), 7.04 (s, 1H), 7.55 (d, 2H), 8.09-8.15 (m, 3H), 8.90 (d, 1H), 9.43 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 395.2 [M+H]<com:Sup>+< / com:Sup> Example 217. Trans-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)amino)cyclohexan-1-ol Using Trans-(4-aminocyclohexyl)methanol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). [Image disponible dans le document PDF, Image available in the PDF document] 2.05 (m, 1H), 3.71-3.74 (m, 1H), 3.84-8.37 (m, 1H), 4.46 (br, 1H), 7.04 (s, 1H), 7.55 (d, 2H), 8.09-8.15 (m, 3H), 8.90 (d, 1H), 9.43 (d, 1H), 9.69 (s, 1H); MS (ESI, m / z): 395.2 [M+H]<com:Sup>+< / com:Sup> Example 218. 4-(4-chlorophenyl)-6-(4-(2-methoxyethyl)piperazin-1-yl)-2-(pyridin- 3-yl)pyrimidine Using 1-(2-methoxyethyl)piperazine and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 9.83 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.0, 0.8 Hz, 1H), 9.59 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.2, 2.0, 1.5 Hz, 1H), 8.95 (d, <com:Math><semantics>J=5.7<annotation encoding="application / x-tex">J = 5.7< / annotation>< / semantics>< / com:Math>, 1.5, 0.7 Hz, 1H), 8.28 (d, 2H), 8.19 (dd, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math>, 5.7, 0.7 Hz, 1H), 7.54 (d, 2H), 7.44 (s, 1H), 3.82-3.77 (m, 4H), 3.77-3.50 (m, 4H), 3.49-3.43 (m, 7H); MS <com:Math><semantics>(ESI,m / z):410.2[M+H]+<annotation encoding="application / x-tex">(ESI, m / z): 410.2 [M+H]^+< / annotation>< / semantics>< / com:Math> Example 219. (3S,4R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3- fluoropiperidin-4-ol Using (3S,4R)-3-fluoropiperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 9.74 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.7, 0.8 Hz, 1H), 9.52 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.2, 1.9, 1.5 Hz, 1H), 8.92 (dd, <com:Math><semantics>J=5.7<annotation encoding="application / x-tex">J = 5.7< / annotation>< / semantics>< / com:Math>, 1.5, 0.8 Hz, 1H), 8.21 (dd, 2H), 8.19-8.14 (m, 1H), 7.51 (d, 2H), 7.30 (s, 1H), 4.56-4.47 (m, 1H), 4.47-4.33 (m, 1H), 4.17-4.06 (m, 1H), 4.04-3.94 (m, 1H), 3.94-3.82 (m, 1H), 3.82-3.68 (m, 1H), 2.18-2.05 (m, 1H), 1.74-1.60 (m, 1H); MS (ESI, m / z): 385.1 [M+H]<com:Sup>+< / com:Sup> Example 220. (3R,4S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3- fluoropiperidin-4-ol Using (3R,4S)-3-fluoropiperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 9.74 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.7, 0.8 Hz, 1H), 9.52 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.2, 1.9, 1.5 Hz, 1H), 8.92 (dd, <com:Math><semantics>J=5.7<annotation encoding="application / x-tex">J = 5.7< / annotation>< / semantics>< / com:Math>, 1.5, 0.8 Hz, 1H), 8.21 (dd, 2H), 8.19-8.14 (m, 1H), 7.51 (d, 2H), 7.30 (s, 1H), 4.56-4.47 (m, 1H), 4.47-4.33 (m, 1H), 4.17-4.06 (m, 1H), 4.04-3.94 (m, 1H), 3.94-3.82 (m, 1H), 3.82-3.68 (m, 1H), 2.18-2.05 (m, 1H), 1.74-1.60 (m, 1H); MS (ESI, m / z): 385.1 [M+H]<com:Sup>+< / com:Sup> Example 221. (3R,4R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3- fluoropiperidin-4-ol Using (3R,4R)-3-fluoropiperidin-4-ol and separation method of PREP. HPLC, the title compound was obtained as described for the example 1 (Scheme 1. General procedure A.). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> [ppm] = 9.74 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.7, 0.8 Hz, 1H), 9.52 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.2, 1.9, 1.5 Hz, 1H), 8.92 (dd, <com:Math><semantics>J=5.7<annotation encoding="application / x-tex">J = 5.7< / annotation>< / semantics>< / com:Math>, 1.5, 0.8 Hz, 1H), 8.21 (dd, 2H), 8.19-8.14 (m, 1H), 7.51 (d, 2H), 7.30 (s, 1H), 4.56-4.47 (m, 1H), 4.47-4.33 (m, 1H), 4.17-4.06 (m, 1H), 4.04-3.94 (m, 1H), 3.94-3.82 (m, 1H), 3.82-3.68 (m, 1H), 2.18-2.05 (m, 1H), 1.74-1.60 (m, 1H); MS (ESI, m / z): 385.1 [M+H]<com:Sup>+< / com:Sup> Example 222. (3S,4S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)py...
Claims
Claims
1. A compound of Formula (I), or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof: [Formula (I)] [Image disponible dans le document PDF, Image available in the PDF document] (I) wherein: <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> are N; <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CR2<annotation encoding="application / x-tex">CR^2< / annotation>< / semantics>< / com:Math>; Ar<com:Sup>1< / com:Sup> and Ar<com:Sup>2< / com:Sup> are each independently selected from substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heteroaryl and substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl; D and E, together with the atoms to which they are attached, are combined to form substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring; G is ether(-O-), thioether(-S-), sulfinyl(-SO-), sulfonyl(-SO<com:Sub>2< / com:Sub>-), -SO<com:Sub>2< / com:Sub>NR<com:Sup>4< / com:Sup>-, -NR<com:Sup>4< / com:Sup>SO<com:Sub>2< / com:Sub>-, carbonyl(-(CO)-), -(CO)NR<com:Sup>4< / com:Sup>-, -NR<com:Sup>4< / com:Sup>(CO)-, ester(-(CO)O-), substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> cycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl, or substituted or unsubstituted mono- or bicyclic C<com:Sub>5-10< / com:Sub> heteroaryl; <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is halo, cyano, hydroxy, amino, <com:Math><semantics>N(R5)2<annotation encoding="application / x-tex">N(R^5)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>OR5<annotation encoding="application / x-tex">OR^5< / annotation>< / semantics>< / com:Math>, substituted or unsubstituted <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>1-5< / com:Sub> alkylhydroxy, C<com:Sub>2-5< / com:Sub> alkenylhydroxy, C<com:Sub>2-5< / com:Sub> alkynylhydroxy, C<com:Sub>1-5< / com:Sub> alkylamine, C<com:Sub>2-5< / com:Sub> alkenylamine, C<com:Sub>2-5< / com:Sub> alkynylamine, substituted or unsubstituted monocyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl, phosphate, or substituted or unsubstituted C<com:Sub>1-3< / com:Sub> alkyl phosphate; R<com:Sup>2< / com:Sup> is H, halo, cyano, or hydroxy; <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is H, substituted or unsubstituted <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl, substituted or unsubstituted <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkoxy, or substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid; and R<com:Sup>5< / com:Sup> is H, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl, substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkoxy, or substituted or unsubstituted C<com:Sub>1-5< / com:Sub> alkyl carboxylic acid.
2. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, wherein the Ar<com:Sup>1< / com:Sup> is substituted or unsubstituted monocyclic C<com:Sub>5-7< / com:Sub> heteroaryl comprising one or more hetero atoms selected from the group consisting of N, O and S.
3. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the Ar<com:Sup>1< / com:Sup> is monocyclic C<com:Sub>5-6< / com:Sub> heteroaryl comprising one or two hetero atoms selected from the group consisting of N, O and S, which is unsubstituted or substituted with <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl.
4. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the Ar<com:Sup>1< / com:Sup> is pyrazole or pyridine which is unsubstituted or substituted with methyl.
5. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the <com:Math><semantics>Ar2<annotation encoding="application / x-tex">Ar^2< / annotation>< / semantics>< / com:Math> is mono- or bicyclic <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl comprising one or more hetero atoms selected from the group consisting of N, O and S, which is unsubstituted or substituted with halo.
6. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the Ar<com:Sup>2< / com:Sup> is phenyl which is unsubstituted or substituted with chloro.
7. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the D and E, together with the atoms to which they are attached, are combined to form substituted or unsubstituted mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring comprising one or more hetero atoms selected from the group consisting of N, O and S.
8. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 7, the mono- or bicyclic C<com:Sub>3-10< / com:Sub> heterocycloalkyl ring is unsubstituted or substituted pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, or octahydropyranopyridine.
9. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, the G is ether(-O-), thioether(-S-), sulfinyl(-SO-), sulfonyl(-SO<com:Sub>2< / com:Sub>-), -SO<com:Sub>2< / com:Sub>NR<com:Sup>4< / com:Sup>-, -NR<com:Sup>4< / com:Sup>SO<com:Sub>2< / com:Sub>-, carbonyl(-(CO)-), -(CO)NR<com:Sup>4< / com:Sup>-, -NR<com:Sup>4< / com:Sup>(CO)-, ester(-(CO)O-), substituted or unsubstituted mono- or bicyclic C<com:Sub>3-8< / com:Sub> cycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl, substituted or unsubstituted mono- or bicyclic C<com:Sub>6-10< / com:Sub> aryl, or substituted or unsubstituted mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl, wherein the mono- or bicyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl and mono- or bicyclic C<com:Sub>5-8< / com:Sub> heteroaryl comprises one or more heteroatoms selected from the group consisting of N, O and S.
10. The compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1, R<com:Sup>1< / com:Sup> is halo, cyano, hydroxy, amino, N(R<com:Sup>5< / com:Sup>)<com:Sub>2< / com:Sub>, OR<com:Sup>5< / com:Sup>, substituted or unsubstituted C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-4< / com:Sub> alkylhydroxy, C<com:Sub>2-4< / com:Sub> alkenylhydroxy, C<com:Sub>2-4< / com:Sub> alkynylhydroxy, C<com:Sub>1-4< / com:Sub> alkylamine, C<com:Sub>2-4< / com:Sub> alkenylamine, C<com:Sub>2-4< / com:Sub> alkynylamine, substituted or unsubstituted monocyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl, phosphate, or substituted or unsubstituted C<com:Sub>1-3< / com:Sub> alkyl phosphate, wherein the monocyclic C<com:Sub>3-8< / com:Sub> heterocycloalkyl comprises one or more heteroatoms selected from the group consisting of N, O and S. Claim 11 A compound which is selected from the compounds 1 to 376, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof:
1. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-1-ol 2. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 3. (S)-2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)amino)propan-1-ol 4. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-2-methylpropan-1-ol 5. 2-((4-(4-chlorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)amino)-2-methylpropan-1-ol 6. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)ethan-1-ol 7. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 8. (S)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-2-ol 9. (R)-1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-2-ol 10. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane-1,2-diol 11. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propan-1-ol 12. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1-ol 13. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1- ol 14. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylbutan-1- ol 15. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-1-ol 16. 2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propane-1,3-diol 17. (R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1-phenylethan-1- ol 18. (S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)-1-phenylethan-1- ol 19. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-((tetrahydro-2H-pyran-4- yl)methyl)pyrimidin-4-amine 20. N¹-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N³,N³-dimethylpropane-1,3- diamine 21. 6-(4-chlorophenyl)-N-ethyl-2-(pyridin-3-yl)pyrimidin-4-amine 22. 6-(4-chlorophenyl)-N-propyl-2-(pyridin-3-yl)pyrimidin-4-amine 23. N-butyl-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 24. 1-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 25. 6-(4-chlorophenyl)-N-(cyclopropylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 26. 6-(4-chlorophenyl)-N-cyclopentyl-2-(pyridin-3-yl)pyrimidin-4-amine 27. 4-(4-chlorophenyl)-6-(4-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 28. N-(tert-butyl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 29. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-01 30. (1S,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-01 31. 6-(4-chlorophenyl)-N-(pyridin-2-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 32. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine 33. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyridin-4-ylmethyl)pyrimidin-4-amine 34. trans-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1-ol 35. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1-ol 36. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)methanol 37. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)ethan-1-ol 38. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-ol 39. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-ol 40. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 41. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-ol 42. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanol 43. 2-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)ethan-1-ol 44. 3-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)propan-1-ol 45. 4-(4-chlorophenyl)-6-(4-methoxypiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 46. 4-(4-chlorophenyl)-6-(piperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 47. 4-(4-chlorophenyl)-6-(2-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 48. 4-(4-chlorophenyl)-6-(3-methylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 49. 4-(4-chlorophenyl)-6-(2,6-dimethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 50. 4-(4-chlorophenyl)-6-(3,5-dimethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 51. 4-(4-chlorophenyl)-6-(3,3-difluoropiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 52. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(3-(trifluoromethyl)piperidin-1-yl)pyrimidine 53. 4-(4-chlorophenyl)-6-(3-ethylpiperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 54. 6-(4-chlorophenyl)-N-(piperidin-4-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 55. 6-(4-chlorophenyl)-N-(piperidin-3-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 56. 6-(4-chlorophenyl)-N-(piperidin-4-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 57. 6-(4-chlorophenyl)-N-(1-methylpiperidin-4-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 58. 6-(4-chlorophenyl)-N-(2-(piperidin-4-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 59. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-2-yl)methanamine 60. (R)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-amine 61. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-amine 62. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanamine 63. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3- yl)methanamine 64. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-amine 65. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanamine 66. (1R,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-01 67. (1S,2S)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan- 1-01 68. trans-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclopentan-1-ol 69. (1R,2R)-2-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexan-1- ol 70. cis-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-2,6-dimethylmorpholine 71. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)morpholine 72. 6-(4-chlorophenyl)-N-(morpholin-2-ylmethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 73. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)morpholine 74. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)thiomorpholine 75. 6-(4-chlorophenyl)-N-(3-morpholinopropyl)-2-(pyridin-3-yl)pyrimidin-4-amine 76. (R)-4-(4-chlorophenyl)-6-(2-methylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 77. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-3-methylpiperazin-1- yl)(phenyl)methanone 78. methyl (R)-4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2- carboxylate 79. (R)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-yl)methanol 80. 4-(4-chlorophenyl)-6-(4-(2,3-dichlorophenyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 81. 4-(4-chlorophenyl)-6-(4-(2,5-dimethoxybenzyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine 84. 4-(4-chlorophenyl)-6-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 85. 4-(4-chlorophenyl)-6-(4-(2-fluorophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)methanone 87. 4-(4-chlorophenyl)-6-(4-phenethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 88. 6-(4-chlorophenyl)-N-(2-(piperazin-1-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 89. 4-(4-chlorophenyl)-6-(4-(pyridin-2-yl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 90. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrimidine 91. 4-(2-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1- yl)ethyl)morpholine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine 93. trans-4-(4-chlorophenyl)-6-(4-cinnamylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 94. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-one 95. 4-(4-chlorophenyl)-6-(4-phenylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 96. 4-(4-chlorophenyl)-6-(4-propylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 97. 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-6-(4-chlorophenyl)-2-(pyridin- 3-yl)pyrimidine 98. (S)-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-2-yl)methanol 99. 4-(4-chlorophenyl)-6-(4-(4-fluorophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 100. 6-(4-chlorophenyl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2-(pyridin-3- yl)pyrimidin-4-amine 101. 6-(4-chlorophenyl)-N-(piperidin-3-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 102. 4-(4-chlorophenyl)-6-(piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 103. Trans-4-(4-chlorophenyl)-6-(2,5-dimethylpiperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 104. Cis-4-(4-chlorophenyl)-6-(3,5-dimethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 105. 4-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 106. 4-(4-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 107. 4-(4-chlorophenyl)-6-(4-(methylsulfonyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 108. 1-(4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazin-1-yl)ethan-1-one 109. 4-(4-chlorophenyl)-6-(3-ethylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 110. ethyl 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-1- carboxylate 111. 4-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2-carboxylic acid 112. methyl 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperazine-2- carboxylate 113. (S)-4-(4-chlorophenyl)-6-(2-phenylpiperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 114. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(o-tolyl)piperazin-1-yl)pyrimidine 115. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(p-tolyl)piperazin-1-yl)pyrimidine 116. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(m-tolyl)piperazin-1-yl)pyrimidine 117. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(4-(3-(trifluoromethyl)phenyl)piperazin-1- yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine 121. 4-(4-chlorophenyl)-6-(4-(4-nitrophenyl)piperazin-1-yl)-2-(pyridin-3-yl)pyrimidine 122. 4-(4-chlorophenyl)-6-(3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidine 123. 4-(4-benzhydrylpiperazin-1-yl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidine 124. 4-(4-chlorophenyl)-6-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-2- (pyridin-3-yl)pyrimidine 125. 1'-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)spiro[indene-1,4'-piperidine] 126. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin-4-amine 127. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-yl)pyrimidin-4-amine 128. (R)-6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(pyrrolidin-3-ylmethyl)pyrimidin-4- amine 129. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrimidin-4-amine 130. 6-(4-chlorophenyl)-2-(pyridin-3-yl)-N-(3-(pyrrolidin-1-yl)propyl)pyrimidin-4- amine [Image disponible dans le document PDF, Image available in the PDF document] 4-amine 132. N-(1-benzylpyrrolidin-3-yl)-6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-amine 133. (3R,4S)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)pyrrolidin-3- ol 134. (3S,4R)-4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)pyrrolidin-3- ol 135. 4-(4-chlorophenyl)-2-(pyridin-3-yl)-6-(pyrrolidin-1-yl)pyrimidine 136. 4-(4-chlorophenyl)-6-(2-methylpyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidine 137. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-ol 138. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)methanol 139. (R)-4-(4-chlorophenyl)-6-(3-fluoropyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidine 140. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-amine 141. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-N-methylpyrrolidin-3-amine 142. methyl (6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)prolinate 143. N-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-yl)acetamide 144. (2R,3R)-3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 145. 3-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)butan-2-ol 146. 1-(4-((6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)piperidin-1- yl)ethan-1-one 147. (R)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 148. (S)-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-3-yl)methanol 149. 6-(4-chlorophenyl)-N-(2-(piperidin-1-yl)ethyl)-2-(pyridin-3-yl)pyrimidin-4-amine 150. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidine-4-carbonitrile 151. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-4-(3- (trifluoromethyl)phenyl)piperidin-4-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-o1 [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] oxopropanoate [Image disponible dans le document PDF, Image available in the PDF document] yl)acetate [Image disponible dans le document PDF, Image available in the PDF document] 1-01 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] amine [Image disponible dans le document PDF, Image available in the PDF document] dimethylethan-1-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)acetate [Image disponible dans le document PDF, Image available in the PDF document] trifluoroacetate [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclopentan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)propan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] carbonitrile [Image disponible dans le document PDF, Image available in the PDF document] 3-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclopentan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)butan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclohexan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] c]pyridine [Image disponible dans le document PDF, Image available in the PDF document] c]pyridin-4-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] 195. (S)-6-(4-chlorophenyl)-N-(2-(methoxymethyl)pyrrolidin-1-yl)-2-(pyridin-3- yl)pyrimidin-4-amine 196. (S)-4-(4-chlorophenyl)-6-(3-fluoropyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] 199. 4-(1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3- yl)morpholine [Image disponible dans le document PDF, Image available in the PDF document] one [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-amine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 4-amine [Image disponible dans le document PDF, Image available in the PDF document] amine [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)pyrrolidine-2-carboxylate [Image disponible dans le document PDF, Image available in the PDF document] 2-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] isopropylpyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1-01 [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)cyclohexyl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] hydroxyethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] methoxyacetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1(2H)-yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] hydroxypropanamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxyacetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-yl acetate [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] hydroxypyrrolidin-3-yl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidin-4-yl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] (hydroxymethyl)piperazine-1-carboxylate [Image disponible dans le document PDF, Image available in the PDF document] yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)methanesulfonamide [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3,4-diol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] 4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] one [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)morpholin-3-one [Image disponible dans le document PDF, Image available in the PDF document] acid [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] 3-o1 [Image disponible dans le document PDF, Image available in the PDF document] morpholinophenyl)acetamide [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidin-4-yl)phenol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] acid [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] 316. (S)-1-(6-(4-chloro-2-hydroxyphenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-ol 317. (S)-3-(6-(3-hydroxypyrrolidin-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)pyridin-2-ol 318. (1-(6-(6-fluoropyridin-3-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)methanol 319. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azetidin-3-ol 320. (1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azetidin-3-yl)methanol 321. 4-(4-chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-6-(4-(methylsulfonyl)piperazin- 1-yl)pyrimidine 322. (S)-1-(6-(4-chlorophenyl)-2-(3-hydroxyphenyl)pyrimidin-4-yl)pyrrolidin-3-ol formate 322. (S)-1-(6-(4-chlorophenyl)-2-(3-hydroxyphenyl)pyrimidin-4-yl)pyrrolidin-3-ol 323. (S)-1-(6-(4-chlorophenyl)-2-(5-fluoropyridin-3-yl)pyrimidin-4-yl)pyrrolidin-3-ol 324. (S)-1-(6-(4-chlorophenyl)-2-(pyridin-4-yl)pyrimidin-4-yl)pyrrolidin-3-ol 325. 4-(4-chlorophenyl)-2-(5-fluoropyridin-3-yl)-6-(4-(methylsulfonyl)piperazin-1- yl)pyrimidine 326. 4-(4-chlorophenyl)-6-(4-(methylsulfonyl)piperidin-1-yl)-2-(pyridin-3-yl)pyrimidine 327. (S)-1-(2-(5-fluoropyridin-3-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-4- yl)pyrrolidin-3-ol 328. 4-(4-chlorophenyl)-6-(4-(cyclopropylsulfonyl)piperazin-1-yl)-2-(pyridin-3- yl)pyrimidine 329. (S)-1-(6-(4-chlorophenyl)-2-(pyridazin-4-yl)pyrimidin-4-yl)pyrrolidin-3-ol 330. 1-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)azepan-4-ol 331. 2-(6-(4-chlorophenyl)-2-(pyridin-3-yl)pyrimidin-4-yl)-5-(methylsulfonyl)-2,5- diazabicyclo[2.2.1]heptane [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidin-3-ol [Image disponible dans le document PDF, Image available in the PDF document] 1-yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (trifluoromethyl)phenyl)pyrimidine [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)pyrrolidine-3,4-diol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] ol [Image disponible dans le document PDF, Image available in the PDF document] yl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] hydroxypropan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)piperazin-1-yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] 4-o1 [Image disponible dans le document PDF, Image available in the PDF document] 3-01 [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (methylsulfonyl)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] (dimethylamino)piperidin-4-yl)methanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)amino)ethanol [Image disponible dans le document PDF, Image available in the PDF document] hydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)propan-1-ol [Image disponible dans le document PDF, Image available in the PDF document] dihydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] dihydroxybutan-1-one [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] yl)pyridin-2-ol [Image disponible dans le document PDF, Image available in the PDF document] yl)phenyl)morpholin-3-one [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] yl)sulfonyl)propane-1,2-diol 370. 2-((4-(2-(isothiazol-4-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)piperazin-1- yl)sulfonyl)ethanol [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 373. (S)-3-(4-(3-fluoro-4-morpholinophenyl)-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-2- yl)pyridin-2-ol 374. (S)-1-(6-(4-((2-(dimethylamino)ethyl)amino)phenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)pyrrolidin-3-ol 375. (S)-1-(6-(4-(2-(dimethylamino)ethoxy)phenyl)-2-(pyridin-3-yl)pyrimidin-4- yl)pyrrolidin-3-ol, and [Image disponible dans le document PDF, Image available in the PDF document]
12. A pharmaceutical composition comprising the compound according to claim 1 or claim 11, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition according to claim 12 for use in the prevention and / or treatment of a disease or condition mediated by aryl hydrocarbon receptor (AhR). Claim 14 The pharmaceutical composition according to claim 13, wherein the disease or condition mediated by aryl hydrocarbon receptor (AhR) is cancer, cancerous consitions, tumor, fibrotic disorders, or conditions with dysregulated immune responses or other disorders associated with aberrant AhR signaling.
15. The pharmaceutical composition according to claim 12, for use in inhibiting proliferation, tissue invasion, metastasis and angiogenesis of cancer cells in a subject having a cancer, a cancerous condition, or a tumor. Claim 16 The pharmaceutical composition according to claim 14, wherein the cancer is selected from the group consisting of a breast cancer, squamous cell cancer, lung cancer, a cancer of the peritoneum, a hepatocellular cancer, a gastric cancer, a pancreatic cancer, a glioblastoma, a cervical cancer, an ovarian cancer, a liver cancer, a bladder cancer, a hepatoma, a colon cancer, a colorectal cancer, an endometrial or uterine carcinoma, a salivary gland carcinoma, a kidney or renal cancer, a prostate cancer, a vulval cancer, a thyroid cancer, a head and neck cancer, a B-cell lymphoma, a chronic lymphocytic leukemia (CLL); an acute lymphoblastic leukemia (ALL), a Hairy cell leukemia, and a chronic myeloblastic leukemia.
17. The pharmaceutical composition according to claim 14, wherein the fibrotic disorder is selected from the group consisting of hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis, scleroderma, morphea, keloids, hypertrophic scarring, naevi, diabetic retinopathy, proliferative vitroretinopathy and sarcoidosis.
18. The pharmaceutical composition according to claim 14, wherein the condition with dysregulated immune responses is selected from the group consisting of sepsis, multiple organ failure, inflammatory disorders of the kidney, chronic intestinal inflammations, pancreatitis, peritonitis, inflammatory skin disorders and inflammatory eye disorders, rheumatoid diseases, systemic lupus erythematosus and multiple sclerosis.
19. Use of the compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1 or claim 11 for manufacturing a medicament for modulating AhR activity in a subject.
20. Use of the compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1 or claim 11 for manufacturing a medicament for preventing or treating a disease or condition mediated by aryl hydrocarbon receptor (AhR) in a subject. Claim 21 Use according to claim 20, wherein the disease or condition mediated by aryl hydrocarbon receptor (AhR) is cancer, cancerous consitions, tumor, fibrotic disorders, or conditions with dysregulated immune responses or other disorders associated with aberrant AhR signaling.
22. Use according to claim 21, wherein the cancer is selected from the group consisting of a breast cancer, squamous cell cancer, lung cancer, a cancer of the peritoneum, a hepatocellular cancer, a gastric cancer, a pancreatic cancer, a glioblastoma, a cervical cancer, an ovarian cancer, a liver cancer, a bladder cancer, a hepatoma, a colon cancer, a colorectal cancer, an endometrial or uterine carcinoma, a salivary gland carcinoma, a kidney or renal cancer, a prostate cancer, a vulval cancer, a thyroid cancer, a head and neck cancer, a B-cell lymphoma, a chronic lymphocytic leukemia (CLL); an acute lymphoblastic leukemia (ALL), a Hairy cell leukemia, and a chronic myeloblastic leukemia.
23. Use according to claim 21, wherein the fibrotic disorder is selected from the group consisting of hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis, scleroderma, morphea, keloids, hypertrophic scarring, naevi, diabetic retinopathy, proliferative vitroretinopathy and sarcoidosis. Claim 24 Use according to claim 21, wherein the condition with dysregulated immune responses is selected from the group consisting of sepsis, multiple organ failure, inflammatory disorders of the kidney, chronic intestinal inflammations, pancreatitis, peritonitis, inflammatory skin disorders and inflammatory eye disorders, rheumatoid diseases, systemic lupus erythematosus and multiple sclerosis.
25. Use of the compound, or an enantiomer, diastereomer, racemate, solvate, hydrate, or pharmaceutically acceptable salt thereof according to claim 1 or claim 11 for manufacturing a medicament for inhibiting proliferation, tissue invasion, metastasis and angiogenesis of cancer cells in a subject having a cancer, a cancerous condition, or a tumor.
